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ABSTRACT
FACTORS THAT INFLUENCE THE DECISION REGARDING HORMONE 
REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN
by
Ruth A  Rogers Reilly 
University of New Hampshire, May 1998
Cardiovascular disease is the leading cause of death in women in the United States 
today. Prior to menopause women have lower rates of heart disease than men; however, 
after menopause a woman’s risk for heart disease rises dramatically. This is thought to be 
due the ovaries’ decreased production of estradiol, but the mechanisms for this effect have 
not been fully elucidated. The need exists to investigate the impact of healthy lifestyles on 
attenuating the risk of cardiovascular disease in women as they age.
The majority of research on hormone replacement therapy (HRT) has focused on 
the biomedical model suggesting that menopause reflects an estrogen “deficiency” and is 
treatable by pharmaceutical intervention. Little information is available that views 
menopause from a broader perspective which includes psychological and social factors. 
This research tested the hypothesis that postmenopausal women who practice positive 
lifestyle interventions, such as health supporting diets and regular exercise, will 
demonstrate positive biological, social and psychological outcomes independent of HRT.
Seventy healthy postmenopausal women, aged 48-66, who had experienced a 
surgical or natural menopause were categorized into one of three groups: (1) no hormone
xiii
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replacement therapy (n=36); (2) estrogen only (n=l 1); and (3) estrogen and progestin 
(n=23). Subjects donated a fasting blood sample and completed a comprehensive lifestyle 
and medical questionnaire that gathered information regarding health, menopause, 
decision making, self-esteem, and mood states. Subjects also completed a food frequency 
and three-day food diary. Anthropometric measurements were performed to determine 
body mass index and waist hip ratios. Biological assays of collected blood samples 
included estradiol and progesterone concentrations, lipid profiles, serum beta-carotene and 
vitamin E in total serum and in LDL, total antioxidants and the resistance of LDL to 
oxidation. Results indicated that lifestyle factors including quality of dietary intake, 
duration and intensity of exercise, and body weight may be better predictors of disease risk 
than use of HRT in postmenopausal women. Results suggest that, regardless of hormone 
use, positive lifestyle interventions will provide improved quality of life in women as they 
age.
xiv
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CHAPTER I
INTRODUCTION
Cardiovascular disease is the leading cause of morbidity and mortality in women in 
the industrialized world: one out of every two women will eventually die of heart disease 
or stroke (1). Prior to menopause women have lower rates of heart disease than men, but 
at menopause a women’s risk of cardiovascular disease rises dramatically. This is thought 
to be due in part to the ovaries’ decreased production of estradiol. The cardioprotective 
effects of estrogen appear to be modulated through several mechanisms which are 
currently being investigated. These mechanisms include estrogen’s beneficial effects on 
carbohydrate metabolism, clotting factors, antioxidant ability and effects on the vascular 
system.
Menopause is defined as the end of menstruation. In industrialized countries this 
occurs at the average age of 51 (2) and it is diagnosed clinically with the cessation of 
menses for at least one year (3). Consequences of menopause include vasomotor 
instability, vaginal dryness, and mood swings and an increased risk for chronic diseases 
such as coronary heart disease and osteoporosis. The most common medical intervention 
used to treat both the acute and chronic symptoms of menopause is HRT.
Results of 30 epidemiological studies (4), (5), (6) are now available and have been
summarized and compared in three meta-analyses. These studies have shown a significant
reduction (relative risk of 0.56-0.65) in the incidence of fatal and nonfatal cardiovascular
events in postmenopausal women using HRT. In spite of the fact that the
1
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health benefits of exogenous hormone use is well documented, compliance among women 
is poor. In 1994 Hammond estimated that less than 20% of postmenopausal women in the 
United States have been prescribed HRT. Of the women who use HRT, less than 40% 
will continue its use after one year, and overall 70% of these women are non-compliant 
(7). This may be due to a number of factors including fear of cancer, side effects, and 
unacceptable bleeding patterns. This suggests that women and health care providers need 
more information and education regarding the risks and benefits of the use of HRT during 
menopause.
Historically, research on menopause and HRT has been dominated by the medical 
model, which characterizes menopause as a deficiency disease requiring treatment (8).
Less information or research is available that has investigated menopause from a 
psychological or social perspective. The question of how women make the important 
decision to use or not to use HRT remains virtually unanswered. There has been limited 
research into the contributions of lifestyle interventions, such as modifications in diet and 
exercise, as a alternative or adjuvant to HRT.
There is evidence that the oxidative modification of low-density lipoprotein 
cholesterol (LDL-C) plays a key role in the development of atherosclerosis. It has been 
proposed that estrogens alone (9) or with progestins (3) may protect against 
atherosclerosis in part by inhibiting the oxidation of LDL-C. In addition, the antioxidant 
nutrients a-tocopherol (vitamin E) and beta-carotene ({3-carotene) also inhibit the 
oxidation of LDL-C (10), (11). LDL carries in it antioxidants, such as 3-carotene and 
vitamin E, which can modify free radicals and prevent the oxidation of LDL. As a result, 
the cardioprotective effect of estrogen may be conferred in part by its influence on the
2
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antioxidant content of LDL. One focus of this research is to evaluate the influence of 
dietary intake of vitamin E and (3-carotene, in modulating the risk profile of cardiovascular 
disease in postmenopausal women.
The contribution of the biological research on menopause and HRT would be 
strengthened by the inclusion of the social and psychological aspects of menopause. The 
biopsychosocial perspective attempts to understand health status by recognizing how the 
biological, psychological, and social elements are related to one another(12). Studies by 
Engel (13), (14) discussed the limitations of limiting explanations of a dysfunction to any 
one of its three major components (biological, psychological, social) and emphasized the 
benefits of their simultaneous inclusion in research models. These three factors have a 
synergistic effect on one another and their complex interplay should be considered in 
research protocols (15). Another focus of this research is to apply the biopsychosocial 
model to a population of women who are making decisions regarding HRT.
Specific Aims of the Study
1. To assess the biological consequences of the choice regarding HRT on cardiovascular 
risk profiles in postmenopausal women by evaluating the effect of HRT use or disuse 
on antioxidant ((3-carotene and a-tocopherol) concentrations in serum vs. LDL in 
postmenopausal women.
2. To investigate the effect of positive lifestyle interventions (healthy diet and 
moderate, frequent exercise) on biological, social and psychological parameters 
independent of HRT use in postmenopausal women.
3. To investigate the variables influencing a woman’s choice of HRT from a 
biopsychosocial (biological, psychological, and social) perspective.
3
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Hypotheses
This research seeks to investigate several hypotheses generated by the
biopsychosocial model:
Biological
1. Postmenopausal women who use HRT will have higher concentrations of P-carotene 
and a-tocopherol in both the serum and LDL lipoproteins, and thus less susceptibility 
to oxidation of LDL than women who do not use HRT.
2. Serum estradiol concentrations would be positively correlated with serum 
concentrations of P-carotene and oc-tocopherol, LDL ac-tocopherol and LDL P- 
carotene, p-carotene/LDL and oc-tocopheroI/LDL ratios, and lipid profiles in 
postmenopausal women.
3. The use of HRT will positively affect serum cholesterol and lipoprotein concentrations 
Lp(a), high density lipoprotein, and low-density lipoprotein in postmenopausal 
women.
4. Postmenopausal women who practice positive lifestyle interventions (health 
supporting diets and moderate and frequent exercise) will demonstrate a decreased 
risk of cardiovascular disease regardless of their use of HRT.
5. Postmenopausal women who use HRT will have lower body mass indexes (BMI) and 
waist-hip ratios than women who do not use HRT.
Psychological
6. Concerns regarding cancer will be the primary reason reported for not using HRT, or 
for discontinuing its use in postmenopausal women.
4
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7. Postmenopausal women who practice positive lifestyle interventions (health 
supporting diets and moderate and frequent exercise) will report less severe 
postmenopausal symptoms, as well as more positive self-esteem and moods regardless 
of their use of HRT.
Social
8. Postmenopausal women will report that their choice to use HRT was strongly affected 
by outside influences in their lives (medical professionals, media, and significant 
others).
9. Postmenopausal women will report that acute symptom relief and concern over 
chronic disease (osteoporosis and/or heart disease) were the most influential factors in 
making the decision to use HRT.
10. Postmenopausal women who use HRT will consume diets lower in fat and saturated 
fat than those who do not use HRT.
11. Postmenopausal women who use HRT will be more likely to have used oral 
contraceptives (OC) in the past when compared to women who do not use HRT.
5
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CHAPTER E
REVIEW OF THE RELATED LITERATURE 
Decision Making
One of the most controversial issues in women’s health today is the use of HRT. 
Women experiencing menopause will be offered advice regarding the risks and benefits of 
exogenous hormone use. A great deal of the information disseminated to women is 
contradictory. There is much debate as to whether menopause should be viewed as an 
endocrine deficiency requiring long-term management with HRT, or as a natural stage in 
a woman’s life requiring little or no medical intervention. These opposing opinions and 
recommendations communicated to women may compromise their ability to make an 
informed decision with respect to HRT (16).
There is great variability in the reported prevalence of HRT use in the United 
States. It is estimated that 50% of women will take HRT at some point in their lifetime 
(17), and estimates of current HRT use range from 5.3% (18) to 39.3% (19). These 
estimates vary depending on age, geographic location, study population, and time of the 
study (20).
The Commonwealth Foundation National Survey on Women's Health indicated 
that either perimenopausal or immediately postmenopausal women were most likely to use 
HRT, and also use of HRT decreased with advancing age (21). The strongest factors 
influencing the initiation of hormone use is surgical menopause (20), (7) and
6
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vasomotor instability (22). Women who have had a surgical menopause are two to three 
times more likely to use unopposed estrogen after menopause (23).
Historically, the research on HRT has focused on middle-class white women who 
have the greatest access to health care. Women who are currently using HRT tend to 
participate in more preventative health care behaviors including nutrient-rich diets and 
exercise (24). They also tend to be leaner (25),(26), (27), (28), of higher socioeconomic 
status (25), more highly educated and exercise on a regular basis (27). Hormone users are 
more likely than nonusers to view menopause as a medical condition and are less likely to 
consider natural alternatives to treat menopausal symptoms (29).
Several studies have reported that the most important reasons for starting HRT 
were recommendation of a physician (29), (16), (30), (31), followed by the possible relief 
of the acute symptoms of menopause (29). It has also been reported that only 19% of 
physicians allow their patients to stay on HRT for more than three years (32), (33) and 
that physicians are reluctant to prescribe hormone therapy for women with diabetes, 
hypertension, or known heart disease (24), (34). In one of the first studies evaluating 
women’s knowledge and attitudes (31) about ERT, 64% of the women who had not used 
estrogen replacement reported never discussing it with their physician. Asked if their 
physician recommendation would have an effect on their decision, 75% reported that it 
would. This study (31) also reported that women who receive care from a gynecologist 
are much more likely to be prescribed HRT than women who receive care from other 
medical disciplines and that, in general, women who discontinue HRT use, do so upon the 
advice of a physician. It is clear that a woman’s decision to use HRT is strongly 
influenced by the medical community.
7
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A survey conducted by the North American Menopause Society (35) determined 
that physicians were more likely to discuss the short-term effects o f menopause than 
information on long-term risks such as osteoporosis and heart disease with their patients. 
When discussing treatment options to women, 84% of the physicians focused on HRT, 
3% discussed exercise, and 2% diet. Other lifestyle interventions were mentioned even 
less frequently. This suggests that physicians tend to focus on the medical treatment of 
menopause and that women are not receiving information on interventions such as diet 
and exercise in treating menopausal symptoms and the prevention o f chronic disease.
In spite of the fact that the health benefits of long-term estrogen use for the 
prevention of heart disease and osteoporosis have been well demonstrated, compliance is 
poor. Hammond (7) estimated that less than 20% of postmenopausal women in the 
United States have ever been prescribed HRT. Of those women on HRT, less than 40% 
will continue its use after one year, and 70% of all women on HRT are not compliant and 
the motivation to continue HRT diminishes over time. Women who have experienced a 
ovariectomy (20) or who have diagnosis of osteoporosis are most likely to use HRT on a 
long-term basis. Women with a natural menopause are the most likely to use HRT for a 
short period of time for the relief o f the acute symptoms of menopause (20).
The Massachusetts Health Study (20),(29) demonstrated the problems with 
compliance and continuance of HRT in a longitudinal study of women aged 45-55. In this 
cohort of 2,425 subjects, 20% stopped treatment within nine months, 10% took the 
prescription sporadically, and 20-30% never filled the prescription. Women discontinued 
HRT use because of disappearance o f menopausal symptoms, complicated and confusing 
treatment schedules, side-effects and fear of endometrial and/or breast cancer. Women
8
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
rate unacceptable bleeding pattems(31), (36) and fear of cancer as the main reasons for 
discontinuing HRT (37).
Discontinuance of HRT is sometimes treated in the medical literature as a 
compliance problem that could be solved by more education and better designed drug 
packaging. In discussing compliance among women using HRT, Kaufert (38) refers to a 
phrase used by Weintraub (39), “Intelligent Noncompliance”. This term is defined as a 
situation “where prescribed medication is purposely not taken and the patient’s reason for 
noncompliance appears valid when analyzed dispassionately”. It is suggested that a 
woman makes the decision to use or not to use HRT by intelligently weighing the risks 
and benefits of HRT (38). Doren and Schneider (40) suggest that physicians’ 
understanding of compliance involves a unidirectional decision that is synonymous with 
the patient’s acceptance of medical authority.
There are few studies on how women view and utilize the information available to 
them to make judgments regarding HRT. After controlling for perceived levels of 
menopausal distress, Logothetis (16) investigated women’s beliefs about menopause. She 
reported that women who were currently using estrogen perceived themselves to be more 
susceptible to difficulties in menopause and viewed HRT as beneficial in treating these 
problems. It was found that women make decisions regarding HRT based on their 
perception of the risk-benefit ratio. The recurrent theme among women in this study was 
the need for more accessible and reliable information relative to HRT and menopause. A 
preliminary study, conducted by Rothert et al. (41) collected data for the purpose of 
designing and evaluating an educational intervention to assist women in becoming more 
effective decision makers during menopause. The data collected found that women were
9
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capable of processing information regarding the risk and benefits of HRT, could apply the 
information given to them consistently, and were influenced by personal and social factors 
in making their decisions. However, it was also reported that women did not have access 
to the information needed to enable them to participate in their own health care.
One study (42) investigated attitudes and knowledge of HRT among 600 female 
graduates of Stanford University with a mean age of 50. Forty-nine percent of these 
women used HRT. The women in this study perceived their risk of developing heart 
disease to be low, and breast cancer risk as high. Only 25% of the current users of HRT 
considered the potential protection against heart disease in their decision to use HRT. 
When asked what disease they feared most, three times as many women feared breast 
cancer (48%) when compared to heart disease (16%). This study demonstrates that even 
though highly educated women know that HRT could possibly reduce their risk of 
developing heart disease, they do not perceive themselves as vulnerable to heart disease. 
This group of women reported that they felt use of HRT on a long-term basis would 
increase their risk of breast cancer. Logothetis (16) compared the characteristics of 
current estrogen users to nonusers and found that only 10% of the current users reported 
prevention of chronic disease (heart disease or osteoporosis) as a reason for taking HRT 
and 75% reported use for less than 2 years.
In a recent study (43), questionnaires were mailed to 126 women, aged 45-55, to 
determine what factors influenced women’s decision making to use HRT. The majority of 
the women surveyed (81%) knew that the risk for osteoporosis increased after 
menopause; however, only 53% knew that the risk for heart disease increased as well. 
Only 48% of the women surveyed realized the inverse relationship between HRT use and
10
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heart disease risk. This study also found that the most important predictor of HRT use 
was the recommendation of the health care provider.
To assist women in the decision making process, a mathematical model has 
recently been developed at New England Medical Center. The purpose of developing this 
model was to examine the effect of HRT on life expectancy in postmenopausal women 
with different risk factors for breast cancer, hip fracture, and heart disease. Results 
indicated that the use of HRT would increase life expectancy in most women. It also 
concluded that only women with a high risk o f breast cancer and a low risk of 
cardiovascular disease would not benefit from HRT use. These researchers have 
developed a checklist that can be used by women and their physicians to evaluate their 
own individual risks and benefits to make an informed decision regarding HRT (44).
One factor in the reluctance to use HRT, as well as the low compliance, may be 
that the available information is confusing and difficult to obtain. Educational programs 
need to be developed to inform women about the physiology of menopause and the risk 
and benefits of HRT (40). Health care professionals also need to be better informed and 
to take an active role and become partners in the decision process. When provided with 
accessible and reliable information, women will be more capable of making an informed 
decision on whether to use or not to use HRT.
Current Status of Cardiovascular Disease In Women 
Cardiovascular disease (CVD), which includes heart disease and stroke, is the 
leading cause of death in American women and accounts for nearly 500,000 deaths 
annually (1). CVD rarely occurs in premenopausal women, but risk for CVD in women
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increases steadily after menopause. The Framingham Heart Study reported that only 6 of 
every 1600 premenopausal women died of coronary heart disease (45); however CVD 
represents the leading cause of death in older women and accounts for nearly 53% of all 
deaths in women over 50 years of age (46). CVD also impacts the quality of life in older 
women, as heart disease and stroke are the two major causes o f morbidity and disability in 
postmenopausal women (47).
Compared to men, women are most often diagnosed with chronic rather than acute 
heart disease and develop heart disease on average 10 years later than men (45). In the 
past, the diagnosis and treatment of heart disease was different for men and women. 
Women tended to undergo evaluations and treatments for cardiac disease substantially less 
frequently than men with similar or less severe symptoms, particularly for the evaluation of 
chest pain (48). A woman who suffered a myocardial infarction was more likely than a 
man to have a recurrence and to die in the recovery period (49). In fact, 45% of women, 
compared to 10% of men, were likely to die within a year following a heart attack and 
40% of women compared to 13% of men reinfarcted within a year (50). Until the middle 
1990’s, the rate of early death after a myocardial infarction was higher in women than in 
men and the mortality rate for women who underwent coronary angioplasty or bypass 
surgery was higher than that of men. It is not clear if these adverse outcomes were due to 
older age, smaller body size and more frequent and severe coexisting illnesses sometimes 
seen in women, or because of substandard or delayed care as compared to men (52). 
Recently, several coronary care centers have reported similar mortality rates in men and 
women undergoing angioplasty since 1995. This is thought to be due to gender
12
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
appropriate angioplasty devices designed for women’s smaller arteries (53), as well as 
earlier diagnosis and treatment of heart disease.
Historically, there has been a lack of research on cardiovascular disease in women. 
Women of childbearing age were excluded from studies presumably due to the perceived 
confounding factor of the menstrual cycle. Older women were excluded because of co­
morbidities. Until recently there had been almost no prospective data on primary 
prevention strategies for women, and most clinical decisions about the choice and dose of 
cardiac drugs was based on studies done primarily on middle-aged men (54).
The increased risk of CVD seen in women during the menopausal transition has 
been suggested to be, at least in part, due to changes in total cholesterol and lipoprotein 
concentrations. Cross-sectional studies have demonstrated that postmenopausal women 
have higher levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), 
very low-density lipoprotein cholesterol (VLDL-C), lipoprotein (a), and triglycerides (TG) 
(55), (28), (56), (57). Conversely, high-density lipoprotein cholesterol (HDL-C) shows 
only a small decrease at the time of menopause (58), (59). Prospective studies have 
shown that HDL-C decreases slightly years before the last menstrual cycle, whereas the 
rise in LDL-C coincides with the end of menses (60). It has also been noted that after 
menopause, women develop more of the smaller, denser LDL-C particles which correlate 
with an increased triglyceride and decreased HDL-C concentrations. These conditions are 
considered to be atherogenic (61), (62).
A 1990 longitudinal study (60) investigated the influence of menopause on lipids 
and lipoproteins in women experiencing the menopausal transition. The 170 women who 
were not taking HRT were followed at 6 week intervals for two to three years. Serum
13
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
lipids and lipoprotein profiles were examined cross-sectionally dependent on menopausal 
status: premenopausal, perimenopausal, and postmenopausal. Total cholesterol, LDL-C, 
and triglyceride serum concentrations increased, and HDL-C decreased as a result of 
menopause. Ail these changes occurred within six months of cessation of menses.
Prospective studies suggest that HDL-C may be the best predictor of coronary 
heart disease (CHD) in women (63), (64), (65). HDL-C was shown to be the strongest 
predictor CHD in women in the Framingham Study (66), Lipid Research Clinic (4), and 
Donolo-Tel Aviv studies(67). The Framingham and Lipid Research studies both 
demonstrated an association between HDL-C concentration and CVD when it was shown 
that a lOmg/dL increase in HDL-C serum concentration was correlated with a 40-50% 
decrease in CVD risk. In the Tel-Aviv study, high total cholesterol concentrations were 
essentially neutralized by high concentrations of HDL-C. In this study, subjects with high 
concentrations of HDL-C and high levels of total cholesterol (>250mg/dL) had age 
adjusted rates of heart disease that were not different than the rates in women with lower 
cholesterol levels. These findings suggest that in postmenopausal women, HDL-C is a 
critically important factor in determining the risk for cardiovascular disease. It also 
indicates that interventions such as diet and exercise, which increase HDL-C 
concentrations, can potentially decrease heart disease risk in women.
There is no direct evidence that decreasing serum cholesterol concentrations in 
women will decrease coronary morbidity and mortality except at higher concentrations of 
total cholesterol (68). Studies do concur that women with a total cholesterol 
concentration of >265mg/dL have three-fold increased risk of CVD when compared to 
women having the lower cholesterol concentrations (64). However, the evidence is less
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consistent in women with “borderline high” total cholesterol levels (200-240mg/dL). Only 
when HDL-C is taken into consideration is the relationship between total cholesterol and 
cardiovascular risk in postmenopausal women consistent (69).
Lipoprotein (a) [Lp(a)] is an atherogenic particle that is structurally similar to 
LDL-C, but contains a molecule of apolipoprotein (a) attached to apolipoprotein A-100 by 
a disulfide bond. Elevated serum concentrations of Lp(a) have been shown to be an 
independent risk factor for cardiovascular disease (70). Lp(a) concentrations are 
genetically determined and are resistant to alterations in diet and pharmaceutical 
treatments. Although supplemental niacin does appear to decrease Lp(a) concentrations 
(71). The Framingham Offspring Study reported that Lp(a) serum concentrations were 
6% higher in postmenopausal women as compared to premenopausal women (70). 
Epidemiological studies have reported that Lp(a) concentrations increase with menopause, 
and that postmenopausal women taking HRT have lower concentrations of Lp(a) than 
those who do not use HRT (72). Kim et al. (72) showed that a combination HRT 
(estrogen and progestin) lowered Lp(a) in postmenopausal women. This effect was 
greatest in subjects with the highest basal levels of Lp(a). Perrone et al. (73) found that 
Lp(a) was not effected by HRT use in 42 hypercholesterolemic postmenopausal women. 
Lp(a) has been shown to be a predictor of CHD in both pre- and postmenopausal women 
(74). The role that Lp(a) plays in the pathogenesis of heart disease in women and the 
effect of diet or exercise on Lp(a) concentrations requires further clarification.
Clearly there is a strong biological component to cardiovascular risk in women.
The risk factors for women include family history of CHD, menopausal status, 
hypertension, obesity and central adiposity, diabetes mellitus, current cigarette smoking,
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physical inactivity, elevated LDL-C and low HDL-C concentrations (75), (76). When 
multiple risk factors are taken into consideration, it is evident that this disease is not 
purely biological. It involves social and psychological factors as well, including low 
educational level and stress.
Hormone Replacement Therapy 
The fact that a woman’s risk for heart disease increases after menopause suggests 
that hormonal factors play a role in the development of heart disease (68). Data suggests 
that HRT is the treatment of choice for relief of acute symptoms of menopause and the 
prevention of such chronic diseases as heart disease and osteoporosis. The use of 
hormone replacement has increased in the last decade. One-fourth of all postmenopausal 
women in the United States are currently using some form of HRT (77).
The first commercial estrogen preparations became available in 1926, but were not 
widely used until the 1960’s when the link between menopause and cardiovascular disease 
and osteoporosis began to be widely researched (78). Unopposed estrogen (estrogen 
without the addition of progestin) was used to prevent these chronic diseases until the 
1970’s when reports started to appear in the literature linking ERT with an increased risk 
of endometrial cancer (79). At this time progestin was added to the prescription to 
eliminate this risk and HRT became the treatment of choice. Currently HRT is the term 
more frequently used to indicate estrogen alone or in combination with a progestin.
The goal o f postmenopausal hormone therapy is to replace lost endogenous 
estrogen to minimize the health risks associated menopause. For women who do not need 
endometrial protection (women without a uterus), unopposed estrogen is prescribed.
16
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Estrogen: Estrogen preparations constitute a wide variety of pharmaceutical options. 
Exogenous estrogen can be classified by chemical composition (natural or synthetic) or by 
route of administration (oral or parenteral).
Natural preparations of HRT are six to seven times less potent than the lowest 
dose of synthetic estrogens (80). The natural estrogens include conjugated equine 
estrogen (CEE), estradiol (either micronized or as the valerate ester) and estrone sulfate. 
Premarin™ (CEE) is the most commonly prescribed estrogen in the United States. This 
CEE is made from the urine of pregnant mares and is a mixture of three estrogens. The 
first component is estrone sulfate, an estrogen synthesized by both humans and horses, 
composes 50-60% of the preparation. The other two components equilin sulfate ( 20- 
30%) and 17 a-dihydroquilin sulfate (15%), are both horse estrogens (81). Other types 
of oral estrogens include micronized estradiol (Estrace™), esterified estrogens 
(Estratab™), and estropipate, or piperazine estrogen sulfate (<9ge«™). In Europe, 
estradiol valerate (Progynin™) is the most commonly used oral estrogen. The synthetic 
estrogens ethinyl estradiol (Estinyl™), quinesterol (Estrovis™), and diethylstibestrol 
(DES), are rarely used today (82).
When taken orally, estrogen is absorbed through the intestinal wall where it begins 
to be converted to estrone and estradiol. These products are subsequently absorbed via 
the blood, and progress to the liver. The oral administration of estrogen results in 
hormone concentrations in hepatic sinusodial blood that are four to five times higher than 
those in the peripheral blood (83). This is called the “first pass” effect and it promotes the 
hepatic synthesis and secretion of coagulation factors, renin substrates, sex hormone
binding proteins and a variety of lipid apoplipoproteins (84).
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Parenteral routes of estrogen administration include injection, transvaginal 
(creams, tablets, and silastic rings), transdermal (“patch”), subcutaneous pellets, intranasal 
and percutaneous (gel) administration (81). The estrogen patch in particular is very 
popular in Europe and is gaining popularity in the United States. Estraderm™, the most 
commonly used patch, releases 17 (3-estradiol, and consists of four layers. Since use of the 
patch can also result in endometrial hyperplasia, it is commonly used in combination with 
an oral progestin. The most common side effect with patch use is skin irritation, but 
because the patch does not adversely affect liver function its use is increasing (85).
Parenteral administration does not result in alterations in renin substrate or clotting 
factors and the effect on lipoprotein concentrations varies with dose and route of 
administration. This is thought to be due to the fact that these preparations enter the 
systemic circulation before reaching the liver and thereby avoid the “first pass” hepatic 
effect (84).
Progestins: Progestins are added to the estrogen prescription to prevent endometrial 
hyperplasia in women with a uterus. Numerous types, doses, and schedules are used. 
Synthetic progestins are the most frequently used because progesterone is poorly absorbed 
(84). The synthetic progestins are usually two basic types: the
19-nortestosterones (Medrogestone and Norethisterone acetate) and 17-a progestagens 
(medoxyprogesteroneacetate-MPA-Provera™). A natural progesterone in a micronized 
form is currently available in pill or cream form throughout Europe and in Canada. 
Micronized progesterone is made by breaking progesterone into small pieces to facilitate 
better absorption of the drug. In the United States it is available only through alternative
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pharmacies although is expected to be approved by the FDA for use in the United States 
in the near future (86).
Estrogen and progesterone can be taken continuously or cyclically. In cyclical 
therapy, estrogen is typically taken daily and progestin for only the first twelve days of the 
month, when most women experience breakthrough bleeding. In continuous therapy, 
both estrogen and progestin are taken daily which results in less breakthrough bleeding. A 
new formulation, Prempro™, combines Premarin™ and Provera™ in one tablet and is 
approved for use in the United States (87).
Testosterone: The possible effects of androgen replacement have not been fully examined. 
Androgens alone or in combination with estrogen or with estrogen and progestin are 
widely prescribed to postmenopausal women for relief of menopausal symptoms, 
especially depression and decreased libido. Clinical trials addressing the efficacy of 
prescribing testosterone to postmenopausal women are few; and the existing data is 
fraught with cofounders such as differences in study populations (surgical or natural 
menopause), lack of controls, blinding and randomization. Also, the association between 
libido and serum testosterone levels is tenuous. Exogenous testosterone appears to only 
effect women whose blood concentrations of testosterone are low prior to treatment (82). 
In women who have experienced a surgical menopause, there has been an improvement in 
menopausal symptoms demonstrated at very high concentrations of testosterone.
However, lower doses of testosterone used with women who have experienced a natural 
menopause have failed to show the same results. The Nurses' Health Study (88) found an 
increased risk of breast cancer in women taking androgens (relative risk 1.64; 95% 
confidence interval, 0.53 to 5.09). Also, the effect that these preparations have on
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cholesterol levels is not well-defined (89). There is a need for more studies to determine 
the risk and benefits of androgen replacement therapy use during menopause (90).
Research on HRT is a field of study that is expanding very rapidly as women 
continue to seek more information regarding the risk/benefit equation of these therapies. 
Thompson (78) suggests that it is illogical to assume that all women will respond in the 
same way to exogenous hormones considering the variations in absorption, first-pass 
metabolism with oral preparations, and plasma binding, all of which can affect the 
bioavailability of the drug. Therefore, hormone replacement therapy needs to be 
individualized according to the woman’s symptoms, risk factors, and response to the 
specific dose and type of hormone used.
The Cardioprotective Effect of Estrogen 
The first clinical trial investigating estrogen and heart disease was conducted on 
men and demonstrated an increased risk of myocardial infarction in those subjects 
receiving supraphysiologic (2.5 mg or 5 mg Premarin™) doses of estrogen (91). In 1979, 
Nachtigall (200) conducted the first prospective randomized clinical trial on estrogen and 
heart disease on 168 institutionalized women and followed them for ten years. In this 
study there were eighty-four pairs o f randomly assigned postmenopausal women, half 
receiving no HRT, and the other half receiving a cyclic combination of Premarin™ and 
progestin. Although not statistically significant, the hormone-treated women 
demonstrated more positive lipid profiles.
Animal studies have also shown a positive correlation between HRT use and 
decreased risk of cardiovascular disease. Cynomolgus macaque females (Macaca
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fascicularis) are excellent models for research on coronary heart disease in both pre-and 
postmenopausal women. Cynomolgus monkeys are susceptible to atherosclerosis.
Females have a twenty eight-day menstrual cycle, sex hormone patterns similar to human 
females, and natural menopause occurs later in their lifespan (93). Like women, 
premenopausal females of this species have higher plasma concentrations of HDL-C than 
postmenopausal females. These monkeys apparently have protection from atherosclerosis 
premenopausally, but also experience loss of this protection and progressive coronary 
artery disease with age. Adams et al. (94) used this animal model to investigate the 
influence of HRT on diet-induced atheroscelerois in ovariectomized adult female monkeys. 
All the animals were fed an atherogenic diet and menopause was induced by ovariectomy. 
The animals were then randomly assigned to three treatment groups. Group one received 
no HRT (n=17). Group two was given continuously administered 17-0 estradiol plus 
cyclical progesterone (n=20), and group three was given continuously administered 17-0 
estradiol (n=18) only. Physiologic concentrations of plasma estradiol and progesterone 
were maintained by the administration of the hormones using subcutaneous implants. The 
experiment lasted for 30 months.
At autopsy, the extent of atherosclerosis was evaluated by measuring the intimal 
area of carotid arteries and aortas. In the untreated group (no hormone replacement) 
atherosclerosis was significantly more extensive (50%) than in animals in the two hormone 
treated groups. There was no significant difference between the two hormone replacement 
groups. The decreased risk was found to be independent of variations in total plasma 
cholesterol, LDL-C, apolipoprotein A-l and B concentrations, as well as HDL-C, and 
LDL-C particle size.
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Haarbo et al. (50) had similar findings when he studied orally administered 
!7{3-estradiol alone or with progestins in ovariectomized cholesterol-fed rabbits. All 
hormone treated animals demonstrated reductions in aortic cholesterol accumulation, as 
well as significant reductions in cholesterol concentrations.
Endogenous estrogen has been shown to confer a positive effect on lipid and 
lipoprotein concentrations in women prior to menopause. Endogenous estrogen stimulates 
VLDL-C catabolism by transferring surface components to HDL-C, thus increasing 
HDL-C levels (95). Total cholesterol and LDL-C increase with age in both genders, but 
women tend to have lower levels than men. This may be because estradiol stimulates 
lipoprotein lipase and enhances hepatic uptake o f LDL-C, which results in lower LDL-C 
concentrations (75). In spite of the positive effect endogenous estrogen has on lipids and 
lipoprotein concentrations, the relationship of physiological levels of estradiol and CHD is 
based largely on observational studies. Studies on postmenopausal women have 
demonstrated no positive association between endogenous estrone or estradiol levels and 
cardiovascular risk factors, especially HDL-C (96). One prospective study followed 
women through menopause and found a concurrent decrease in estradiol and HDL-C (59).
In 1995 Barrett-Connor and Goodman-Gruen (82) conducted a study in Rancho 
Bernardo, California to examine the association between serum concentrations of 
androstenedione, testosterone, and estrone on risk of death from cardiovascular disease in 
651 postmenopausal women who were not taking exogenous estrogen. They found no 
correlation between concentrations of these three sex hormones and risk of heart disease 
in these subjects. These studies indicate that although endogenous sex hormones seem to
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have a beneficial effect on lipids and lipoproteins, they do not appear to confer protection 
against heart disease in postmenopausal women.
Observational studies have consistently found a decrease risk of heart disease in 
postmenopausal women using HRT. In 1991, Stampfer and Colditz (5) conducted a 
meta-analysis of all studies to date that had investigated the link between estrogen 
replacement therapy and heart disease. They reported a relative risk of 0.56 (95% 
confidence interval, 0.50-0.61) for all studies. The same research team conducted a 
second study in 1996 and examined the relationship between heart disease in 
postmenopausal women using estrogen and progestin. They reported a relative risk of 
0.39 (95% confidence interval, 0.19-0.78) in women using estrogen and progestin, and a 
relative risk of 0.60 (95% confidence interval, 0.43-0.83) in women taking estrogen only 
when comparing both to women taking no hormone replacement (97). This data 
suggested that progestin taken in combination with estrogen, is not as strongly correlated 
with a decreased cardiovascular risk in postmenopausal women as when estrogen used 
alone.
Bush et al. (4) followed 2,270 women (aged 40-69) for 8.5 years in the Lipid 
Research Clinics Prevalence (LRC) Study. The age-adjusted relative risk for cardiac 
disease was 0.34 (95% confidence interval, 0.12-0.81) for estrogen users compared to 
nonusers. HDL-C was also shown to be inversely correlated with cardiovascular death in 
this study. The protective effect demonstrated in estrogen users may be due to the 
increased HDL-C concentrations seen in the subjects who used estrogen.
The Leisure World Study (98) followed 8,841 women (aged 40-101) for 5-1/2 
years (40,919 person years) using a detailed health survey. The all-cause mortality for
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estrogen users had a relative risk of 0.80 (95% confidence interval, 0.70-0.91) as 
compared to nonusers, and for fatal MI the relative risk was 0.59 (95% confidence 
interval, 0.42-0.82). After 7.5 years of follow-up (99), women reporting a history of 
estrogen use had an age-adjusted all cause mortality risk that was 20% lower than non- 
estrogen users. Mortality was shown to decrease with increasing duration of estrogen use, 
and was lower in current users when compared to women who had used estrogen in the 
past.
In 1996 (100) a cohort of 292 postmenopausal women (aged 55-99) volunteered 
to participate in a study that was designed to assess the relationship between lipids and 
lipoprotein concentrations, and unopposed estrogen or combination hormone (estrogen 
and progestin) replacement use. Estrogen, unopposed or in combination, was negatively 
correlated to total cholesterol, LDL-C and positively related to HDL-C. This study 
showed no reduction in the beneficial effect found with unopposed estrogen in the women 
using combined HRT.
In contrast to the other observational studies, early reports from the Framingham 
Heart Study (101) reported an increased risk for cardiovascular disease in 1,234 
postmenopausal women (aged 50-83) who used HRT. The subjects were followed for 
eight years. Women who reported using estrogen , at one or more examinations, had 
over a 50% increased risk of cardiovascular morbidity (p< 0.01) as women who did not 
use HRT. However, when the data from this study was reanalyzed (102), excluding an 
endpoint of angina pectoris, the use of HRT was associated with coronary heart disease in 
only a small group of women who were 60-69 years old at baseline.
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The Nurses' Health Study is the largest ongoing observational study on the 
relationship of HRT and mortality in women to date (103). The study was initiated in 
1976 when questionnaires were mailed to 121,964 female registered nurses aged 30-55. 
Questionnaires sought information on personal and family medical history, menopause, 
smoking, height and weight, use of oral contraceptives and/or HRT, cancer, and 
cardiovascular risk factors. A total of 32,317 postmenopausal women without prior CHD 
have been followed for over twenty years for a total of 105,786 person years. Information 
has been updated with biennial questionnaires since 1976 to determine the relationship 
between postmenopausal hormone use and mortality among participants. Death was 
documented by medical records. Follow-up studies since 1985 (104), (105), (106), (97) 
have consistently reported a reduced risk of cardiovascular disease in women using HRT.
The most recent study reported by these researchers investigated the relationship 
between the use of postmenopausal hormones and mortality among participants of the 
Nurses' Health Study (107). Current hormone users were found to be at decreased risk of 
death (relative risk 0.63; 95% confidence interval, 0.56-0.70) compared to subjects who 
had never used hormones. However, this benefit was found to decrease after 10 or more 
years of HRT use because of the increase in mortality from breast cancer. It was also 
found that current users with coronary risk factors demonstrated the greatest reduction in 
mortality (relative risk 0.51; 95% confidence interval, 0.45-0.57), but subjects with low 
risk demonstrated less benefit (relative risk 0.89; 95% confidence interval, 0.62-1.28).
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The Effect of HRT on Lipids and Lipoproteins
Exogenous estrogen has been demonstrated to exert a cardioprotective effect on 
postmenopausal women. This is thought to be due in part to alterations in lipids and 
lipoprotein concentrations. Over the past 30 years, there have been countless studies 
investigating the effect of postmenopausal HRT on lipid and lipoprotein concentrations. 
The earlier studies involved unopposed estrogen, and the later studies the addition of 
progestins. This has offered researchers the opportunity to investigate the effect of 
estrogen independently and subsequently the modifying role of progestins. A large number 
of cross-sectional and longitudinal studies have assessed the influence of postmenopausal 
HRT on plasma lipoprotein concentrations, but the results of these studies reflect 
differences in study design, the size and characteristics of the subject pool, hormone 
formulations, treatment regimes, duration of hormone use, and laboratory methods (108).
A 1994 hypothetical decision analysis evaluated the relative risks and benefits of 
iong-term estrogen use in a cohort of 10,000 women at age 50. Health outcomes were 
extrapolated to age 75 (17). The results suggested that estrogen use for 25 years would 
decrease fatal CHD events by 48% and deaths from hip fractures by 49%. It is also 
indicated, however, that HRT use would increase deaths from breast cancer by 21% and 
endometrial cancer by 207%. In conclusion, the study suggested that the health benefits 
of 25 years of postmenopausal estrogen therapy exceeded the risks in this theoretical 
population.
Oral unopposed estrogen has been consistently shown to reduce total cholesterol 
and LDL-C, while increasing HDL-C and triglyceride concentrations. All forms of ERT 
(oral, transdermally, percutaneously, or subcutaneously) decrease total cholesterol plasma
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concentrations. Whitehead (109) reported that various studies have demonstrated 
between 5% and 20% lower values depending on the type of estrogen, the route of 
administration, and the dose. A review by Bush (110) of 10 randomized crossover studies 
of normolipidemic women showed an increase in serum triglyceride concentrations of 20- 
24% over baseline levels and an decrease in LDL-C concentration with oral estrogen use. 
Walsh (111) showed a dose dependent reduction of LDL-C, 15% with 0.625 mg CEE and 
19% with 1.25 mg CEE. The reduction in LDL-C with estrogen use is thought to be due 
to increased LDL-C catabolism that results in an increased number of LDL receptors and 
activity (112). Oral estrogens have been shown to increase HDL-C concentrations by 10- 
15% (110). The Lipid Research Clinics Study (113) reported a 10% higher HDL-C 
concentrations in subjects using CEE when compared to nonusers.
The Addition of Progestins to ERT: During the 1970's reports were appearing in the 
literature linking ERT with an increased risk of endometrial cancer (79). In order to 
minimize this risk, progestin was added to ERT. This study appeared to eliminate the risk 
and HRT became the treatment of choice. There was a concern, however, that the 
addition of progestins to the prescription might modulate the positive effects of estrogen 
on the cardiovascular and skeletal systems. A recent controlled clinical trial, The 
Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (63), was designed to 
investigate the effect of the addition of progestins to ERT on cardiovascular risk factors in 
postmenopausal women. This study involved 875 healthy postmenopausal women, aged 
45-64, who were randomly assigned to placebo, unopposed estrogen, or one of three 
combined estrogen/progestin regimes. Four aspects related to the risk of CVD were 
chosen as endpoints: HDL-C plasma concentrations, systolic blood pressure, serum
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insulin, and fibrinogen concentrations. The results of this study indicated that estrogen 
alone, or in combination with a progestin, improved lipoprotein concentrations and 
lowered fibrinogen levels without affecting insulin or blood pressure. The PEPI Trial 
provides clear evidence that unopposed estrogen has a more favorable effect on HDL-C 
than estrogen given with continuous or cyclic progestins. However, all hormone 
treatments were significantly better than the placebo in increasing HDL-C and lowering 
LDL-C.
It appears that the metabolic effects of the addition of progestin to ERT are 
related to dose, the relative androgenic potency of the hormone preparation, and the 
accompanying dose of estrogen. The addition of progestin is associated with increased 
triglyceride and VLDL-C plasma concentrations beyond what is seen with unopposed 
estrogen. Progestins increase hepatic lipase activity and appear to decrease hepatic VLDL- 
C production. In general, the 19-northestosteron derivatives, which have high androgenic 
activity, oppose the positive effects of estrogen on lipoprotein metabolism, decreasing 
HDL-C and increasing LDL-C concentrations. The 17-hydroxyprogesterone derivatives 
(low androgenic activity) have predominantly neutral effects on lipid and lipoprotein 
cholesterol levels (62). This was demonstrated in a controlled study conducted by 
Tremollieres et al. (114) in 1995 which assessed the long-term effect of a low androgenic 
progestin (Promegestone™) on serum lipids, renin substrate, and antithrombin activity. 
Thirty-five postmenopausal women were randomly assigned to a placebo or progestin 
group and were followed for 2 years. The results of this study showed no statistically 
significant differences in the biological parameters between the two groups.
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A study reported by Miller et al. (115) in 1994 investigated the qualitative and 
quantitative effects of two doses of estrogen before and after the addition of progestin. 
The 103 postmenopausal women in this study were randomly assigned to one of three 
groups for 4 months: no estrogen, 0.625 mg/day, or 1.25 mg/day. At four months the 
estrogen groups were given 10 mg/day medroxyprogesterone acetate (MPA) for 8 
months. After 1 year of treatment, the estrogen treated groups showed a decrease in 
LDL-C, but an increase in HDL-C and triglyceride concentrations when compared to the 
placebo group.
Nabulsi et al. (116) reported on a cross-sectional study of approximately 5000 
postmenopausal women. Subjects were categorized according to current hormone use: 
unopposed estrogen users, estrogen/progestin users, nonusers who had used HRT in the 
past, and those who had never used hormone replacement. Subjects using hormone 
replacement had higher triglyceride, HDL-C, and HDL2 than nonusers, as well as lower 
plasma concentrations of LDL-C. These researchers concluded that subjects who used 
combination HRT appeared to have a lower cardiovascular risk than those using 
unopposed estrogen.
A Medline search conducted of English-language articles published from 1981- 
1995 summarized the effect o f hormone replacement therapy on lipid and lipoproteins in 
postmenopausal women (117). The pooled results from 42 studies demonstrated a 
decrease in total cholesterol o f 14.4 mg/dL with continuous and 14.9 mg/dL with 
sequential HRT; a decrease in LDL-C of 17 mg/dL with continuous and 18.4mg/dL with 
sequential HRT; as well as an increase in HDL-C of 1.9 mg/dL with continuous and 3.1 
mg/dL with sequential HRT.
29
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The majority of studies conducted in the United States on postmenopausal 
hormone therapy and heart disease have used estrogen and most often Premarin™. There 
is a need for more randomized, controlled, clinical trials that utilize different forms of 
estrogen and include the addition of progestin to the formulations. Two new studies, the 
Women's Health Initiative and the HERS Study, will address these issues in the near 
future.
The Women's Health Initiative is the largest clinical study ever undertaken by the 
National Institutes of Health (NIH). Subjects were recruited from 45 communities 
throughout the United States in the fall of 1993 (118). This study o f approximately 
57,000 women aged 50-79 year old, will address the risks and benefits o f unopposed 
estrogen and estrogen plus progestin, a low fat diet, and a calcium and vitamin D 
supplement on cardiovascular disease, cancer, and osteoporosis. Results of the study are 
expected to be available in 2008 (92).
The HERS (Heart and Estrogen-Progestin Replacement Study) will investigate if 
HRT can prevent a second myocardial infarction (MI) in women who have already had a 
heart attack, coronary bypass surgery, angioplasty, or have been diagnosed as having less 
than 50% narrowing of one or more major coronary arteries. Results o f this study are 
expected within the next few years (24).
The use of exogenous hormones has been shown to result in favorable lipoprotein 
profiles in postmenopausal women. It is important to note that the changes demonstrated 
with hormone use is dependent on type, potency, combination, and dose of the hormones 
used. It is still unclear to what extent the alterations in lipoproteins contribute to the 
decreased incidence of cardiovascular disease demonstrated with HRT.
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Other Mechanisms
It is presently believed that =20-25% of the cardioprotective effects of estrogen 
are mediated by the beneficial changes seen in lipids and lipoproteins (109). The remaining 
75-80% is proposed to be mediated by several other mechanisms including estrogen’s 
beneficial effects on carbohydrate metabolism, clotting factors, antioxidant ability and its 
direct effects on the vascular system.
Disturbances in glucose metabolism have been shown to be predictive of 
subsequent coronary artery disease (119). This increased risk is accompanied by 
hyperinsulinemia and insulin resistance. It has been shown that insulin resistance increases 
progressively in postmenopausal women. It is also evident that ERT increases the 
pancreatic secretion of insulin and decreases insulin resistance. Androgenic progestins, 
however, may oppose these beneficial effects (120).
Interest in the effect of HRT on a woman’s homeostatic mechanism is growing. It 
has been demonstrated that the overall balance between coagulation and fibrinolysis results 
in a reduction in thrombosis in women using HRT (121). The effects of HRT on 
coagulation and fibrinolytic factors is variable depending on the type and dose of the 
hormone used (120). A recent study (122) demonstrated the beneficial effects ofHRT on 
fibrinolysis in 30 postmenopausal women (mean age 55 ±5 years). The oral administration 
of CEE alone or in combination with MPA (medroxyprogesterone acetate) inhibited 
plasminogen activator inhibitor (PAI-1) by 50%. The Framingham Offspring Study (123) 
reported high concentrations of PAI-1 in postmenopausal women when compared to 
premenopausal women. This increased concentration of PAI-1 is believed to contribute to 
the increased risk of atheroslerosis seen in postmenopausal women. In another group of
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women, transdermal estrogen administration, with and without progestin, did not decrease 
PAI-1 levels. It appears that only oral estrogen has an effect on PAI-1 and this suggests 
that the hepatic effects of estrogen regulate PAI-1 synthesis, clearance, or both in an 
important way.
A case-controlled study (124) was conducted as part of the UNHWHS that sought 
to determine the effect of HRT use on the risk of thrombotic disease in 171 healthy 
women aged 38-65. The use of HRT was not found to increase the risk o f thrombotic 
disease. The mechanism for protection involves lowing antithrombin III or protein C.
The authors suggest that the use of HRT in postmenopausal women could be protective 
by increasing circulating protein C concentrations.
There is also good evidence that estradiol has a direct and protective effect on the 
arteries. Animal studies have shown that there are active estrogen receptors present in 
both the heart and major vessels (125). Losordo et al. (127) showed that the intima and 
media of most atherosclerotic coronary arteries of both pre- and postmenopausal women 
lacked estrogen receptors, but receptors were found in the majority of atherosclerosis free 
vessels. Another study (127) also observed a decreased number of estrogen receptors in 
the coronary arteries of women with atherosclerosis when compared to normal control 
subjects, suggesting the receptor levels may be altered in disease states.
There is a growing body of evidence suggesting that a great deal of the 
cardioprotection of estrogen is mediated by its direct action on the vascular wall (128). 
Estrogen appears to enhance vasodilation and reduce vascular resistance, which in turn 
leads to an increased blood flow (129). Estrogen, directly or indirectly, may retard the 
development of fibrous plaque, favorably affect the vulnerability of existing plaque, or
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reduce the risk of an occlusive thrombus (130), (131). Exogenous estrogen use was 
found to reduce the incidence of restenosis in 204 postmenopausal women who had 
undergone a coronary angioplasty or atherectomy. This was thought to be due to 
estrogen’s effect on vasodilation in the coronary arteries, which works to reduce the 
pathologic vasodilation often seen after angioplasty (132). It is now clear that the 
beneficial effects of estrogen are mediated by many mechanisms other than its effect on 
lipid and lipoprotein serum concentrations. It is plausible that the cardioprotective effect 
of estrogen is mediated by a combination of mechanisms resulting in the overall beneficial 
effect seen with HRT.
Vitamin E and B-carotene as Antioxidants 
It has been suggested that estrogen alone, or in concert with the antioxidant 
nutrients, may confer protection against the oxidation to LDL-C, thereby preventing the 
development of heart disease. Epidemiological studies (133), (134) and clinical trials
(135), (136) indicate that populations with high intakes of antioxidants have a lower risk 
of heart disease. It is suggested that vitamin E (a-tocopherol) and beta-carotene (0- 
carotene) and may prevent the initiation of atherosclerosis and thereby reduce the 
morbidity and mortality o f coronary artery disease.
High serum levels of LDL-C are associated with the development of heart disease. 
Studies suggest that the atherogenicity of LDL-C is greatly enhanced by oxidative damage 
(137). In vitro, oxidized LDL shows a diminished affinity for the LDL-C receptor and an 
increased affinity for the macrophage scavenger receptor. This results in foam cell 
formation. The uptake of oxidized LDL by macrophages is not down-regulated by
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internalized LDL-C, and this results in the lipid loading of the cells. Oxidized LDL-C is 
cytotoxic towards vascular cells, and chemotactic towards monocytes (138).
Antioxidants may inhibit the oxidation of LDL-C, hence decreasing the risk for the 
development of atherosclerosis. The possibility that antioxidants may prevent or retard 
LDL-C oxidation is suggested by the fact that the core of LDL-C contains lipophilic 
antioxidants, such as a-tocopherol, 3-carotene, lycopene, ubiquinoi-10, crytoxanthin, and 
phytofluene (10), as well as estrogenic compounds. The antioxidants present in the LDL- 
C are believed to prevent the oxidation of polyunsaturated fatty acids within the LDL-C 
(11). The antioxidant vitamins, 3-carotene and a-tocopherol, react with highly reactive 
free radicals and inhibit LDL-C oxidation in in vitro systems and at pharmacological doses 
in vivo (139).
Vitamin E and 3-carotene reside in circulating lipoproteins and lipid membranes. 
These antioxidants are able to terminate chain reactions and quench free radicals that 
could ultimately result in LDL-C oxidation. Due to its lipid solubility, 3-carotene 
partitions in the lipid domain of biological membranes and lipoprotein particles. Alpha- 
tocopherol is the most abundant isomer of the vitamin E family and is the principle lipid- 
soluble chain-breaking antioxidant in tissue and plasma (140). Vitamin E has been shown 
to inhibit the proliferation of smooth muscle cells in vitro (140). When added to plasma, 
it increases the resistance of LDL-C to oxidation (141). Thus, LDL-C carries within it a 
number of natural antioxidants that can trap free radicals and interfere with and possibly 
prevent LDL-C oxidation (142).
Several studies have investigated the correlation between several dietary 
antioxidants and coronary artery disease with conflicting results. The Scottish Heart Study
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(143) investigated the correlation between diet and risk of coronary artery disease in 
10,359 men and women (aged 40-59). The men with the highest vitamin E intake 
demonstrated a significant reduction in risk of coronary heart disease. The trend was not 
found to be significant in women. The Optimal Vitamin Study, a follow-up to 
WHO/MONICA Core Study (134), evaluated 16 European populations regarding age 
specific CHD mortality. The results demonstrated a strong inverse correlation between 
lipid standardized a-tocopherol concentrations and CHD mortality rates.
The Nurses’ Health Study (144), (145) followed 87,245 female nurses (aged 34- 
59) for eight years to evaluate their consumption of vitamins through food and dietary 
supplements. There was an inverse relationship between risk of CHD and consumption of 
antioxidant vitamins. Women in the highest quintile of vitamin consumption, compared to 
those in the lowest quintile, demonstrated a relative risk of 0.66 (95% confidence interval, 
0.50-0.87) for vitamin E, a relative risk of 0.78 (95% confidence interval, 0.59-1.03) for 
p-carotene, and a relative risk of 0.70 (95% confidence interval, 0.53-.92) for vitamin A. 
All the results reported were adjusted for age, smoking, and other CHD factors.
The Physicians Health Study (135), a randomized, double-blind, placebo-
controlled 2x2 factorial trial of 22,071 US male physicians (aged 40-84) included a trial of
P-carotene and its role in preventing heart disease. Among the physicians who received
the P-carotene there was a 50% reduction in the risk of major coronary events, and a 54%
reduction in the risk of major vascular events. The Health Professionals Follow-Up Study
(136) evaluated dietary intake of vitamin E and P-carotene and the risk of cardiovascular
disease in a subset o f 39,910 healthy male professionals, aged 40-75. After controlling for
age and several coronary risk factors, the men with higher intakes of vitamin E had a 41%
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lower risk of coronary artery disease when compared to the men with the lowest intake. 
The greatest reduction in risk was found in men consuming 100-249 IU of vitamin E a 
day. (3-carotene intake was not associated with a lower risk for coronary artery disease in 
those men who never smoked, but was inversely correlated with current and former 
smokers.
The Relationship Between Antioxidants and HRT 
There have been several in vitro studies that have demonstrated the antioxidant 
properties of estrogen. When 17(3-estradiol was infused directly for 20 minutes into the 
brachial arteries of postmenopausal women, it delayed the onset and rate of copper- 
initiated oxidation of isolated LDL when compared to baseline values. Administration of 
estradiol for three weeks with a transdermal patch resulted in a similar protection from 
oxidation. This response was elicited at one third of the estradiol plasma concentration 
when compared to the acute administration method. This study demonstrated an 
antioxidant effect of physiological levels of estradiol (9).
Recent studies have suggested that estrogen alone or in combination with 
progestin may exert an antioxidant effect on LDL-C and lipids in the plasma membrane 
(9). One of the first in vivo studies to evaluate the antioxidant activity of three major 
estrogens found in PremaririrM, involved eight postmenopausal women in a prospective 
randomized cross-over study (146). Each subject received a randomized schedule of an 
oral treatment of estrone sulfate, equilin sulfate, or 17 a-dihydroequilin sulfate for 30 days 
each. The oxidation resistance of LDL-C was determined by the duration of the Iag-phase 
in copper-ion induced oxidation. The lag time was significantly increased with all three
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estrogens, with estrone sulfate conferring the greatest antioxidant activity. This study may 
explain in part the cardioprotective effect seen with the use of exogenous hormones in 
postmenopausal women.
A similar study demonstrated the effect of a combination of estrogen and progestin 
on LDL-C oxidation in a longitudinal prospective study of 39 healthy postmenopausal 
women (147). The subjects received a cyclic administration of conjugated estrogen 
(Premarin™) and medrogestone (Colpro™). After one year of treatment, this sequential 
hormone treatment resulted in beneficial effects on lipoprotein concentrations, but the 
results of LDL oxidizability were inconsistent.
A 1995 study (148) investigated if the cardioprotective effect of estrogen may be 
conferred in part by its antioxidant influence on LDL-C. Along with dietary assessments, 
changes in serum lipids, apolipoprotein B, a-tocopherol, P-carotene, retinol, LDL 
tocopherol, LDL P-carotene, and the susceptibility of LDL to oxidation, were determined. 
Measurements were taken at five intervals across two menstrual cycles in ten women 
cycling normally, and ten women taking oral contraceptives. Results showed significant 
and different changes in serum LDL-C, apolipoprotein B and total cholesterol across 
cycles in both groups. Serum and LDL P-carotene concentrations, and length of the lag 
phase varied significantly across cycle phase during the menstrual cycle. Serum retinol 
concentrations were significantly higher and LDL P-carotene concentrations were 
significantly lower in the group taking the oral contraceptives. These findings demonstrate 
a number of hormone related changes that influence the antioxidant protection of LDL-C 
in conjunction with dietary intakes of these micronutrients.
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Since there is a strong association of lipophilic vitamins with lipoprotein particles, 
some authors have suggested that this relationship should be expressed as the ratio of 
a-tocopherol and P-carotene serum levels to LDL content (149), (51). Clemente et al. 
(150) investigated whether HRT could confer an antioxidant effect on lipids and therefore 
preserve the vitamin E and 3-carotene in the LDL. Fifteenpostmenopausal women were 
treated with a cyclic administration of transdermal estradiol and oral medroxyprogeserone. 
After six months of treatment, there was a significant reduction in total cholesterol and 
LDL-cholesterol in the subjects. Although the serum levels of a-tocopherol and 3- 
carotene did not change, there was a significant increase in a-tocopherol/LDL and 3- 
carotene/LDL ratios. This study suggests that HRT may preserve and enrich the content 
o f a-tocopherol and P-carotene in LDL particles, as well as keep LDL in a reduced 
antioxidant state.
There appears to be evidence to support the protective effect of a-tocopherol and 
estrogen in decreasing the susceptibility of LDL to oxidative stress. The evidence for a 
similar effect due to P-carotene seems less clear. There is a need for more studies to 
evaluate the effect of an increased dietary intake of vitamin E and/or 3-carotene (alone or 
with supplements) and different regimes of hormone replacement therapy on the 
oxidizability of LDL.
Lifestyle Interventions
Lifestyle factors have been suggested to influence the development of heart
disease. Obesity, smoking, and central adiposity result in increased risk, whereas weight
control, regular exercise, stress reduction, and the cessation of smoking result in a
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decreased risk. Much of the research on the prevention and treatment of cardiovascular 
disease in women has focused on HRT. The benefit of positive lifestyle interventions 
(health supporting diet and exercise) on the overall health and well-being of older women 
has not been well documented. Little information is available as to the influence o f lifestyle 
factors in alleviating the acute symptoms of menopause and in preventing the development 
of chronic disease.
Diet: The role that diet plays in the management of plasma lipid concentrations has been 
recognized for some time (151). Diets low in total fat, cholesterol, and saturated fat, and 
high in soluble fiber and mono- and polyunsaturated fat have resulted in positive changes 
in serum lipid profiles in women. Many epidemiological and dietary studies have shown 
that increased intake of dietary sources of the antioxidant nutrients (3-carotene, vitamin C, 
and vitamin E) may also inhibit the development of cardiovascular disease (136), (152).
Epidemiological studies have shown that people who consume high amounts of 
antioxidant vitamins through diet and supplements have a decreased risk of cardiovascular 
disease (133). This link between antioxidants and disease is based primarily on evidence 
involving dietary intake or blood levels that reflect dietary choices, rather than 
supplements (153). Kushi et al. (154) surveyed 34,486 healthy postmenopausal women 
using a questionnaire on dietary intake of vitamins from food and supplements. After 
seven years of follow-up, the women with the highest dietary intake of vitamin E 
demonstrated the lowest risk of coronary artery disease; women with the lowest intake, 
the highest risk. No such association was found when intake from supplements and diet 
was included. This study suggests that women can lower their risk of heart disease 
without using supplements. No such association was found for 3-carotene in this study.
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Many dietary factors affect plasma lipids and lipoproteins. Studies have shown 
that dietary factors are predictive of blood lipid concentrations in women. High dietary 
intake of saturated fat is a negative predictor of serum total cholesterol, LDL-C, and 
HDL-C in premenopausal women (155), (156). In a study on aging and nutrition, Garry 
et al. (157) assessed dietary intakes and blood lipid concentrations in 92 postmenopausal 
women over a nine year period. This study found that decreased intakes of total and 
saturated fat were correlated with beneficial changes in plasma total cholesterol and 
triglyceride concentrations.
Techniques for Measuring Dietary Intake: Many methods are used to evaluate food intake 
in research studies. Food records are used to provide quantitatively accurate information 
on food consumed during the recording period. Food records are considered the "gold 
standard" against which other dietary assessments are compared. By recording foods as 
they are consumed, the problem of omission is decreased and foods and portions are 
described more fully. The food record is a prospective instrument that is used frequently 
in research and clinical environments (158).
The food frequency questionnaire is a method that is utilized to evaluate the 
dietary intake of particular foods or food groups on a daily, weekly, or monthly basis.
This method determines usual frequency and consumption of foods over the past year and 
can circumvent recent changes in diet. Unlike the food record, it is retrospective and 
requires recall on the part of the subject (158). The use of both the food frequency 
questionnaire and a three day food record in a research study can offer both a prospective 
and retrospective analysis of dietary intake, and is felt to represent a more comprehensive 
evaluation of a subject's diet.
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Changes in Body Composition with Aging: Menopause is associated with changes in 
body composition and fat distribution. During this time there is a decrease in lean body 
mass and an increase in fat mass, as well as a shift from a gynoid to an android fat 
distribution (159). Of the 541 women involved in the Healthy Women Study, 20% gained 
20 or more pounds with an average five pound weight gain during the perimenopausal 
time (160). The subjects in this study, based on a 24 hour recall and a food frequency 
questionnaire, reported eating approximately 37% of total calories from fat (13% 
saturated fat). Few women ate diets with less than 20% total calories from fat.
All levels of overweight are associated with an increased risk of cardiovascular 
disease in women, although being obese with a body mass index (BMI) of greater than 29 
carries the greatest risk (161), (162), (163). Obesity is not an independent risk factor for 
coronary heart disease, but is associated with other cardiovascular risk factors such as 
hypertension, dysplipidmia, hyperinsulinemia, insulin resistance, and diabetes mellitus 
(162). Data from the Nurses ’ Health Study (164) found that the lowest mortality rates 
were in those women who weighed 15% less than the US average for women of the same 
age, and among those women who had maintained their weight since age 18. Added to 
the deleterious effects of body weight on the lipoprotein blood profile, some data suggests 
that obese subjects (BMI >30) may also have a blunted response to a low fat diet when 
compared to leaner subjects (165). Denke et al. (166) reported that a higher BMI in 
both pre- and postmenopausal women was associated with higher triglyceride levels (+35- 
48mg/dL) and lower HDL-C levels (-5-9mg/dL) than average weight women. Stevenson 
et al. (167) investigated the influence of age and menopause on serum lipids and 
lipoproteins in 542 non-obese pre-and postmenopausal women (aged 18-70). This study
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found that BMI was related positively to both total cholesterol and low-density lipoprotein 
concentrations.
The increase in body fat, particularly upper body (android) fat, that is seen 
following menopause appears to be an important risk factor in postmenopausal women 
(168). Although obesity and weight loss affect plasma lipids and lipoproteins, a number of 
studies have shown that centrally distributed adiposity affects both plasma lipoproteins and 
the incidence of ischemic heart disease and myocardial infarction (MI) (68). A waist/hip 
ratio of greater than 0.80 and/or a BMI of greater than 25 is considered high risk in 
women. In contrast to men, localization of adipose tissue appears to be more important 
than obesity in the risk of heart disease in women (169). Greater upper body fat and 
weight gain are positively correlated with high triglycerides, hypertension, and lower 
HDL-C concentrations (170). In 1,275 women in the Rancho Bernardo Study (aged 50- 
89), fasting triglyceride levels were positively correlated with waist/hip ratio and inversely 
correlated with HDL (171).
There is a common perception among women that the use of HRT may result in 
weight gain. Reubinoff et al. (159) reported on the effect of HRT use on body weight and 
body fat distribution in 63 postmenopausal women (aged 44-54). After one year of use, 
HRT neither prevented nor increased weight gain and fat accumulation, but did minimize 
the shift from gynoid to android fat distribution. Changes in body composition (BMI and 
waist-hip ratios) have been shown to have deleterious effects on lipoprotein profiles in 
postmenopausal women. It is therefore important to evaluate body composition when 
determining cardiovascular risk factors in aging women.
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Exercise During and After Menopause: The increased risk of heart disease seen in 
postmenopausal women is related both to the aging process and the cumulative effects of 
adverse lifestyle habits, especially diet and exercise. The role that exercise plays in 
reducing this risk is complex and to date the data is inconclusive and lacking for the 
amount and type of exercise needed to reduce CVD risk.
Exercise has been shown to beneficially affect the plasma lipoprotein levels in 
women. Exercise has been shown to stimulate the production of HDL-C providing a 
cardioprotective effect and active women have higher HDL-C concentrations than their 
sedentary counterparts (172). Cross-sectional studies report a consistent relationship 
between exercise and increased plasma HDL-C levels, however few studies have 
controlled for exercise intensity and duration, age, gender, hormonal status, body weight 
and composition (67).
Although there is strong evidence of the beneficial effects of exercise in women, 
studies to date have been difficult to evaluate for several reasons. It was not until the early 
1980’s that studies on physical activity included women. A 1987 review by Powell (173) 
of the role of physical activity in the primary prevention of coronary heart disease 
concluded that physically active individuals are at lower risk for coronary heart disease 
than less active people. Of the 43 studies included in this review, only five presented data 
on women separately. Historically, studies on physical fitness have used men, and those 
who have included women have demonstrated inconsistent results. The flaw in assessing 
physical activity in women tends to be the instrument used. Most studies have used 
questionnaires that have been validated and used on men. These questionnaires tended to 
focus on sports activities and other physical activities in which women typically did not
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participate. Since women have traditionally engaged in less vigorous activities than men, 
the results tended to demonstrate that there was no decreased risk to women engaging in 
physical activity. Thus, these studies did not adequately evaluate the activities that women 
were involved in at the time (child care and homemaking) and therefore miscalculated the 
exposure variable. When leisure-time activities were included, the differences 
disappeared (174).
Some research has also suggested that there may be a gender difference in 
response to exercise. Body composition and hormonal factors may account for the 
differences in exercise capacity and occurrence of cardiovascular disease. Heart rate is 
higher and VO2 max is lower in women than in men at all ages. When Blair (175) used 
treadmill performance as a measurement of physical fitness in women he reported a 
relative risk over eight years of 3.92 for women and 1.82 for men in the lowest fitness 
group as compared to the highest fitness group, suggesting different physiological 
responses to exercise between women and men. In this study, the lack of an association 
between inactivity and mortality demonstrated in women was likely due to inadequate 
measurements of physical activity (176). This suggests that women should not be 
evaluated in the same way as men in regard to physical fitness and exercise.
Until the 1960's, there was considerable doubt as to whether middle-aged and 
older people could benefit from exercise, due to the perception that there was a decline in 
cardiorespiratory function with age. For women over 50, it was thought that the decline 
in function would mitigate the beneficial effects of exercise, and that the hormonal 
changes associated with menopause could decrease aerobic fitness. White et al. (177) 
followed a group of previously sedentary women between the ages of 50-63 through a six
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month program of either aerobic dance or walking. The women were matched with 
respect to age, weight, past activity, and pretest fitness. Both groups engaged in their 
respective exercise for 30 minutes a day, four days a week at 70% of their maximal heart 
rates. At the end of the six months, both groups demonstrated increases in fitness and 
strength and decreases in resting and recovery heart rates.
Cowen and Gregory (178) investigated the responses of 20 pre- and 18 
postmenopausal women to aerobic conditioning throughout their participation in a 
progressive walking program to determine the ability to improve cardiorespiratory 
endurance and body composition. The subjects participated in a progressive walking 
program four days a week for nine weeks at 80% of maximum heart rates. Both 
premenopausal (mean age 41.3) and the postmenopausal (mean age 55.7) group improved 
their cardiorespiratory endurance, by 12.1% and 19% respectively, and significantly 
reduced their percent body fat when compared to controls. Notelovitz et al. (179) also 
challenged the theory that hormonal changes contribute to cardiorespiratory decline when 
comparing pre- and postmenopausal women on a bicycle ergometer test. Results showed 
no significant differences in their estimated aerobic capacity values. These studies 
demonstrate that women can benefit from physical training programs regardless of 
menopausal status, and that cardiorespiratory fitness does not decrease with age in 
physically active women.
In 1991 the American College of Sports Medicine Prevention and Rehabilitative 
Exercise Committee recommended that healthy women should participate in continuous 
physical activity a minimum of 20 minutes a day, 3 days a week. The aerobic activity 
should sustain a heart rate of 70-85% maximal heart rate to avoid a decline in
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cardiorespiratory fitness (180). In 1995, an expert panel (181) comprised of researchers 
with an expertise in issues related to the health implications of physical activity was 
established by the Centers of Disease Control and Prevention and the American College of 
Sports Medicine. The members of this panel reviewed all the pertinent physiological, 
epidemiological, and clinical evidence from primary and review articles on the health 
implications of physical fitness. Their recommendation was that every American adult 
should engage in 30 minutes or more of moderate-intense physical activity most and 
preferably all days of the week. It was also determined that this activity could take place 
in short bouts, and that intermittent and moderately intense activity (gardening, 
housework, walking) confers substantial benefits in decreasing the risk of cardiovascular 
disease.
Two recent studies have applied the recommendations of the expert panel 
specifically to women. An hour a day of moderate activity (brisk walk or swimming) was 
found to reduce the risk of heart attack by 44% and ischemic stroke by 56% in women 
compared to sedentary controls (182). The second was a case-controlled study (183) that 
evaluated the benefits of leisure-time activity in postmenopausal women. The case 
subjects were 268 women who had been hospitalized for a heart attack and the control 
subjects were 925 healthy matched controls. The women who engaged in modest leisure 
activity for 30-45 minutes at least three times a week had a 50% decreased risk of having 
a heart attack when compared to sedentary counterparts.
Although there has been documentation on the benefits of moderate exercise on 
cardiovascular risk in women, many experts assumed that higher levels of physical activity 
were needed to impact HDL-C concentrations. Williams (184) evaluated the response of
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HDL-C to exercise and found that women who exercised at levels exceeding the current 
guidelines had the most substantial increases in their HDL-C plasma concentrations. The 
Stanford Weight Control Project II (185) investigated the effect of diet with or without 
exercise on HDL-C concentrations in moderately overweight men and women. The 112 
women in the study were randomly assigned to one of three groups: control, diet only 
(low fat and low calorie), or diet and exercise combined. After one year of treatment, 
both intervention groups lost weight and demonstrated a decrease in LDL-C, but the 
exercise groups also showed an increase in HDL-C that was not seen in the diet only 
group. This study demonstrated that physical activity and diet can have interactive effects 
in improving lipoprotein patterns, thus decreasing risk of coronary heart disease in 
women.
Since exercise is also known to reduce stress, physical activity may be useful in 
alleviating some of the secondary symptoms associated with menopause such as fatigue, 
depression, and tension. Empirical research has clearly established the effects of exercise 
on physical and psychological well-being. Exercise has been shown to decrease 
depression and anxiety while positively affecting self-esteem and general mood state 
(186). A recent study (187) measured mood states and symptoms reported by 93 
premonopausal, 32 perimenopausal, and 54 postmenopausal without HRT, and 41 women 
currently using HRT. Two validated instruments were used to measure moods and 
symptoms in these women.
The first instrument is the POMS (Profile o f Mood States) (188) which consists of 
65 items and provides subscales on six mood states: depression, tension, anger, fatigue, 
confusion, and vigor. The second instrument is the WHQ (Women's Health
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Questionnaire) (189), a 37-item scale that is designed to assess well-being in middle-aged 
women. It provides scores on nine factors: depressed mood, memory and concentration 
problems, somatic symptoms, vasomotor symptoms, anxiety and fears, sleep problems, 
sexual dysfunction, menstrual symptoms, and perceived physical attractiveness.
The women in the study who exercised regularly (aerobic floor exercises or brisk 
walking, for a minimum of 2 times a week for 30 minutes a session) were compared to 
sedentary women using the two instruments. Across all menopausal groups, women who 
exercised scored significantly higher than sedentary women on seven of nine subscales of 
the WHQ and on five of the six subscales of the POMS. As a whole, women who 
exercised and postmenopausal women who were using and not using HRT, and exercised 
regularly reported fewer symptoms than sedentary women. The same study also 
investigated the effect of an acute bout of exercise (45-minute aerobic class) on moods 
and symptoms found significant enhancements in mood and reductions in symptoms 
immediately following this type of exercise. When evaluated together, these results 
suggest that women, regardless of menopausal status and use of HRT, exhibit similar and 
beneficial responses to exercise in regard to mood and symptom relief.
There have been suggestions that exercise might also reduce the incidence and 
severity of vasomotor instability due to an increase in endorphin levels (190). One study 
(191) found that physically active women reported fewer moderate to severe hot flashes 
than women who were sedentary. Women who participated in aerobic exercise reported a 
increased sense of well-being and were better able to manage stress (68). McCann and 
Holmes (242) reported that depressed women who did strenuous exercise had significantly
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greater decreases in depression than women who did relaxation exercises or no exercise at 
all.
The literature clearly demonstrates the beneficial effects of positive lifestyle 
interventions on the health profiles of postmenopausal women. More research needs to be 
directed at determining the effect of lifestyle changes as an alternative or adjunct to 
hormone replacement therapy.
The Psychological and Social Aspects of Menopause
Women’s attitudes towards menopause may influence their menopausal 
experience. Experiences associated with menopause include vasomotor symptoms, such as 
hot flashes and night sweats; psychosomatic symptoms including palpitations and 
dizziness; and psychological symptoms, such as fatigue, nervousness, forgetfulness, 
irritability, and loss of concentration (192). The research does not support the occurrence 
of these symptoms in the majority of women. Of these symptoms, only vasomotor 
instability has been unequivocally linked to menopause (193). Although 75% of all 
women experience hot flashes (22), only 12% report that they have symptoms severe 
enough to interfere with work or social life (194). Many women start HRT to relieve hot 
flashes (22) and it has been suggested that some of the symptoms reported during 
menopause are due to hot flash induced insomnia (195). Most women report that their 
symptoms are mild and transient and the majority of women regard the menopausal 
experience as uneventful.
A. Medline search was conducted for the years 1984-1994 for the purpose of 
identifying the articles on menopause. The number of articles on menopause from all
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sources was 9,018. The majority of these articles focused on the medical treatment of 
menopause, the most frequent topic being HRT. Articles having a social or psychological 
focus totaled 500 (« 6%) and the majority o f these dealt with depression or moods. A 
parallel search of the PsychLit database cited 227 articles on menopause and only 67 
(w 30%) were related to psychosocial aspects of menopause; and the most frequent topics 
were distress and depression (196).
Menopause is a highly complex event with multiple and diverse influences that 
requires understanding of the psychological, social and cultural influences as well as the 
biological factors involved (197). To date the majority of information on menopause has 
focused on the biological aspects and there is a need to include other factors in research 
on menopause and hormone replacement.
Several authors have suggested that this lack information on the social and 
psychological aspects of menopause is due to the “medicalization” of menopause (198), 
(199), (200). Medicalization is defined by Schneider and Conrad (201) as “defining and 
treating human experiences as medical problems”. This also raises the question as to 
whether menopause is a disease state due to an estrogen deficiency or a natural transition 
in a woman’s life. As Freeman commented in 1989 (202), “menopause remains the one 
normal female process that is still overtly referred to as a disease in the medical literature”.
The impact of these negative perceptions of menopause is confirmed by the 
literature. In The Healthy Women Study (203), (204), an ongoing study of the natural 
history of menopause, 541 healthy women (aged 42-50) were recruited in Allegheny 
County, Pennsylvania. These women were not using any type of medication, including 
HRT upon entry into the study in 1993-1994. At this time, the women’s attitudes toward
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menopause and symptoms were evaluated. The women were followed longitudinally at 2, 
5, and 8 years and were reevaluated when they had either stopped menstruating or had 
used HRT for twelve months. At the same time, age-matched premenopausal women 
were reevaluated so that comparisons could be made cross-sectionally. Women had 
negative expectations regarding menopause, but were more optimistic about their own 
experiences than that of other women. At study entry, 80% of the women agreed that 
women were likely to get depressed during menopause and 55% thought they would get 
depressed. In actuality, when these women were compared with the premenopausal 
control group, no differences were found in standardized measures of depression, 
menopausal symptoms, anxiety, or anger in the women who did not use HRT. The 
postmenopausal women reported less stress in their lives over time, when compared to the 
control group. This study concluded that natural menopause did not have negative mental 
health consequences for the majority of women. Several other studies have reported 
similar results and concluded that menopausal status is not related to psychological 
distress (195), (205), (206). Even though women have negative expectations prior to 
menopause, these are for the majority of women unfounded.
The common belief that menopausal women are anxious and depressed is not 
confirmed by research studies. Epidemiological studies from the United States (30),
(207), Sweden (208) and England (209) have consistently failed to document an increase 
in depressive symptoms at the time of menopause compared to other times. In fact clinical 
depression is rarely seen in menopause and is most likely to occur in women who have 
previously experienced depression (210).
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Depression during menopause has been shown to be more prevalent in 
perimenopausal (211) rather than postmenopausal women. It is also evident that women 
who have undergone a surgical menopause tend to score lower on depression scores than 
women who had experienced a natural menopause (206). Lennon (212) found that the 
timing of menopause was an important factor in the reported stress associated with 
menopause. She found that women who reported menopause during mid-life (ages 44-54) 
did not experience psychological distress. She did however find that women who 
experienced either an early (<age 44) or late (> age 54) menopause exhibited a significant 
increase in distress and depression scores.
Attitudes, symptoms, and degree of depression were measured by validated 
instruments in a random sample of 149 women (aged 35-65) stratified by occupation, age, 
and race in a study by Wilbur (3). Unlike the majority o f studies to date that have 
involved only middle-class white women, this study included 44% African American and 
56% white women. The majority of the women, regardless of ethnicity, education, 
occupation, or socioeconomic status, had neutral feelings toward menopause, with 
postmenopausal women reporting the most positive attitudes. A significant correlation 
was found between positive attitudes toward menopause and an increased number of 
children, particularly in white women. In contrast to previous reports, this study found 
that women who had experienced a surgical menopause did not have higher levels of 
depression, and that physical symptoms were not related menopausal attitudes. A 
negative attitude toward menopause was associated with depression and low well-being in 
both white and African-American women independent of age and menopausal status. As
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confirmed by other studies, depressed women have more negative attitudes toward 
menopause.
It is important to consider the fact that many women in mid-life are often 
experiencing other changes in their personal lives concurrent with the menopausal 
experience. Menopausal women are disproportionately at risk for divorce, illness or death 
of spouse. Also death or disability of a parent, children leaving home, and other major life 
events (187), (38) are likely to occur at this time. Many of the symptoms reported during 
menopause may be due to environmental factors or the aging process that are independent 
of menopause.
The National Health Examination Follow-up Study (195) examined whether 
menopause was associated with three measures of psychological distress: depression, lack 
of well-being, and sleep disturbances. A cohort o f3,049 women aged 40-60 were 
assigned to four groups based on their menopausal status: premenopause, perimenopause, 
natural menopause, and surgical menopause. In the ten year follow-up interval, no 
increase in any of the three psychological distress categories was associated with the 
menopausal transition, the number of years since menopause or the timing of the 
menopausal transition.
Social, cultural, individual, and environmental factors intersect to influence the 
menopausal experience in each individual woman (211) and it is important to consider all 
of these when investigating menopause and the impact of HRT.
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Conclusions
After an extensive review of the related literature, the focus of this dissertation 
research was to investigate menopause from a comprehensive perspective that involved 
the physiological, psychological and social factors that influence a woman's choice in 
regard to hormone replacement therapy and the consequences of that choice.
Physiologically speaking, a woman's risk for certain chronic diseases, including 
heart disease and osteoporosis, increases following menopause, as do acute symptoms, 
presumably due to the decreased production of estrogen. Psychologically, a woman’s 
choice may be influenced by moods, depression, or other psychological distress. There are 
many social influences as well, including expectations and ideals surrounding the aging 
process. It is important to consider all of these factors when exploring the decision 
women make regarding HRT.
Physiological studies (4), (213) suggest that between 25-50% of estrogen’s 
positive effects on heart disease risk is due to the changes in HDL-C and LDL-C levels. 
This implies that ~50-75% of the beneficial effects of estrogen is through other 
mechanisms. These may include estrogen’s beneficial effects on carbohydrate metabolism, 
clotting factors, antioxidant ability and its effects on the vascular system. LDL-C 
oxidation is an important occurrence in atherogenesis (214). It has been proposed that 
estrogen, aside from its effect on lipoprotein metabolism, may protect against 
atherosclerosis by inhibiting the oxidation of LDL-C, an important component in 
atherogenesis (214). The antioxidant nutrients, a-tocopherol (vitamin E) and B-carotene, 
have been shown to also inhibit oxidation of LDL-C (215).
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Psychological factors may also influence a woman’s choice regarding HRT. The 
idea that women suffer debilitating symptoms and depression during menopause is 
unfounded. Although 75% of all women report vasomotor instability during this time, the 
majority do not report that the symptoms are severe enough to result in disruption of 
normal life. The idea that menopause leads to depression is also unfounded. Only women 
who are depressed prior to menopause report depression during menopause. The primary 
reason for the institution of HRT is for the relief to vasomotor instability. Research has 
demonstrated that for the majority of women, menopause is uneventful and that most 
women report that their expectations of adverse reactions is unfounded.
Cultural and social factors may influence a woman’s choice regarding HRT use 
also. Attitudes regarding menopause have been created largely by a medical model which 
portrays menopause from a negative perspective. A 1988 survey mailed to physicians and 
menopausal women reported that 21% of the physicians when asked to name the major 
health problem of mid-life women responded with "menopause"; none of the women 
surveyed offered this response. In regard to attitudes toward menopause and women's 
health, women in this study were found to be more positive than the physicians 56% of the 
time (216).
It is also important to take into consideration the limitations of previous studies on 
when interpreting the HRT-heart disease association. The majority of early studies on 
HRT and cardiovascular disease involved unopposed and almost exclusively Premarin™. 
The research on HRT has focused on highly educated, middle-class white women who 
have the greatest access to health care. Socioeconomic status is a powerful predictor and 
inversely associated with mortality and morbidity, for almost every disease and condition,
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including heart disease and cancer (217). There is also a linear relationship between 
educational attainment and mortality (218). Thus, subjects in these vanguard studies may 
enjoy a “healthy cohort effect” which could result, in part, to the decreased risk seen in 
postmenopausal women using HRT (34). Fifteen years ago physicians were reluctant to 
prescribe HRT to women with a high risk for heart disease or diabetes, leaving the healthy 
women to take HRT (34). Women who undergo a surgical menopause are more likely to 
use HRT and to continue its use on a long-term basis. They are also younger, utilize the 
health care system more and are more likely to have early diagnoses and treatment of 
medical problems than women who experience a natural menopause. Many studies include 
both types of menopause without defining the groups. Although women with a surgical 
menopause should be included in menopause studies, they should be studied, analyzed, 
and reported as a separate group. There is also confusion in many studies in regard to 
duration and type of hormone use, with unclear definitions of “current” vs “ever” vs 
“past” hormone replacement use. (219).
It is estimated that one fourth of all postmenopausal women in the United States 
are taking some type of HRT (77). Women who are currently using estrogen tend to 
participate in more preventative health care regimens and show greater behavior change 
(17). Hormone replacement therapy is often not available to the women at greatest risk of 
chronic disease because these women do not typically have access to health care and 
diagnosis of chronic diseases are often delayed.
Much of the data on the association between CVD and HRT comes from The 
Nurses' Health Study. The results of this study provide an indication of the health risks 
faced by women who have good access to health care, exercise programs, and healthy
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diets. Kaufert (38) warns that generalizations beyond this social context have to made 
with extreme caution.
Much research on hormone replacement therapy has been focused on physiological 
outcomes and treatment of menopausal symptoms. There is a need to also investigate 
how women view and experience menopause. Understanding menopause merits 
consideration of the social, cultural, and psychological as well as the biological factors 
(196).
At the turn of the century, the average life expectancy for an American women 
was 50, today it is almost 80. Forty million American women are in or past menopause 
and another 20 million are due to reach menopause in the next decade (220). With 
increased awareness and emphasis on women’s health issues, women are now better able 
to obtain the knowledge and information necessary to exercise control over their health 
and well-being.
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CHAPTER El




Subject protocol. A cohort of 70 healthy postmenopausal women, aged 48-66 with a 
mean age 55.84 (± 4.43 years), who had experienced a surgical or natural menopause and 
were nonsmokers, were recruited from faculty and staff at the University of New 
Hampshire in May 1995 and Plymouth State College, Plymouth, New Hampshire in May 
1996. Subject were divided into one of three groups dependent on their use of exogenous 
hormones: no hormone replacement (n = 36); estrogen only (n = 11); and estrogen and 
progestin (n = 23). Menopause was confirmed by the cessation of menses for at least one 
year. The women who were taking estrogen and progestin confirmed that they had not 
had a menstrual cycle for at least one year prior to initiating use of HRT. All women in 
the hormone replacement groups had been on medication for at least one year. The 
women in the no hormone group had not used any type of hormone replacement for at 
least one year.
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Volunteers for the study responded to a letter of interest (Appendix C) mailed to 
all faculty and staff at the two institutions as part of the University o f New Hampshire 
Women’s Health Study. Women interested in participating were contacted by phone to 
confirm that they were non-smokers, postmenopausal, and to determine the dose and type 
of HRT they were presently using. A brief description of the study and the candidate's 
participation was explained. Those qualified and interested were scheduled for evaluation 
and blood sampling within a month’s time.
Once accepted into the study, the subjects reported in a fasted state to the study 
site at the University of New Hampshire or at Plymouth State College. They were then 
asked to sign a consent form approved by the University of New Hampshire Institutional 
Review Board (Appendix C). A medical history was taken to verify the type and dose of 
hormone replacement, as well as prescription and non-prescription drugs and personal and 
family health risk factors (Appendix C). The subjects also completed a comprehensive 
lifestyle and medical questionnaire that gathered information regarding health, menopause, 
decision making, self-esteem, and mood states {University o f New Hampshire Women's 
Health Study Questionnaire: Appendix C). Each questionnaire was identified by the 
number of the subject only to insure confidentiality.
Anthropometric assessments were conducted which included height and weight, 
body-mass index, and determination of waist-hip ratio. Each participant was weighed in 
light street clothes without shoes on a balance-beam institutional scale. Height was 
measured without shoes with subjects facing straight ahead with head against the 
measuring tool on the balance beam. Body-mass index was calculated using weight in 
kilograms divided by the square of height in meters. Using a tape measure, waist-to-hip
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ratio was taken by measuring the waist circumference (at the umbilicus) and the hip 
circumference (at the largest point between waist and buttocks).
The dietary information on the subjects was obtained by using both a food 
frequency questionnaire and a three-day food record. The three-day food record 
(Appendix C) included all foods and beverages consumed for two consecutive weekdays 
and one weekend day. Portion size was demonstrated using food models (Nasco Inc., 
Fort Atkinson, WI). The data from the food records was then analyzed with a 
microcomputer using two computerized analysis programs. The food frequency 
questionnaire utilized the Health Habits and History Questionnaire: Diet History and 
Other Risk Factors Dietary Analysis System (DIETSYS Version 3.0) developed by the 
National Cancer Institute Information Management Services, Inc. Block Dietary Data 
Systems (Appendix C). The three-day food diary analysis system was based on data from 
the United States Department of Agriculture using Nutritionist IV™ for Windows Diet 
Analysis (version 4.1) software (First DataBank, San Bruno, CA).
Collection and Analysis of Blood Samples 
A fasting blood sample was drawn from the antecubital vein into four vacutainers: 
13 cc serum separation vacutanier tube, 7cc plasma separation vacutainer with EDTA 
(K3), 7cc plasma separation vacutainer with freeze-dried sodium heparin, and 7cc plasma 
separation vacutainer with sodium citrate. The blood draws were conducted in the 
Nursing Laboratory at the University of New Hampshire and Plymouth State College
After the blood was drawn, the tubes were immediately wrapped in aluminum 
foil to protect the photosensitive pigments from exposure to light. The serum samples
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were then allowed to clot at room temperature for thirty minutes. Both the sera and 
plasma were then centrifuged at 1400G for 15 minutes at 4°C, and aliquoted into 
cryovials. Samples were stored at -70°C until assayed.
The analyses of the samples was conducted as follows:
1. * Serum triglyceride, total cholesterol. LDL- and HDL-concentrations.
2. Serum antioxidant concentrations fa-tocopherol and B-carotenel concentrations.
3. Serum progesterone and estradiol concentrations.
4. Serum oxygen radical absorbencv capacity fORACI for total antioxidants.
5. Plasma -»LDL isolation—»protein concentration—> LDL antioxidant concentrations.
6. Plasma —>LDL isolation—>protein concentration—> LDL susceptibility to oxidation.
7. Plasma lipoprotein (a).
* Fresh sera was used in these assays.
Serum Total Cholesterol. Serum total cholesterol concentrations were determined 
utilizing the Sigma Diagnostics #352 Kit. This method measures cholesterol 
enzymatically and is a modification of the method of Allain et al (221). A cholesterol 
reagent is used that hydrolyzes the cholesterol esters in the serum to cholesterol. The 
cholesterol is then oxidized by cholesterol oxidase to cholest-4-en-3-one and hydrogen 
peroxide. The hydrogen peroxide produced is then coupled with the chromogen to yield a 
quinoneimine dye which has an absorbence maximum of 500 run. The intensity of the 
color produced is directly proportional to the total cholesterol concentration in the sample.
In the assay the lyophilized reagent is reconstituted with 100 mL of deionized 
water and mixed by inversion. A series of test tubes are set up and 1.0 mL of reagent is
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added to each tube. This is followed by the addition of 10ml of deionized water to the 
blank, calibrator, control, and sample respectively and each tube is vortexed briefly. All 
tubes are then incubated for 10 minutes at 30° C and read on a spectrophotometer at 500 
nm within 30 minutes after end of the incubation time. Total cholesterol concentration is 
calculated in mg/dL:
A test-A Blank X Calibrator (198 mg/dL)
A Calibrator-A Blank
Serum Triglyceride. Serum triglyceride was quantified using Sigma Diagnostics Kit
#336. The reagent creates an enzymatic reaction in which triglycerides are first
hydrolyzed by lipoprotein lipase to glycerol and free fatty acids. Glycerol is then
phosphoryiated by adenosine-5-triphosphate (ATP) to form glycerol-1-phosphate (G-l-P)
and adenosine-5-diphosphate (ADP) in a reaction catalyzed by glycerol kinase (GK). The
G-l-P is oxidized to dihydroxyacetone phosphate (DAP) with the concomitant reduction
of nicotinamde adenine dinucleotide (NAD) to NADH in the reaction catalyzed by
glycerol-1-phosphate dehydrogenase (G-l-PHD). The NADH is oxidized with the
simultaneous reduction of 2-(p-iodophenyl)-3-nitrophenyl-5-phenyltetrazolium chloride
(INT) to ENTH (formazan in the presence of diaphorase). The resulting formazan is
highly colored and has an absorbence at 500nm. The intensity of the color produced is
directly proportional to the concentration of triglyceride in the sample.
In the assay the lyophilized reagent is reconstituted with 100 ml of deionized water 
and mixed by inversion. A series of test tubes are set up and 1.0 mL of reagent is added 
to each tube. This is followed by the addition of 10 pi of deionized water to the blank, 
calibrator, control, and sample respectively and vortexed briefly. All tubes are then
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incubated for 10 minutes at 30°C and read on a spectrophotometer at 500 nm within 30 
minutes after end of the incubation time. The triglyceride concentration is calculated in 
mg/dL:
A test-A Blank X Calibrator (250 mg/dL)
A Calibrator-A Blank
Serum HDL Cholesterol. Serum HDL cholesterol was quantified using Sigma
Diagnostics Kit #352-3. Dextran sulfate and Mg ions precipitate LDL and VLDL,
leaving the HDL fraction in solution. The cholesterol in the supernatant is then assayed
with the same procedure used for determining total cholesterol concentration, using the 50
ml of HDL reagent and 500 mL of sample. The calculation used to determine HDL
concentration in mg/dL:
A test-A Blank X 50 X 1.1 
A Calibrator-A Blank
Serum LDL Cholesterol. Serum LDL-C concentration was then calculated using the
following formula validated by Friedewald, et al (222).
LDL-C (mg/dL) = Total Cholesterol -  HDL Cholesterol -  *Triglycerides/5
*Provided Triglycerides are less than 400 mg/dL
Serum x-tocopherol. B-carotene and retinol. The HPLC (high performance liquid 
chromatography) procedure was used to quantify concentrations of serum 
3c-tocopherol, (3-carotene, and retinol. Four hundred ml of serum was precipitated with 
200 ml of 100% ethanol, using 200 ml o f retinyl acetate and tocopherol acetate in alcohol 
as an internal standard, and then extracted twice with hexane. The hexane layer was 
collected in an amber glass vial and evaporated under nitrogen and the sample was then 
reconstituted in 200 ml of 100% ethanol. The HPLC system (Beckman 338) is a reverse-
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phase HPLC with a C18 Baker Bond wide-pore (5um) column (J.T. Baker, Phillipsburg, 
NJ), a variable wavelength spectrophotometer (Beckman 406), and a Beckman 167 
Scanning Detector Module (Beckman Instruments, Wakefield, MA). The mobile phase 
uses a gradient, changing from solvent A (methanol and 1% ammonium acetate) to solvent 
B (methanol: methylene chloride (80:20) and 1% ammonium acetate) over the first four 
minutes of the run. The wavelengths are set at 292nm for alpha-tocopherol, 325nm for 
retinol and 452 nm for beta-carotene. The flow rate was set at 1.5ml/min. Twenty pi of 
sample is injected twice for each sample. The internal standard is used to correct for any 
volume lost during the preparation.
Isolation of LDL. The LDL was isolated from plasma to determine protein concentration, 
susceptibility to oxidation, and antioxidant concentrations. The LDL was isolated by a 
single spin density gradient ultracentrifugation at 65,000 RPM for 1 hour and 
20 minutes at 7°C, with a NVT 65.2 rotor, as previously described by Chung et al. (222). 
Prior to ultrcentrifiigation, the density of the plasma was adjusted to about 1.21g/ml by the 
addition of 0.4898 g KBr (potassium bromide) to 1.5 mL of serum. The sample was then 
layered under 3.3 ml of saline (0.154 M NaCl) in a Beckman Optiseal tube using a 5cc 
syringe with a 3" flat bottom 20 ga needle. After centrifugation the LDL band is removed 
from the Optiseal tube using a 1 mL syringe with a 25G5/8 needle, and then filtered 
through a acrodisc filter into a test tube.
Quantification of x-tocopherol. B-carotene and retinol in the LDL fraction in plasma. 
After isolation of the LDL, HPLC was used to determine the plasma concentrations of x- 
tocopherol, P-carotene, and retinol by method described previously.
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LDL protein. Protein determinations were made on the LDL isolates using a modification 
of the Lowry method (223). In the procedure, 100 mL of reagent A (2.0% Na2COs,
0.4% NaOH, 0.16% sodium tartrate, and 1.0% SDS, in H2O) was mixed with 1 mL of 
reagent B (4% CuS0 4 (5H2 0 ) in H2O) to form reagent C, which is the alkaline copper 
reagent. Folin-Ciocalteau reagent was diluted 1:1 with FLO, for a final concentration of 
IN. Bovine serum albumin (BSA) was used as the standard, and the concentrations of the 
standard curve ranged from 0 to 100 ug/ul. Three mL of reagent C is then added to 50 pi 
of sample and allowed to incubate at room temperature for 10 minutes. This was followed 
by the addition of 300 pi of Folin-Ciocalteau reagent while votexing. After a 45-minute 
incubation at room temperature, the optical density (O.D.) of all standards and samples 
were read at 660 run, and measured against a blank. Protein concentrations were then 
determined from the standard curve.
LDL Resistance to oxidation ex vivo. LDL isolated from the plasma and protein was 
determined as described above. The susceptibility of LDL to oxidation was determined by 
the measurement of conjugated diene formation as previously described by Esterbauer 
(224). Q 1SO4  was used to initiate the formation of a peroxyl radical. The LDL sample 
(100 pg protein/assay), saline (to increase volume to 710 pi), 250 pi of 20 mM HEPES, 
and 40 pi of 80 uM CuSC>4 were added to a cuvette. After mixing 2 to 3 times by 
inversion, the absorbency of each sample was recorded at 37°C every 10 minutes for 10 
hours on a Varian Cary 1, UV/VTS spectrophotometer (Vaarian Associates Inc., Palo 
Alto, CA). Ten samples were analyzed simultaneously. Measurements of the lag phase, 
propagation phase, and total diene formation were determined from the oxidation curve.
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Serum estradiol concentrations. An ELISA (Enzyme-Linked Immunosorbent-Assay) was 
used for the quantitative analysis of plasma estradiol concentrations. The fundamental 
principle of this assay involves antigen-antibody reactions and utilizes a 
96-well microplate and is used for establishing a standard curve. TheMaxiStop™1 Nunc 
microplate is used that is precoated with anti-Estradiol rabbit antibody on each well. The 
assay is specific for 173-estradiol (100%). Before conducting the ELISA assay, the 
estradiol must be extracted from the plasma using ethyl ether. One hundred pi of plasma 
is pipetted into glass tubes to which 1 ml of ethyl ether is added. The tubes are votexed 
for 30 seconds and the phases are allowed to separate. The organic phase is transferred 
into a clean tube and the solvent is allowed to evaporate with a stream of N2. The residue 
is then dissolved in 500 pi of EIA buffer, votexed and incubated in a 37° water bath for 
approximately 15 minutes.
A standard curve is established using a stock solution and EIA buffer in increasing 
concentrations: 0, .02, .04, .10, .20, .40, 1.00, and 2.00 ng/ml. Fifty pi of standards and 
samples are then added to appropriate wells in the plate in duplicate, followed by the 
addition of 50pl of diluted enzyme conjugate, called horseradish peroxidase (HRPO), is 
added to each well and mixed by shaking gently and then allowed to incubate. After 
incubation the contents of the plate is dumped on a clean lint-free towel. Each well was 
washed with 200pl o f washing buffer three times and 1.5pl ofK-Blue Substrate is added 
to each well, mixed by shaking the plate gently and allowed to stand at room temperature 
for 30 minutes to 1-1/2 hours. At the end of this time the plate is shaken gently to insure 
uniform color throughout each well and read on a microplate reader at 650 nm. A
standard curve was then established and concentrations were interpolated from this.
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Serum concentration of Progesterone. Serum progesterone concentrations were 
determined using the Milenia™  Progesterone enzyme immunoassay kit. This assay 
utilizes liquid-phase kinetics and a microplate format. The standard curve is established by 
pipetting 25 pL (in duplicate) of a stock solution in increasing concentrations of 0, 0.25, 
1.0, 5.0, 10, 20, and 40 ng/ml into appropriate wells in the microplate. Twenty-five pi of 
samples (in duplicate) are then added to the remaining wells that have been coated with 
anti-rabbit antibody. One hundred pi of Ligand-Labeled progesterone is then added to all 
wells, followed by 100 pi of Progesterone Antiserum. The plate is then covered, mixed 
gently, and then rotated on an automatic plate mixer (set at 1300 revolutions/minute and 
an amplitude of 5) for exactly 60 minutes. After completion of the rotation, 25pl of 
progesterone enzyme-labeled anti-ligand is added to all wells and the microplate is then 
rotated again for 30 minutes on the plate reader. After the 30 minute rotation, the plate is 
decanted and washed four times, each time with 300 pi of wash buffer per well. Two 
hundred pi of substrate working solution is next added to all wells and the plate is 
incubated without shaking in the dark for 30 minutes. After the incubation period, 50pl of 
Stop solution is added to each well and the plate is shaken gently to mix to ensure uniform 
color throughout each well. The plate is then read on a microplate reader at 450 nm. A 
standard curve was then established and concentrations were interpolated from this.
Total Antioxidant. Frozen serum samples were transported on dry ice to Dr. Ronald L. 
Prior at the USDA Human Nutrition Research Center on Aging at Tufts University in 
Boston Massachusetts. The automated assay or (ORAC) oxygen radical absorbance 
capacity with the COBAS FARAII method was used to determine total antioxidant 
concentrations (225).
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ORAC is a sensitive method for quantifying the oxygen radical absorbance 
capacity of antioxidants in a biological system. Antioxidant systems include enzymes 
(superoxide dismutase, catalase, glutathione peroxidase), large molecules (ferritin, and 
albumin), as well as small molecules (x-tocopherol, P-carotene, ascorbic acid). This 
assay has been automated utilizing the COB AS FARAII centrifugal analyzer with 
flourescence. P-phycoerythrin (P-PE) is used as the indicator protein, 2,2’-azobis (2- 
amidinopropane) dihydrochloride (AAPH) as a peroxyl radical generator and 6-hydroxy- 
2,5,7,8-tetramethylchroman-2-carboxyIic acid (Trolox) as a calibrator for antioxidant 
activity. This assay is allowed to go to completion and is able to quantify both inhibition 
time and degree of inhibition (225).
Lipoprotein (aV Lipoprotein (a) i£Lp(a)” concentrations were determined using the 
Macra™ Enzyme Immunoassay Kit. A standard curve was established by the addition of 
100 pi (in duplicate) of prediluted standards (0, 5, 10, 40, and 80mg/dL) and two controls 
to the bottom of test wells of a microtiter plate. Plasma samples were diluted 1:201 by 
adding lOpl of the sample to 2mL.of sample diluent and vortexed to mix completely. One 
hundred pi of prediluted samples (in duplicate) were added to the bottom of the remaining 
wells. The plate was incubated at a controlled room temperature (18°-25°C) for one hour 
± 2 minutes on a rotator at 120 rpm. After the incubation period, the plate was aspirated 
and washed four times with wash buffer. The plate was inverted and forcefully tapped on 
an absorbent pad to remove any excess wash solution. Using a multi-channel pipet, lOOpl 
of Anti-Lp(a) conjugate was dispensed to the bottom of all wells and the washing 
procedure was repeated. The plate was then incubated on a rotator again for 20 minutes.
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After this incubation period, lOOp.1 of color substrate was added to each well and 
plate incubated for an additional 20 minutes and then 50|ji of stop reagent was dispensed 
into each test well. The plate was read on a plate reader at 490 nm. a. standard curve was 
then established and concentrations were interpolated from this. A standard curve was 
then established and concentrations were interpolated from this.
UNH Women’s Health Study (UNHWHS1 Questionnaire 
This questionnaire (Appendix C) was developed as a collaborative effort by 
several researchers at the University of New Hampshire. The questionnaire was pilot 
tested on 120 women in the summer of 1994. A Jury of Experts (Appendix A) reviewed 
the questionnaire for content and validity and offered comments and suggestions for 
review. The questionnaire was then revised using the suggestions and comments of the 
experts. The questionnaire collected information on the following:
Demographics: Age, ethnicity, religion, occupation, education, marital status.





Types, brands, and dose of all prescription and non-prescription 
drugs and vitamin and mineral supplements.
Type, frequency, intensity, and duration of present exercise routine 
and number of years subject had exercised at the present rate. 
Information on use of special diets, food allergies, and weight loss 
history.
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Menstrual History: Changes in menses in last twelve months, past use of oral 
contraceptives, menopausal status.
HRT History: Present use of HRT (type and dose). Past use o f HRT. Factors
influencing use of HRT.
The questionnaire was mailed to each participant upon entry into the study. A 
cover letter (Appendix C) was included that provided instructions on how to complete the 
questionnaire and that they did not have to answer any question that they chose not to.
All questionnaires were returned with only a code number to identify the questionnaire to 
subject.
A coding system was developed (Appendix C) to compile information from the 
questionnaires for entry into the computer for analysis.
Evaluation o f Dietary Intake
Dietary intake of participants was quantified using the Dine Score System (226), 
(227) from nutrient values obtained from the three-day dietary analysis. In this system, 
macro- and micronutrients categories are assigned points based upon eating foods that 
contain nutrients within recommended ranges. The scoring process assigns pluses, zeros, 
and minuses to the subject’s dietary intake. Each category is comprised of one, two or 
three nutrients with a range of scores from 0-10 points. The Dine Score descriptors (10 = 
perfect; 9-8 = excellent; 7-6 =good; 5-4 = fair; 3-2 = poor; 1-0 = very poor) measure 
dietary status for eating behavior, determined by the number of nutritional guidelines 
achieved by the subject. (Appendix C : Dine Score System).
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Psychological and Social Assessments 
Self-esteem. A 10-item Rosenberg (228) Likert-type scale was used to measure 
differences in self-esteem among groups. Respondents were asked to rate each of the 10 
items on the instrument as: strongly disagree (1), disagree (2), agree (3), or strongly 
agree (4). Items #4 and #5 received negative weights in calculating the total score. The 
scores for each respondent were then added together and divided by 4 to obtain a total 
self-esteem score. The range of scores for the self-esteem inventory was 2.5-10 with a 
higher score indicating a more positive self-esteem. (Appendix C UNH Women’s Health 
Questionnaire).
Moods. A 65-item (POMS) Profile of Mood States Inventory (103) was used to measure 
six identifiable mood or affective states: Tension-Anxiety(T); Depression-Dejection (D); 
Anger-Hostility (A); Vigor-Activity (V); Fatigue-Inertia (F); and Confusion- 
Bewilderment (C); as well as a total Mood State, or POMS Score. In this self­
administered survey, subjects are asked to respond to the stem, “How have you been 
feeling during the past week including today”? Examples of the various sub-scales: tense, 
on edge, uneasy (T); unhappy, sad, worthless (D); peeved, spiteful, angry (A); energetic, 
active, lively (V); listless, worn out, weary (F); and confused, panicky, uncertain (C).
The ranking of scores included: not at all (0); a little (1), moderately (2), quite a bit (3), 
or extremely (4). To obtain a score for each mood factor, the sum of the responses was 
obtained for the adjectives defining the factor. (Refer to Table 11a and 1 lb for factor 
loading criteria of each sub-scale). All items defined in each factors were keyed in the 
same direction except for two items, "relaxed” on the Tension-Anxiety scale and 
“efficient' on the Confusion scale. These two items received negative weights in
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calculating the factor scores. A Total Mood Disturbance Score was obtained by summing 
the scores (with vigor weighted negatively) on the six primary mood factors. The five 
sub-scale scores were then added together and vigor is subtracted from these scores. The 
range of scores for the POMS sub-scales was T= 0-36; D= 0-60; A=0-48; F= 0-28; C= 
0-28; and V= 0-32. The range of possible scores for the Total Mood Disturbance Score 
was 0-168 with higher scores indicating a more negative mood state. (Appendix C. UNH 
Women's Health Questionnaire).
The reliability of the POMS instrument is moderate to high. Internal consistency 
on all subscales is .90 or above. The test-retest reliability ranges from .65 for vigor to .74 
for depression. The correlations for reliability were taken from patients entering treatment 
at a medical center psychiatric clinic. Product-moment correlations among POMS scores 
were evaluated at three time points: pretreatment, immediately before the first session, 
and six weeks post-treatment. The correlation between pretreatment and the first session 
are lower bound estimates of reliability because of changes in emotional states associated 
with finding sources of psychiatric treatment. Stability of a fluctuating state like mood is 
expected, thus rank ordering of individual scores would be expected. Extremely high 
stability coefficients for mood measures could be taken as evidence of lack of construct 
validity (103).
Experiences. Symptoms of menopause were evaluated with a 28-item Likert scale that 
described various symptoms that women experience during menopause. The subject were 
asked to rank their experiences at present or within the last six months from 0= No to 4= 
always. The responses to the 28 items from each subject were then added together to 
obtain a total experience score for each subject. The range of possible scores was 28-112
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with scores weighted toward negative symptoms. (Appendix C: UNH Women's Health 
Questionnaire).
Attitudes Regarding Hormone Replacement Therapy. Subjects responded to several 
questions regarding their attitudes and use of HRT. The responses involved several major 
areas of interest: (1) factors that influenced their decision to use HRT;
(2) the sources that have provided them information on menopause; (3) other therapies 
used for treatment of menopausal symptoms; (4) factors that influenced their decision not 
to use HRT; and (5) factors leading to discontinuance of the use of HRT. Responses to 
each of the questions were calculated and frequency of the answers was determined. 
(Appendix C. UNH Women’s Health Questionnaire).
Statistical Analyses
All analyses were conducted using SPSS® (Statistical Package for the Social 
Sciences): Graduate Pack™ Advanced Class Version 7.0 for Windows. Chicago, EL. 
Significance was defined as p<0.05.
Data collected in this study was statistically analyzed in two ways: Comparison I 
investigated relationships between three groups: no hormone replacement therapy 
(NHRT), estrogen only (EO) and estrogen and progestin (E/P). Comparison II 
investigated differences and relationships between two groups: no hormone replacement 
therapy (NHRT) compared to data from both hormone groups (HRT)
A one-way Analysis of variance (ANOVA) was used to detect differences in 
Comparison I. After significant differences were detected, a least significant difference
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(LSD) post-hoc test was used to determine which groups differed significantly. An 
independent sample t-test was used to detect differences in Comparison EL
The Pearson product correlation was used to determine associations between 
variables that were shown to demonstrate trends on the previous analyses. This analysis 
was also used to compare the average daily intake of selected nutrients based on the three- 
day records to those based on the food frequency questionnaire as well as other pertinent 
variables in this research. Correlation statistics are summarized in Table 18.
Frequency distributions were used to analyze data on factors influencing the 
decision to use HRT, source of information on menopause, alternate therapies use to treat 
menopausal symptoms, and reasons for choosing not to use HRT.
74




The subjects in this study represented a group of healthy free-living 
postmenopausal women who had been using or not using hormone replacement therapy for 
at least one year and who responded to a recruitment letter mailed to all faculty and staff at 
the University of New Hampshire (Durham, New Hampshire) and Plymouth State College 
(Plymouth, New Hampshire). The age range of the subjects was 48-67 years old, with a 
mean age of 55.84 ± 4.43 years. Subject characteristics are presented in Tables la and lb.
All subjects donated a blood sample. Sixty-six (94.3%) returned a completed 
UNH Women's Health Study Questionnaire (Appendix C), 55 (78.6%) a completed three- 
day food diary (Appendix C), and a Health Habits and History Questionnaire (Appendix 
C). Personal and family histories (mortality and morbidity reported in a first degree 
relative) were collected during a personal interview and are summarized in Table 2. 
Subjects using HRT were on a variety of exogenous hormone preparations which are 
summarized in Appendix F.
The majority of the subjects were white (97.0%), and highly educated (42.4% held 
post-graduate college degrees). Sixty-seven percent were married for a mean o f27.45 ± 
7.88 years. Fifteen subjects (21.4%) had experienced a surgical menopause: nine (total- 
simple hysterectomies), four (total hysterectomies with bilateral salpingo-oophorectomies),
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one (removal of ovaries and retention of uterus), and one subject did not know what type 
of hysterectomy she had experienced. Six of the hysterectomized women were not taking 
any hormone replacement therapy. Nine were taking estrogen only.
Of the seventy subjects in this study 82.9% reported having a physical exam, 74.3% 
a mammogram, and 77.1 % a pap smear within the last 12 months. The primary health 
care provider identified by subjects (n=66) included gynecologists (7.6%), nurse 
practitioner (12.1%), internist (36.4%) and family practitioner (43.9%).
There was no significant difference found in number of children, number of 
pregnancies or years of past oral contraceptive (OC) use among groups. As seen in Table 
lb, the women who were presently using HRT (EO and E/P groups) reported 5.44 ± 1.28 
years of past OC use, as compared to the NHRT group with 3.94 ±0.79 years of past 
use of OC. Although not statistically significant there was a trend toward longer OC use 
in the HRT group, thus supporting hypothesis #11 that postmenopausal women who use 
HRT are more likely to have used OC in the past.
The Effect of HRT on Serum Lipids. Estradiol, and Progesterone 
The least square means and standard errors of serum concentrations of total 
cholesterol, LDL-C, HDL-C, triglycerides, Lp(a), estradiol, progesterone and total 
cholesterol/HDL ratio are presented in Tables 3a and 3b. No statistically significant 
differences were found in serum estradiol, progesterone, triglycerides, HDL, LDL, Lp(a) 
concentrations or Total Cholesterol/HDL ratio by HRT use, as seen in Table 3 a. However, 
when the hormone groups were collapsed (Table 3b), a significant difference was found in 
progesterone concentration between the NHRT and the HRT group
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(p< 0.01) There was no correlation found between serum estradiol concentrations and 
serum 3-carotene or a-tocopherol, as well as between LDL 3-carotene and LDL a -  
tocopherol or 3carotene/LDL and a-tocopherol/LDL ratios. An ANOVA was used to 
compare all groups and a t-test to compare the NHRT and HRT group to test hypothesis 
#3 that the use of HRT would positively affect serum cholesterol, LDL-C, HDL-C, Lp(a) 
and total cholesterol/HDL ratio was not supported. The Pearson product correlation was 
used to test hypothesis #3 proposing that HRT would positively affect serum cholesterol 
and lipoprotein concentrations in postmenopausal women. This hypothesis was also not 
supported by the data.
The Effect of HRT on Serum Antioxidants (oc-tocopherol and B-caroteneL 
LDL x-tocopherol and B-carotene. and oc-tocopherol and B-carotene/LDL Ratios.
The least squares means and standard errors of serum antioxidants and LDL 
antioxidant variables are presented in Tables 4a and 4b. No statistically significant 
differences were noted in serum a-tocopherol or serum 3-carotene concentrations by HRT 
use when comparing all three groups (Table 4a). However when the groups were 
collapsed (Table 4b), a trend toward higher concentrations of both antioxidant vitamins in 
the EO and E/P groups was noted. Serum a-tocopherol concentrations was positively 
correlated with LDL a-tocopherol (r = .299, p<0.05) and a-tocopherol/LDL ratio 
(r = .777, p<0.01). The a-tocopherol/LDL ratio was also negatively correlated with serum 
LDL concentration (r = -.269, p<0.05). Serum 3-carotene was positively correlated with 
and LDL 3-carotene ( r = .923, p<0.01) as well as 3-carotene/LDL ratio
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(r = .884, p<0.01).
No statistically significant differences were noted in LDL (3-carotene or LDL 
a-tocopherol concentrations by HRT use. The NHRT group had higher concentrations of 
LDL a-tocopherol (8.556 ± 1.30 mol/mol LDL) than either of the hormone groups; EO 
(7.070 ± 0.71 mol/mol LDL) and E/P (8.500 ± 0.62 mol/mol LDL), although the 
difference were not significant. The NHRT group had lower LDL |3-carotene than either 
hormone group (EO and E/P). LDL oc-tocopherol was positively correlated with 
=c-tocopherol/LDL ratio (r = .260, p<0.05). LDL (3-carotene was positively correlated 
with 3-carotene/LDL ratio (r = .967, p<0.01) and negatively correlated with total 
cholesterol/HDL ratio (r = -.288, p<0.05) and serum triglycerides (r = -.261, p<0.05), as 
well as LDL (r = -.241, p<0.05). The (3-carotene/LDL ratio was found to be negatively 
correlated with serum LDL (r = -.300, p<0.05) and total cholesterol/HDL ratio (r = -.301, 
p<0.05). The a-tocopherol/LDL ratio and 3-carotene/LDL ratio were not found to be 
significantly different between groups by HRT use. An ANOVA was used to compare all 
groups and a t-test to compare the NHRT and HRT group to test hypothesis #1 proposing 
that postmenopausal women who use HRT will have higher concentrations of serum 3- 
carotene and oc-tocopherol in both serum and LDL than women who do not use HRT. 
Although this hypothesis was not supported, a trend was noted towards higher 
concentrations of both antioxidants in the serum in the HRT groups. The Pearson product 
correlation was used to test hypothesis #2 that serum estradiol concentrations would be 
positively correlated with serum concentrations of 3-carotene and oc-tocopherol, LDL
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oc-tocopherol and LDL |3-carotene, and (3-carotene/LDL and oc-tocopherol/LDL ratios, 
and lipid profiles in postmenopausal women. This hypothesis was not supported by the 
data.
Resistance of LDL to oxidation ex vivo 
The values for oxidation of LDL are represented in Tables 4a and 4b. There were 
no statistically significant differences between groups in length of lag phase or maximum 
diene formation by HRT use. There was however, a significant difference found in the rate 
of diene formation between the NHRT and the E/P group (p<0.001). The hormone 
replacement groups (EO and E/P) did demonstrate a trend toward longer lag phases and 
lower rates of diene formation and maximum diene formation than the NHRT group. A 
negative correlation was found between rate o f diene formation, serum tocopherol (r = - 
.366, p<0.01) and serum triglycerides (r = -.277, p=<0.05): and a-tocopherol/LDL ratio (r 
= -.544, p<0.0l). There was a negative correlation between serum triglycerides and 
maximum diene formation (r = -.303, p<0.05).
Table 4a and 4b report the values for total antioxidants (ORAC: Oxygen Radical 
Absorbency Capacity) as both pmol Trolox equivalents/1 and nmol Tolox/mg protein. No 
significant differences were found for either calculation between groups by HRT use.
There was a trend toward higher ORAC values in the NHRT group as compared to the 
hormone groups (EO and E/P). ORAC was found to be negatively correlated with LDL a- 
tocopherol (r = -.250, p<0.05), ac-tocopherol/LDL ratio (r = -.279, p<0.05) and HDL (r = 
-.248, p<0.05). A positive correlation was seen between ORAC and rate of diene 
formation (r = .314, p<0.01).
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HRT Use and Body Composition: BMI. Waist-Hip Ratio and Body Weight 
The least square means and standard errors for body mass index and waist-hip 
ratio values are presented in Tables la  and lb. Height and BMI were the only categories 
where a significant difference occurred according to HRT use. In Table la, a significant 
difference was found between the NHRT group and the E/P group (p< 0.05), and the EO 
and E/P group (p< 0.05) for height; however this was not true when the HRT groups were 
collapsed (Table lb). The EO group weighed more than both the NHRT and E/P group, 
and a significant difference in body mass index was noted between the EO (BMI of 28.42 ± 
1.66) and E/P groups (BMI or 24.50 ± 1.04), (p= <0.05). This difference also disappeared 
when the HRT groups were combined. There were no statistically significant difference 
found in waist-hip ratios between groups. An ANOVA was used to compare all groups and 
a t-test to compare the NHRT and HRT group to test hypothesis #5. The hypothesis that 
postmenopausal women who use HRT will have lower BMTs and waist-hip ratios than 
women who do not use HRT was not supported. The subjects in the EO group tended to 
be heavier than either the NHRT or E/P groups (164.32, 157.69, and 151.74 pounds 
respectively) and to have greater waist-hip ratios (07.86, 07.79 and 07.53 respectively). 
BMI was positively correlated with serum triglycerides (r = .354, p<0.01); LDL (r = .265, 
p<0.05), and total cholesterol/HDL ratios (r = .391, p<0.01). BMI was negatively 
correlated with HDL (r = -.308, p<0.05), serum p-carotene (r = -.273, p<0.05), LDL P- 
carotene (r = -.363, p<0.01), and P-carotene/LDL ratio (r = -.328, p<0.01). Waist-hip 
ratio was positively correlated with total cholesterol/HDL ratio (r = .377, p<0.01) and 
negatively correlated with serum triglycerides (r = -.315, p<0.01), HDL (r = -.342, p<0.01) 
and LDL P-carotene (r = -.256, p<0.05). Body weight was found be positively correlated
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with serum triglycerides (r = .294, p<0.05) and LDL (r = .262, p<0.05); and negatively 
correlated with serum P-carotene (r -.327, p<0.01), HDL (r = -.309, p<0.05), LDL P- 
carotene (r = -.391, p<0.01), and total cholesterol/HDL ratio (r = -.373, p<0.01).
Lifestyle Interventions.
The least square means and standard errors for alcohol consumption and the 
amount and duration of exercise is reported in Tables 5a and 5b. No statistically significant 
differences were found among the three groups, nor when the groups were collapsed, in 
any of the categories. However, as shown in Table 5b, the NHRT group did demonstrate a 
trend toward more frequent episodes of exercise (3.36 ± 0.04 versus 2.58 ± 0.4 times per 
week) and longer duration (129.69 ± 18.8 versus 94.33 i  15.06 minutes per week) in 
exercise regimes than either of the hormone group (EO and E/P). A positive correlation 
was found between times of exercise per week and LDL 3-carotene (r = .292, p<0.05) and 
p-carotene/LDL ratio (r = .291, p<0.05).
The least square means and standard errors of selected nutrients based on the three-
day food records was compared to those based on the food frequency questionnaires using
the Pearson product correlation. Significant correlations were detected between the two
methods for the values for total energy (r = .424, p<0.01), grams of fat (r = .414,
p<0.01), grams of saturated fat (r = .454, p<0.01), percent calories from fat
(r = .637, p<0.01), calcium (r = .579, p<0.01), iron (r = .327, p<0.01), vitamin E
(r = .588, p<0.01), iron (r = .414, p<0.01), and fiber (r = .327, p<0.01). Correlations
between methods for vitamin A, cholesterol, or P-carotene were not significant. The least
squares means and standard errors for the three-day intake is presented in Tables 6a and
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6b, and for the food frequency questionnaire in Tables 7a and 7b. No significant 
differences were found for any of the reported nutrients by HRT use.
Forty-one percent of participants reported using some type of dietary supplement.
In the NHRT group, 13 subjects used a supplement, as compared to 4 in the EO group and 
12 in the E/P group. Of the women who used no hormone replacement therapy (NHRT) 
18.6% reported using a supplement as opposed to 22.9% of the women who used HRT.
The least squares means and standard errors for intake of vitamin E from dietary 
intake, supplements, and total vitamin E intake (diet and supplements) is presented in 
Tables 8a and 8b. No statistically significant differences were found in any of these 
parameters by HRT use. The subjects in the E/P group reported greater daily intakes of 
vitamin E from supplements than either the NHRT or EO groups (224.12 ± 81.1 mg) 
versus (157.26 ± 48.5 mg) and (54.44 ± 30.7 mg), respectively. When the groups were 
collapsed the daily total vitamin E intake (Table 8b) was greater in the HRT groups than 
the NHRT group (179.91 ± 49.1 mg) versus (158.49 ± 44.1 mg) respectively. Although 
serum ^-tocopherol was not correlated with reported vitamin E intake from the three day 
food diary and the FFQ, it was positively correlated with vitamin E intake from 
supplements (r = .270, p<0.05) and total vitamin E intake (r = .289, p<0.05). LDL 
3c-tocopherol was also positively correlated with dietary vitamin E (r = .443, p<0.05) and 
2c-tocopherol/LDL ratio was found to be positively correlated with vitamin E from 
supplements (r = .443, p<0.01), as well as with total vitamin E (diet and supplements)
(r = .420, p<0.01). Rate of diene formation was negatively correlated with total vitamin E 
intake (r = -.264, p<0.05).
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The least squares means and standard errors for intake of P-carotene from dietary 
intake, supplements, and total P-carotene (diet and supplements) is presented in Tables 9a 
and 9b. No statistically significant differences were found in any of these parameters by 
HRT use. The two hormone replacement groups (EO and E/P) reported greater daily 
intakes of P-carotene from supplements than the NHRT group with EO taking(1000.00 ± 
500.00 RE), E/P reporting (909.19 ± 250.63 RE) and NHRT (692.31± 192.31 RE). The 
NHRT group’s dietary intake of P-carotene was greater than either of the EO or E/P 
groups (3432.88 ± 779.18 RE) versus (1079.39 ± 262.16 RE) and (2778.21 ± 910.94 RE) 
respectively. When the hormone groups were collapsed (Table 8b) a greater total P- 
carotene intake was demonstrated in the NHRT group (4088.02 ± 1188.05 RE) when 
compared to the HRT group (3419.76 ± 1340.36 RE).
There was no statistically significant difference found between serum P-carotene 
and reported dietary intake of P-carotene in the three day food diary or the FFQ.
However, a positive correlation was found between serum 3-carotene and P-carotene from 
supplements (r = .603, p<0.01). LDL P-carotene was positively correlated with dietary P- 
carotene (r = .307, p<0.05), P-carotene from supplements (r=  .408, p<0.01), and total 3- 
carotene (r = .541, p<0.01). The 3-carotene/LDL ratio was found to be positively 
correlated with dietary intake o f 3-carotene (r = .316, p<0.05), 3-carotene form 
supplements (r = .351, p<0.01) and total P-carotene (r = .494, p<0.01).
The least square means and standard errors for the Dine Score to measure dietary 
status are presented in Tables 10a and 10b. The DINE scores indicated “good” dietary 
status for the NHRT (mean score of 6.21 ± 0.31 ) and EO (mean score of 6.75 ± 0.38)
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groups , and “fair” for the E/P (mean score of 5.62 ±0.35) group. An ANOVA was used 
to compare all groups and a t-test to compare the NHRT and HRT group to test hypothesis 
#4 and #10. The subjects in all three groups reported moderate and frequent exercise 
routines and consuming healthy diets therefore supporting the hypothesis #4 that 
postmenopausal women who practice positive lifestyle interventions will demonstrate a 
decreased risk for cardiovascular disease independent of HRT use. However, hypothesis 
#10 was not supported in that there was no significant differences noted in dietary intake of 
fat or saturated fat among groups.
Psychological and Social Factors 
The least square means and standard errors for the POMS M ood States inventory 
are presented in Tables 1 la and 1 lb. No statistically significant differences were found 
among the three groups for identified mood states. In noting the range of scores for each 
mood/affective states in the POMS Inventory, mean scores for all sub-scales, as well as 
Total Mood State scores on the POMS Inventory were low for all groups. The total mean 
scores for the POMS inventory were as follows: NHRT (11.13 ± 5.0), EO (23.22 ±9.1), 
and E/P (6.11 ± 6.3). This is indicative of positive mood states reported among subjects in 
the study.
The least square means and standard errors for the Self-esteem Score are presented 
in Tables 12a and 12b and indicate no statistically significant differences were found by 
HRT use. The scores of the self-esteem inventory were as follows: NHRT (8.62 ± 0.2),
EO (8.07 ± 0.4), and E/P (8.56 ± 0.2). These values are out of a possible 10 points
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indicating positive self-esteem among the participants regardless of hormone replacement 
use.
The least square means and standard errors for and the Experiences (symptoms) 
Inventory are presented in Tables 13a and 13b. The total score on the Experiences 
inventory is weighted toward negative symptoms. The scores were as follows: NHRT 
(50.38 ± 2.8); EO(52.20 ± 4.8); and E/P(48.13 ± 2.0). These scores were out of a possible 
112 points indicating moderate menopausal symptoms among subjects.
An ANOVA was used to compare all groups and a t-test to compare the NHRT 
and HRT group to test hypothesis #7. This hypothesis is supported in that postmenopausal 
women who practice positive lifestyle interventions (health supporting diets and moderate 
and frequent exercise) will report less severe postmenopausal symptoms, as well as positive 
self-esteem and moods regardless of their use of HRT.
Factors Influencing Hormone Replacement Therapy Use.
Percentages of subject’s responses regarding the Factors Influencing the Decision 
to Use HRT is presented in Table 14 and Figure 1. These responses were only from the 
subjects who were using HRT (EO and E/P groups). For the purposes of comparison, the 
subject’s responses were divided into three categories (1) Health concerns (hysterectomy, 
relief of symptoms, concern about heart disease, and concern about osteoporosis); (2) 
Advice of others (advice of MD or health professional; advice of friend, co-worker, or 
family; and advice of partner); and (3) Psychological and Social Factors (mood changes, 
concern about aging, and sexual problems). Responses of “moderately or extremely 
influential” were reported for hysterectomy (13.6 %), relief of menopausal symptoms
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(72.4%), concern about heart disease (77.7%), and concern about osteoporosis (77.4 %) 
in the Health Concerns Category. Responses of “moderately or extremely influential” were 
reported for advice of MD or health professional (82.8 %), advice of friend, co-worker, or 
family (8.3 %), and advice of partner (4.2 %) in the Advice o f Others category. Responses 
of “moderately or extremely influential” were reported for mood changes (26.9 %), 
concern about aging (34.6 %), and sexual problems (4.2 %) in the Psychological-Social 
category.
Table 15 and Figure 2 summarize the responses o f subjects for Sources o f 
Information on Menopause. An MD or health care professional was reported by 70.5 % 
of the subjects as “moderately or extremely informative” sources of information on 
menopause. Other influences, though not as strong, were mother (4.2 %), mediairadio and 
TV (33.4 %), workshops and conferences (40.0 %), books and pamphlets (70.5%), partner 
(0%) and friend or relative (27.1 %). Frequency distributions were used to test hypotheses 
#8 and #9. Hypothesis #8 was supported in that outside influences were important in the 
choice to use HRT in postmenopausal women in this study, with the health care 
professional having the strongest influence in this decision. Hypothesis #9 was also 
supported as postmenopausal women reported that acute symptom relief and concern over 
chronic disease (heart disease and osteoporosis) were the most influential factors in making 
the decision to use HRT.
Alternate Therapies Used to Treat Menopausal Symptoms were reported by 27.3% 
(n=18) of the subjects and results are presented in Table 16. Vitamins and minerals (9.4 
%), exercise (4.7 %), and meditation (6.3%) were the most frequently used alternate 
therapies reported by subjects. One subject identified each of the following (diet, massage
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therapy, natural hormone replacement therapy, relaxation techniques, and vaginal creams) 
as alternate therapies used to treat menopausal symptoms.
Percentages of subjects’ Reported Reasons fo r  Not Using HRT are presented in 
Table 17 and Figure 3. The responses presented here are only from those subjects who 
were not using HRT (NHRT group). The primary reason reported for not using HRT 
(45.9 %) was concern about cancer, personal history of breast cancer (3.8 %), family 
history of breast cancer (11.5 %), family history of other types of cancer (4.0 %), fear of 
breast cancer (3.8 %), concern over uterine or ovarian cancer (7.4 %), and concern over 
cancer in general (15.4 %). Other responses included fibrocystic breast disease (4.0%), not 
liking to take medication (16.0%), no risk factors/no need to use HRT (20.0%), MD or 
health professional discouraged use of HRT (8.0%), not wishing to start menstruating 
again (4.0%), cost of medication (4.0%), and not remembering to take medication (2.9%). 
Figure 3 categorizes the reported reasons for not using hormone replacement therapy as: 
cancer concerns (49.9%), medication concerns (31.7%), MD advice (8.0%), and no need 
to take HRT or no perceived risk factors (20.0%). Frequency distributions were used to 
test hypothesis #6. The hypothesis was supported in that fear of cancer was the primary 
reason reported for not using HRT, or discontinuing its use in this group of subjects.
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CHAPTER V
DISCUSSION
Women entering mid-life today will have many decisions to make concerning 
their health and the quality of their lives as they age. One of the most difficult and 
controversial decisions will be whether or not to use HRT, and if so, for how long. 
Menopause is a life stage that encompasses many facets of a woman’s life. To confine an 
investigation of menopause to only the biological, the psychological, or the social aspects 
would be limiting. By integrating these three aspects of menopause, the results will offer 
an expanded and much more comprehensive view of the complex interplay that effect 
women’s perceptions and choices during this time. The present study, to the best of my 
knowledge, is the first investigation that has utilized the biopsychosocial approach to 
determine the factors that influenced the decision to use hormone replacement therapy in 
seventy postmenopausal women.
This study was an outgrowth of a larger study, The University o f New Hampshire 
Women's Health Study, as well as part of the NE-172 regional project, Assessment o f 
Nutritional Risk in the Elderly. The objectives for both of these studies were integrated 
into the study described in this dissertation. In 1995 the UNHWHS collected information 
on women’s health from 303 questionnaires mailed to women from ages 35-70 in New 
Hampshire. This research is from a cohort of 70 postmenopausal women recruited from
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the larger study population. The subjects in this study were very similar in age, weight, and 
height (Table la and lb). They all reported good access to health care and reported 
regular exercise and consumption of healthy diets.
The impact on cardiovascular disease risk shown by previous research appears to be 
attenuated when study design and subject selection are taken into consideration. Subjects 
who participated in previous studies appeared to enjoy a “healthy cohort effect” (34). The 
majority of these women were healthy, middle-class, and well educated. They were also 
relatively lean (25), exercised on a routine basis (27), (24), and had good access to health 
care. The earlier studies used ambiguous terms (219), such as “current user”, “past user”, 
“never user”, when describing HRT status and estrogen alone (primarily Premarin™) was 
the hormone treatment. The majority of studies were retrospective observational studies 
using mailed questionnaires to collect data and the focus was primarily on biological 
outcomes, with the most common theme being the effect of HRT on lipoprotein 
concentrations. Very few studies included any social or psychological information on HRT 
use. Therefore, the subjects used in these vanguard studies may have been healthy entering 
the study which may have resulted in a decreased risk of CVD, independent of HRT use.
Taking all these factors into consideration, the present study recruited a similar 
group of free-living postmenopausal women some of whom were not taking HRT and 
others who were, on varied doses and formulations of hormone replacement therapy 
(Appendix F) for a least one year. As shown in Table 2 three women reported that they had 
heart disease, five were presently taking medication to treat hyperlipidemia, twelve were 
hypertensive and one had been treated for breast cancer. This similar subject selection 
allowed for comparison with past studies which demonstrated a 50% reduction in
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cardiovascular risk with HRT use (63), (103),(104), (106). Similar to previous studies, 
the subjects in this study were well-educated, healthy, and reported positive lifestyle 
interventions (health supporting diets and frequent exercise). As seen in previous studies, 
the women in the present study appeared to enjoy the “healthy cohort effect” also. It is 
difficult to recruit women at greatest risk for cardiovascular disease. Until recently women 
at greatest risk were often not prescribed HRT. Many of these women did not have good 
access to health care or information on menopause and HRT and therefore would be less 
likely to participate in research protocols. Since the present study was the first study to use 
the biopsychosocial perceptive to investigate menopause and HRT, it was thought that the 
similarity in subject populations would allow comparisons between previous studies and the 
one described in this dissertation. With all this in mind, this research sought to determine 
if postmenopausal women who practice positive lifestyle interventions would demonstrate 
more positive biological, social, and psychological outcomes independent of hormone 
replacement therapy.
The Biological Outcomes Associated with HRT Use 
Since the early 1970’s, HRT has been used to treat acute symptoms of menopause 
(22), (20) and to prevent the onset of chronic disease, such as osteoporosis and 
cardiovascular disease. Research has consistently shown that HRT use can decrease the 
risk of cardiovascular disease in postmenopausal women by as much as 50% (63), (103),
#110], (104), (106). The primary mechanism identified has been the beneficial effect of 
HRT on lipids and lipoproteins (109).
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The subjects in this study had already made their choice regarding HRT. This 
research investigated the biological outcomes of this choice on cardiovascular risk, with 
specific emphasis placed on the role of the antioxidant nutrients of dietary origin 
(oc-tocopherol and P-carotene), and estradiol on cardiovascular risk factors in 
postmenopausal women.
Naturally occurring changes in lipoproteins are seen at the time of menopause.
Total cholesterol, LDL-C (55), (28), (56), (57), and Lp(a) (70) concentrations increase, 
while HDL-C is only moderately affected (58), (59). HRT has been shown to attenuate 
this lipid profile by decreasing total cholesterol, LDL-C (104), (109) and Lp(a) (72) while 
increasing HDL-C (117), although wide variation in these changes are seen dependent on 
type of estrogen, the addition of progestin, the route of administration, and dose (109). 
Various studies have indicted that only —25-50% of the cardioprotective effects of estrogen 
is thought to be mediated by the beneficial changes in lipids and lipoproteins (109). The 
Nurses' Health Study (104), the Healthy Women’s Study (229), and the Lipid Research 
Follow-Up Study (4), (69) have all demonstrated beneficial effects of exogenous hormone 
use. The subjects in the present study did not demonstrate any significant differences in 
triglycerides, HDL-C, LDL-C, total cholesterol or Lp(a) concentrations (Table 3a and 3b).
When evaluating the effect of lipid and lipoprotein concentrations on cardiovascular 
risk in women, it is important to keep several issues in mind. The National Cholesterol 
Education Program s Expert Panel has identified a HDL-C of <35 mg/dL, total 
cholesterol of >240, and a LDL-C of >160 mg/dL all as cardiovascular risk factors in 
women (68). HDL-C is the best predictor of cardiovascular risk in women (63), (64), (67) 
and positive lifestyle changes in diet and exercise can increase HDL-C concentrations (67).
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As depicted in Table 3 a, all three groups of subjects in the present study had HDL-C 
concentrations > 35mg/dL NHRT (52.76 mg/dL ± 2.26), EO (55.91 mg/dL ± 3.75) and 
E/P (51.94mg/dL ±2.62). This was also true for both total cholesterol and LDL-C. The 
three groups had total cholesterol concentrations of (224.59mg/dL ±6.22), (235.32mg/dL 
±11.56), ( 212.48 mg/dL ±8.81) respectively; and LDL-C concentrations of (148.06mg/dL 
±5.26), (147.67mg/dL ± 9.09), and (138.66mg/dL ±7.72) respectively. One might expect 
the women who are taking HRT to have a more positive lipid profile than the women who 
were not using HRT. The similarity in values could be explained by the fact that the 
women had been using HRT for a least a year. The women who chose HRT may have 
done so because of negative lipid profile. HRT use should have resulted in more positive 
concentrations of the lipoprotein concentrations.
HDL-C has been identified as the most important lipoprotein in women. The 
women in this study reported frequent exercise patterns and consumption of healthy diets 
which could have resulted in the positive HDL-C concentrations. The fact that the subjects 
in this study were healthy and practiced positive lifestyle behaviors, including health 
supporting diets, control o f body composition, and routine exercise, may have contributed 
to positive blood lipid profiles independent of HRT use.
Estrogen, both endogenous and exogenous, has been studied widely to determine 
the mechanism involved in its ability to offer protection to heart and bone, while conferring 
deleterious effects on the breast and endometrium. Several studies have demonstrated no 
association between serum estradiol concentrations and the risk of cardiovascular disease in 
women (96), (59), (82). The present study found no significant differences in serum 
estradiol concentrations between the women who used HRT and those who did not. As
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shown in Table 3a and 3b there was little difference in estradiol concentrations between the 
three groups or when the HRT groups were collapsed. The similarity in estradiol 
concentrations could be explained by the fact that the ELISA used to measure estradiol in 
the present study was very specific for 17 P-estradiol and was not able to quantify the other 
estrogens present. There was a wide variability in the types and route of administration of 
HRT regimes among subjects (Appendix F). Most HRT formulations contain a 
combination or estrogens. Oral estrogens are also subject to the first-pass hepatic effect, 
where 60-90% of the drug will be metabolized by the liver. Administration of estrogen by 
transdermal patch does not cause this hepatic effect and serum levels of estradiol remains 
much more constant (230).
It is also important to note that the women in the present study had their blood 
samples drawn after a 12 hour fast and many had not taken their HRT medication in over 
24 hours. This would have modulated the first-pass effect seen with oral estradiol 
administration where serum levels rise acutely for 6-10 hours and then return to baseline 
within 48 hours (231). All subjects in this study had been on HRT for at least one year, 
and it is possible that the women in the NHRT group may not have been suffering from 
acute menopausal symptoms because they had higher concentrations of endogenous 
estrogen to begin with. There is also great intra- and inter variability in serum estradiol 
among women who use HRT, and the limited number of subjects in this study may not 
have been sufficient to see significant differences in estrogen concentrations. In future 
studies the measurements of estrone, the predominant circulating estrogen in 
postmenopausal women, might be a better indicator of endogenous hormone 
concentrations. This study did not measure the total estrogenic activity in these subjects.
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At menopause the production of progesterone is limited to a small amount 
produced by the adrenal gland which is used as a precursor for the synthesis of other 
steroids. Although unexpected, there was a significant difference (p< 0.01) found in 
progesterone concentrations when comparing the NHRT group to the HRT group (Table 
3b). The NHRT group had higher concentrations of progesterone (0.4778 ± 0.08) when 
compared to the HRT group (0.3245 ± 0.02) which at first seemed contradictory. As with 
the estradiol assay, the ELISA used in this study was specific for progesterone and 
therefore did not measure the progestins in the HRT formulations, but rather the 
endogenous progesterone in vivo. Progestins are not well absorbed and are broken down 
by the liver. The stimulation of the liver by the progestins may have stimulated the 
steroidogenic pathway resulting in more endogenous progesterone being utilized as a 
precursor resulting in the lower concentrations of progesterone seen in the HRT group 
seen in this study.
Studies have indicted that only -25-50% of the cardioprotective effects of estrogen 
is thought to be mediated by the beneficial changes in lipids and lipoproteins (109). Several 
other mechanisms are currently being investigated and the present study sought to 
determine the impact of HRT and lifestyle factors on the oxidative modification of LDL-C. 
Previous studies have supported the belief that the oxidative modification of LDL is an 
important step in the development and progression of atherosclerosis (232). Estrogen 
alone or acting synergistically with antioxidants confers protection from oxidation to the 
LDL-C (10), (11), (139). Estrogen affects the synthesis and secretion of lipoproteins by 
the liver and because the lipoproteins are the carriers of the antioxidant nutrients in the
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peripheral circulation, this study investigated the potential effect of estrogen (endogenous 
and exogenous) on the antioxidant content of LDL-C; as well as the oxidizability of 
LDL-C. Human LDL-C is also protected from oxidative modification by lipid soluble 
antioxidants present in the same particle.
The concentration of the two antioxidants of dietary origin were measured in both 
the serum and the isolated LDL. The basis of this research was from a study reported by 
Clemente et al (150) which suggested that the effect of HRT may be its ability to conserve 
and enrich the antioxidants in the LDL-C. Clemente suggests that the ratio of total serum 
antioxidants to LDL antioxidants is a more appropriate way to indicate estrogen’s ability to 
protect LDL-C from oxidative damage. Therefore, a higher ratio would indicate more 
enrichment of the LDL-C, despite of the amount found in the serum. The subjects in the 
present study did not demonstrate significant differences in serum or in LDL 
ac-tocopherol and 3-carotene concentrations (Table 4a). In comparing the NHRT group to 
the HRT group (Table 4b) a trend was noted toward higher oc-tocopherol/LDL (NHRT 
group 34.80 pmol/l ± 1.77 verses HRT group 38.52 pmol ± 2.7) and P-carotene/LDL 
(NHRT group (0.17 ± 0.02 verses HRT group 0.259 ± 0.06) ratios in the HRT group. 
These results suggest that hormone replacement therapy may exert some effect on the 
ability to preserve the antioxidant nutrients in LDL, although further studies would be 
required to determine this effect.
Two in vitro oxidation assays were performed in this study. The in vitro oxidation 
of isolated LDL-C with copper is a more traditional method used to indicate resistance of 
the LDL-C to oxidation. In this method lag phase, rate and maximum diene formation are 
quantified. Longer lag times, the time prior to oxidation when antioxidants are being
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depleted, indicates more protection to the LDL-C. Higher rate of diene formation and 
maximum diene formation values are indicative of more oxidation occuring and therefore 
less protection to the LDL. No significant differences were found in lag phase or maximum 
diene formation among subjects in this study. However, there was a trend toward longer 
lag phase and higher maximum diene formation (Table 4b) in the HRT group. There was a 
significant difference in rate of diene formation between the NHRT (12.94 ±0.33) and HRT 
(11.41 ±0.30) group at p <0.01.
ORAC is a method for quantifying the total antioxidants present in a biological 
system. The subjects using HRT had a lower ORAC value (3769.65 pmol Trolox equiv/1 
±138.73) than the NHRT group (4300.70 pmol Trolox equiv/1 ± 201.700) at p< 0.05 
(Table 4b). This seems contradictory to what might be expected, however ORAC is a 
measure of not only the fat soluble antioxdants (oc-tocopherol and P-carotene); but also 
water soluble vitamin C, and enzymes (superoxide dismutase, catalase, glutathione 
peroxidase), as well as macromolecules such as ferritin, and albumin. It is possible that the 
women who were not using HRT had more total antioxidants regardless of HRT use. This 
data suggests that HRT may have conferred some protection from oxidation to the LDL, 
although further studies are needed to confirm this.
The Effect of Lifestyle Interventions on Cardiovascular Risk Profile 
Positive lifestyle interventions, health supporting diets and routine exercise, result in 
decreased risk for cardiovascular disease. Studies have consistently shown the diets low in 
total fat, saturated fat, and high in monounsaturated fat and fiber result in a decreased 
cardiovascular risk (155), (156). Consumption of high amounts of the antioxidant
96
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
nutrients (oc-tocopherol and 3-carotene) from diet and supplements results in a decreased 
risk of CVD (143), (134), (145), (135), (144). Two validated instruments (three day food 
diary and a food frequency questionnaire) were used in this study to assess the quality of 
dietary intake and to relate dietary intake to the serum measurements. Collecting 
retrospective data from a food frequency questionnaire and prospective data from a three- 
day intake allowed for a comprehensive assessment of the subject’s dietary patterns. 
Information gathered from the three-day food diary (Tables 6a and 6b) indicated that all 
groups were consuming diets that were low in fat, saturated fat, as well as containing 
adequate intakes of vitamin E, calcium, iron, and dietary fiber. Data from the food 
frequency questionnaire (Tables 7a and 7b) indicated similar dietary intakes with the 
exception of percent calories from fat, which was > 30% in all three groups. The overall 
assessment of the subjects’ dietary intake from the DINE Score (Tables 10a and 10b)was 
rated as “good” for the NHRT and EO groups and “fair” for the E/P group. The reported 
dietary intakes from the subjects in the present study indicate the consumption of diets that 
were low in total fat, cholesterol, and saturated fat. The fact that lipid and lipoprotein 
concentrations among subjects met the NCEP guidelines appears to support the hypothesis 
that women who consume health supporting diets will demonstrate a decreased risk of 
cardiovascular disease independent of their use of hormone replacement therapy.
The intakes of the antioxidant nutrients, 3-carotene and ct-tocopherol, from diet 
and supplements is represented in Tables 8a, 8b, 9a, and 9b. The NHRT group consumed 
more vitamin E from dietary sources than either of the hormone replacement groups (15 
mg/day ± 2.2), (13.97 mg/day ± 3.5), and (11.86 mg/day ± 1.3) respectively. However, 
when vitamin E supplements were taken into consideration, the E/P group consumed more
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total vitamin E (234.80 mg/day ± 68.5), than the NHRT group (158.49 mg/day ± 44.1) or 
the EO group (64.57 mg/day ± 28.0) respectively . The NHRT group also consumed 
more P-carotene from dietary sources (3432.88 RE/day ± 779.18) than the two EO 
(1079.39 RE/day ± 262.16) or the E/P group (2778.21 RE/day ± 910.94). However, as 
seen with vitamin E, both HRT groups reported higher intakes from supplements: EO 
(1000 RE/day ± 500), E/P (909.09 RE/day ± 250.63) verses NHRT (692.31 RE/day ± 
192.31). These results suggest that women who use HRT are more likely to use dietary 
supplements and may in general feel more comfortable with the use of “pills” to treat or 
prevent disease. This was also seen with past use of oral contraceptives with the women 
using HRT reporting (5.44 years ± 1.28) of past use as compared to NHRT group 
reporting (3.94 years ± 1.28). Results from all the dietary instruments indicate that all 
three study groups were consuming adequate and health-supporting diets regardless of 
HRT use.
Changes in body composition with age have been shown to be associated with an
increased risk of cardiovascular disease. Although obesity is not an independent risk factor
in cardiovascular disease, it is secondary to hypertension, diabetes mellitus, and
dyslipidemia (162). With age there is a decrease in lean body mass, an increase in fat mass,
and a shift from a gynoid to an android fat distribution (159). Body mass index is
associated with an increase in triglyceride and LDL-C (167) and a decrease in HDL-C
concentrations (166), (170). In the present study the EO group was heavier, had higher
body mass indexes than either the NHRT group or the E/P group. In fact a significant in
BMI was found between the EO group (28.42 ± 1.66) and the E/P group (24.50 ± 1.04) at
(p<0.01). The NHRT and the E/P group were both within desirable ranges for BMI (26.71
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± 0.86) and (24.50 ± 1.04) respectively. However the EO group was slightly above the 
desirable limits with a body mass index of (28.42 ± 1.66). In the present study body mass 
index was positively correlated with serum triglycerides (r= .354, p<0.01), LDL (r= .265, 
p<0.05), and total cholesterol/HDL ratio (r= .391, p<0.01); and negatively correlated with 
HDL (r= -.308, p<0.05) which is consistent with previous research (167), (166).
Although the use of HRT has not been shown to increase or decrease weight in 
women who use it, it has been suggested that its use will prevent the shift to the android fat 
pattern (159) and therefore decrease the risk of cardiovascular disease. All three groups in 
the present study had waist-hip ratios that within desirable limits (<0.8). Waist-hip ratio 
was positively correlated with serum triglycerides (r= .354, p<0.01) and total 
cholesterol/HDL ratio (r= .377, p<0.01) and negatively correlated with LDL P-carotene 
(r= -.256, p<0.05) and serum HDL (r= -.342, p<0.01). Although we are unable to 
determine if HRT affected body composition in this population, the acceptable body mass 
indexes and waist-hip ratios found in the NHRT and E/P groups may have contributed to 
the benefits to serum HDL-C and triglyceride concentrations found in these subjects, which 
in turn would result in lower cardiovascular risk.
It has been shown that postmenopausal women can benefit greatly from engaging in 
routine exercise (177), (178), (179). Exercise has been shown to increase HDL-C, the most 
important lipoprotein parameter in women (172), (67). Exercise also reduces stress (68), 
reduces the severity of vasomotor instability (190) and depression (2). The American 
College o f Sports Medicine Prevention and Rehabilitative Exercise Committee now 
recommends 30 minutes of moderate exercise most, if not all, days of the week to 
decrease cardiovascular risk. It is also suggested that this exercise does not have to be
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continuous, but in fact short bouts of exercise can confer the same benefits (182). In the 
present study, all three groups reported participating in the recommended exercise routine. 
As demonstrated in Tables 5 a and 5b, women had been participating in a routine exercise 
program for an average of 6.62 years ±1.17. Subjects in this study engaged in moderate 
and frequent exercise, report less severe postmenopausal symptoms, more positive self­
esteem and moods regardless of HRT use. All of these factors may have contributed to the 
low cardiovascular risk demonstrated in these subjects.
Factors Affecting the Choice of HRT in Postmenopausal Women 
Women entering menopause today will be given various opinions from the experts 
regarding the risks and benefits of HRT. Reported prevalence rates on the use of HRT 
range from 5.3% (18) to 39.3% (19) throughout the United States. Although women are 
being prescribed HRT at a much greater rate than ten years ago, they continue to take it for 
short-term symptom relief (22) and not for the treatment and prevention of chronic disease 
(20). Women who have had a hysterectomy are also the most likely to use HRT (20), (7). 
There is a great deal of evidence in the literature that women are not compliant (20), (29), 
(40) in following their HRT regimes and tend to discontinue use after one year (7). It is 
important to acknowledge that some of this noncompliance is due to side effects from the 
progestin component of the prescription, such as undesirable bleeding patterns and not to 
women’s indecision regarding the efficacy of HRT. Weintraub (39) describes this as 
“intelligent noncompliance” indicating that women are not using HRT after carefully 
weighing the risks and benefits and making an intelligent and informed choice based on this 
information.
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Table 14 and Figure I represent the factors that influenced the decision to use 
HRT. Subjects reported health concerns as the major factor influencing their choice to use 
HRT. Previous research has reported relief of symptoms as the strongest factors in 
choosing HRT (22). Subjects in the current study also reported concern about 
osteoporosis, and heart disease equally as important as relief of acute symptoms. This may 
indicate that women today have more information on HRT’s role in the prevention of such 
chronic diseases as heart disease and osteoporosis. Although hysterectomy was reported 
as a concern by 13.6% of the subjects, the limited number of women in the hysterectomy 
group may altered interpretation of the results.
Past research has consistently shown that health care professionals strongly 
influence the decision to use HRT (29), (16). As seen in Table 14 and Figure 1, subjects in 
this study also reported that advice of the physician or other health care providers strongly 
influenced their decision to use HRT, with advice of friends, co-workers, family members 
and partners as having little influence.
Women in the present study who chose to use HRT do not tend to use alternative 
therapies to treat menopausal symptoms (31). As represented in Table 16, subjects in the 
present study did not report any significant use of alternative therapies such as meditation, 
yoga, exercise. This could be explained by the fact that this information was gathered after 
women had been using HRT for at least one year and they may have not perceived these 
activities as alternatives or treatment for symptoms that were no longer present. As seen in 
Tables 5a and 5b subjects had been exercising at their present duration and intensity for 
3.35-9.70 years. This indicates that many of the subjects were exercising premenopausally 
and did not see this activity as a method to treat menopausal symptoms.
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Women also reported that their primary source of information on menopause came 
from health care professionals (Table 15). They also reported that psychological or social 
factors (mood changes, concern about aging, or sexual problems) had little influence on 
their choice. Although past research has demonstrated health benefits with the use of 
HRT, women remain reluctant to use HRT and that health care providers have reservations 
about prescribing HRT to women for long term use.
Many factors influence a women’s decision to use hormone replacement therapy 
during menopause. The influence that the health care provider has on a women’s decision 
regarding HRT is well documented in the literature (29), (16), (30), (31). The present 
study demonstrated the same trend as 82.8% of subjects reported that the advice of the 
physician or health care professional was “moderately influential” or “extremely influential” 
in making the decision to use HRT (Figure 1) and 70.5% reported MD or health care 
professional as the “moderately informative” or “extremely informative” in providing them 
with information on menopause (Figure 2). In view of the fact that health care providers 
have such a profound influence on women’s choice of HRT, one might question where 
health care providers are obtaining their information on hormone replacement therapy and 
the efficiency of prescribing it to their patients? The review of the literature attests to a 
wide body of information related to menopause and HRT in professional journals, 
magazines and books; however, physicians also receive much of their information directly 
from the pharmaceutical industry. Recommendations and information from the drug 
representatives or literature mailed to them by the pharmaceutical company also influence 
the information that health care providers disseminate to their patients. In the past, 
physicians have been reluctant to prescribe HRT to women with chronic health problems,
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such as hypertension, diabetes, or heart disease (24). When discussing HRT with their 
patients, physicians are more likely to talk about short-term symptom relief rather than 
treatment of chronic disease or the value of lifestyle changes (35). The message and 
information being conveyed to health care professionals may emphasize symptom relief 
instead of the positive effects that HRT has on heart and bone. In the present study the 
subjects were concerned with relief of symptoms, but more concerned with heart disease 
and osteoporosis. It is therefore important that health care providers convey accurate and 
current information not only on the risks and benefits, but also discussion on alternatives to 
HRT. The role of the health care professional is vital as they serve as the conduit between 
the pharmaceutical industry and their patients.
In spite of the fact that a women’s lifetime risk of developing heart disease is 
greater than that of breast cancer, studies have reported that women have a greater fear 
breast cancer than heart disease (42) and that they do not perceive the risk of heart disease 
as great (16). One out of two postmenopausal women will develop coronary artery 
disease, as compared to a one in eight lifetime chance of breast cancer (77). In the present 
study 45.9% of respondents reported cancer concerns as a reason for not using HRT 
(Table 17, Figure 3). Skafar, et al in a recent article noted that “cardiovascular disease is 
the leading cause of mortality in women, a fact that is underappreciated by women and 
their physicians” (233). Women and their physicians may not perceive heart disease as 
important a risk as breast cancer because cardiovascular disease usually occurs later in life 
after the decision regarding HRT has already been made. The majority of women 
contemplate HRT use when symptoms first appear, which is usually during the 
perimenopausal years when cardiovascular symptoms are not as likely to be present.
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However, this is the time when the threat of breast cancer increases, making women very 
aware of the potential of developing breast cancer. Although both heart disease and breast 
cancer take years to develop, when the diagnosis of breast cancer is made, treatment 
usually begins immediately. On the other hand, cardiovascular disease manifests itself in 
many ways, to different degrees, and with varied symptoms. A women can have heart 
disease without severe or identifiable symptoms. Diagnosis is often not made until there is 
a major cardiovascular event. The increased risk of breast cancer associated with HRT use 
appears to be related to the duration of estrogen use. Women who use estrogen for < 5 
years appear to have no increased risk, but for women who use estrogen 8-15 years the 
relative risk is 1.25-1.3 respectively (6). The most recent evidence from the Nurses ’
Health Study (107) has also shown an increased risk of breast cancer with 10 or more years 
of HRT use. This fact may be one of the reasons that physicians tend to prescribe HRT to 
women for short periods of time, agreeing with their patients that long term use could 
increase the risk of breast cancer.
When evaluating family medical history from all the subjects (Table 2), the NHRT 
had a combined family history of heart disease (heart disease and deaths from heart disease) 
of 66%, and the HRT group a 64% family risk. In contrast the NHRT had a combined 
family history of breast cancer (breast cancer and deaths from breast cancer) of 16.6%, and 
the HRT group a 8.8% family risk. Although the women in the current study reported a 
higher family risk for cardiovascular disease than breast cancer, cancer concerns were the 
primary reason for not using HRT among subjects. The results of the current study 
supports the past research that women are more aware of the risks of breast cancer than of 
heart disease related to the use of hormone replacement therapy (42). Table 17 and Figure
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3 present the reported reasons that the women in the present study chose not to use HRT 
The data supports the original hypothesis as 43.9% of the women surveyed reported cancer 
as a major concern.
In the present study all but one subject in the EO group had experienced a 
hysterectomy. Historically, hysterectomized women have been excluded in HRT studies 
even though they represent a large percentage of postmenopausal women and are the most 
likely group to be using HRT (20), (7). One third of women in the United States will 
experience a hysterectomy by age 65 (234). It is estimated that 570,000 women a year in 
the United States undergo a hysterectomy and for approximately 50% of these women 
surgery includes a bilateral oophorectomy (234). Unlike women without hysterectomies, 
women who have experienced a hysterectomy have a high adherence to HRT over time 
(235). One of the factors that may contribute to the higher adherence and long-term use by 
hysterectomized women may be that they are able to take unopposed estrogen, without 
progestin, and therefore do not suffer from withdrawal bleeding. They also do not have the 
concern of developing endometrial cancer, which may increase adherence rates. It was 
determined that women who had experiences a hysterectomy should be included in the 
present research, however, the lack of sufficient numbers made it difficult to interpret the 
results from this group.
Impact of HRT on Psychological and Social Factors 
The perception that menopause is a negative experienced is not supported by the 
literature (194), (203), (204), (208). In fact most women go through menopause with a 
minimum of stress and women are not more depressed during this time when compared to
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premenopausal counterparts (236), (204). Much of the negative perception of menopause 
has been created by the medical model which characterizes menopause as a “deficiency 
disease” treatable by HRT, as opposed to a natural transition in a woman’s life. The impact 
of media and pharmaceutical public relations literature may be partly responsible for this 
perception. The Healthy Women’s Study reported that women have more negative 
expectations prior to menopause than they actually experience (203), (204). Women who 
are depressed prior to menopause tend to be depressed during menopause also (210). It is 
important to take into consideration that women during mid-life are also likely to be 
experiencing other changes in addition to menopause (children leaving home, aging parents 
and partners, health concerns, career changes) which could also contribute to their 
psychological well-being during this time. It is difficult to separate these factors when 
evaluating women’s reactions to and perceptions of menopause.
The data from the present study demonstrated that women were not depressed or 
overwhelmed with menopausal symptoms. The POMS Inventory (Tables 11a and 1 lb) 
measuring mood states demonstrated that use of HRT did not have an impact on any of the 
sub-scales or total mood score. The women in all three groups demonstrated positive 
mood states using this instrument. The same trend was found in self-esteem scores (Tables 
12a and 12b) with the use of HRT having little effect on women’s self-esteem as all three 
groups reporting high levels of self-esteem. Subjects in this study did not report negative 
symptoms due to menopause, as demonstrated in tables 13a and 13b. All of this data 
supports the past literature that has shown that for the majority of women, menopause is 
not a negative experience. The results also suggest that women who practice positive 
lifestyle interventions (exercise and health-supporting diets) demonstrate less severe
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menopausal symptoms, higher self-esteem, and more positive mood states regardless of 
HRT use.
The perception that menopause is associated with a decline in quality of life is not 
supported by the literature or by the present study.
Limitations o f  the Studv.
1. It is important to acknowledge that the present study is observational and retrospective. 
The information collected was from postmenopausal women one year after they had 
made their choice regarding HRT. The data related to prior health and psychological 
factors is therefore subjective in nature and therefore difficult to evaluate which of 
these elements can be directly attributed to the choice of HRT.
2. Only one blood sample was evaluated in this study. Repeated measures would have 
provided more data and better evaluation o f biological variables.
3. The trends seen in several variables under study might have been statistically significant 
with a larger subject pool.
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CHAPTER VI
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
Heart disease remains the leading cause of death in women and accounts for one- 
third of all hospitalizations in women over the age of 55 (237). An impressive body of 
evidence supports the possibility that HRT offers protection against cardiovascular disease 
in women, although the mechanism/s have not been fully elucidated. It is important to 
remember that epidemiological studies, while suggesting a relationship, do not prove cause 
and effect. Closely controlled clinical trials and observational research protocols are 
needed before it can be determined if HRT decreases cardiovascular risk for the majority of 
postmenopausal women. Until that time, women and their health care providers need to 
collaborate to evaluate the risk-benefit equation for each women individually. Women with 
a strong personal or family history of heart disease and a low risk for breast cancer, may 
chose to use HRT, whereas a woman with a high breast cancer risk may not make the same 
choice. There also needs to be continued research investigating alternatives to HRT for 
women who cannot or chose not to use HRT.
A recent study from a cohort of the Nurses ’ Health Study (238) investigated the
effect of folate intake from diet and supplements on the risk of CHD in 80,000 women with
no cardiovascular risk factors. The women were followed for 14 years and a FFQ was
used to determine dietary intake. Women who consumed 696pg of folate/day as compared
to 158 pg/day had a RR of 0.67 (95% confidence interval (Cl), 0.55-0.87], Folate is a
nutrient that is easily obtained from a variety of foods, is water soluble and therefore
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unlikely to be toxic, and has demonstrated a 67% reduction in cardiovascular disease in this 
study. Results of this study indicate that there may be alternatives to HRT that could 
provide decrease risk from chronic disease without the risks and expense.
The present study involving a free-living population of postmenopausal women 
offered a unique look at the menopausal experience. The women who participated in this 
study were very similar to the subjects in the previous observational studies and therefore 
appropriate for comparison. The use of the biopsychosocial model in this research allowed 
a broader perceptive from which to observe menopause, hormone replacement therapy, and 
the factors that determine a women’s use of HRT.
The results suggests that women who practice positive lifestyle interventions will 
demonstrate low risk for CVD regardless of HRT use. There were no significant 
differences in either physiological outcomes nor in self-esteem, moods, and symptoms 
reporting in relation to HRT. The 70 women participating in the study practiced 
preventative health care, ate health-supporting diets, controlled their body composition, 
and exercised on a routine basis.
Several prospective, randomized placebo-controlled studies are presently in 
progress which may offer more answers to the questions that women and physicians have 
regarding hormone replacement therapy. The Women’s Health Initiative will hopefully 
offer some insight within the next 5-10 years. Until this and other clinical trials offer more 
information, women will need to make the decision regarding HRT use on an individual 
basis, after weighing the risk and benefits of the options. In the future many women will 
have spend a large portion of their adult years on some type of exogenous hormones. The 
efficacy of this choice will be evaluated as each generation reaches menopause. In the
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meantime Susan Love suggests that ‘‘any women taking hormones has to realize that she’s 
part of a large experiment” (87).
Future Research
The research presented in this dissertation investigated the biological, social, and 
psychological outcomes of the choice to use or not to use hormone replacement therapy in 
postmenopausal women who have already made their choice regarding HRT. A 
prospective study would allow evaluation of the biological, social, and psychological 
factors before and after making the choice to use or not to use HRT.
An ongoing study is presently underway that is following the subjects described in 
this dissertation. Subjects have donated a blood sample and biological assays are being 
repeated. Information from a second questionnaire will collect information on present 
health status, current HRT use, and reasons for any change in HRT status one to two years 
after the initial study.
A longitudinal study is also planned to follow the 301 women who completed the 
UNWHS Questionnaire through each phase of the menopausal transition.
More research is needed to determine different dose and methods of administration 
of exogenous hormones so the formulations can be more individualized and safer for 
women. More research is needed on alternatives to hormone replacement therapy, 
including the use of phytoestrogens, natural HRT, and lifestyle interventions.
The findings presented here also indicate a need to examine the mechanisms for the 
effects of the steroidal hormones of hormone replacement therapy on lipids and 
lipoproteins, clotting factors, antioxidants, carbohydrate metabolism, effects on the
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vascular system and the vascular wall. Additional studies are needed to evaluate the effect 
of both endogenous and exogenous hormones on the oxidizability of LDL and the role of 
that antioxidants play in this mechanism.
This research indicates that women need more information on aging, menopause, 
and the risks and benefits of hormone replacement therapy. Health care providers need to 
be educated and updated on these issues to enable them to work as collaborators with their 
patients to offer accurate and timely information.
I l l
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Table la. Subject Characteristics by HRT Use. Comparison of all groups: No Hormone 
Replacement (NHRT), Estrogen Only (EO), and Estrogen & Progestin (E/P).________
NHRT (n=36) EO (n=ll) E/P (n=23)
Age (years) 56.63 (±0.79) 56.00 (± 1.41) 54.57 (± 0.79 )
Height (inches) 64.51 (±0.35)* 63.70 (±0.62)a 66.00 (± 0.52)
Weight (pounds) 157.69 (± 5.27) 164.32 (±9.83) 151.74 (±7.13)
Body Mass Index 26.71 (±0.86) 28.42 (± 1.66)a 24.50 (± 1.04)
Waist/Hip Ratio 0.779 (±0.01) 0.786 (± 0.03) 0.753 (±0.01)
# children 2.19 (±0.23) 2.09 (±0.37) 2.43 (±0.30)
# pregnancies 2.39 (±0.25) 3.36 (±0.62) 2.67 (± 0.40)
Past OC use (years) 3.94 (±0.79) 4.00 (± 1.73) 5.86 (± 1.59)
Values represent least square mean ± SEM.
aGroup significantly different from E/P group (p<0.05).
Table lb. Subject Characteristics by HRT Use. Comparison of No Hormone Replacement 
Therapy (NHRT) Group to Hormone Replacement Group (HRT): Estrogen Only (EO) 
and Estrogen and Progestin (E/P).____________________________________________
NHRT (n=36) HRT (n=34)
Age (years) 56.63 (±0.79) 55.03 (± 0.70)
Height (inches) 64.51 (±0.35) 65.26(± 0.44)
Weight (pounds) 157.69 (±5.27) 155.32 (± 5.78)
Body Mass Index 26.71 (± 0.86) 25.77 (± 0.93)
Waist/Hip Ratio 0.779 (±0.01) 0.764 (±0.01)
# children 2.19 (±0.23) 2.31 (±0.23)
# pregnancies 2.39 (± 0.25) 2.31 (±0.34)
Past OC use (years) 3.94 (±0.79) 5.44 (± 1.28)
Values represent least square mean ± SEM. There were no significant differences among 
groups.
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Table 2. Summary of reported personal and family health history







Breast Cancer 1 (2.8%) 0 (0%) 0 (0%)
Diabetes Mellitus (Type II) 0 (0%) 0 (0%) 1 (4.3%)
Fibrocystic Breast Disease 3 (8.3%) 2 (18.2%) 2 (8.7%)
Heart Disease 1 (2.8%) 1 (9.1%) 1 (4.3%)
Hyperlipidemia being 
treated with medication
4(11.1%) 0 (0%) 1 (4.3%)
Hypertension 9 (25.0%) 2 (18.2%) 1 (4.3%)
Osteoporosis 1 (2.8%) 0 (0%) 2 (8.7%)
Other Cancers 1 (2.8%) 0 (0%) 0 (0%)
Family History
Breast Cancer 3 (8.3%) 0 (0%) 1 (4.3%)
Breast Cancer/Death 3 (8.3%) 2 (18.2%) 0 (0%)
Heart Disease 18 (50%) 7 (63.6%) 6(26.1%)
Heart Disease/Death 6 (16.7%) 5 (45.5%) 4 (17.4%)
Other Cancers 1 (2.8%) 0 (0%) 0 (0%)
Osteoporosis 3 (8.3%) 1 (9.1%) 2 (8.7%)
Table 3a. Serum and Plasma Values of Serum Lipids, Serum Estradiol and Progesterone, 
by HRT Use. Comparison of all groups: No Hormone Replacement (NHRT), Estrogen 
Only (EO), and Estrogen and Progestin (E/P).______________________ ____________
NHRT (n=36) j EO (n=l 1) E/P (n=23)
Serum triglyceride (mg/dL) 118.75 (± 15.07) 165.61 (±34.55) 127.50 (± 12.40)
Serum HDL-cholesterol (mg/dL) 52.76 (± 2.26) 55.91 (±3.75) 51.94 (±2.62)
Serum LDL-cholesterol (mg/dL) 148.06 (± 5.26) 147.67 (± 9.09) 138.66 (±7.72)
Serum total cholesterol (mg/dL) 224.59 (± 6.22) 235.32 (± 11.56) 212.48 (±8.81)
Serum Lp (a) (mg/dl) 20.55 (± 2.86) 20.27 (± 5.43) 14.64 (±3.50)
Total CholesteroI/HDL ratio 4.56 (± 0.25) 4.27 (± 0.27) 4.44 (± 0.32)
Estradiol (pg/ml) 16.93 (± 2.08) 21.85 (±9.46) 17.87 (±2.05)
Progesterone (ng/ml) 0.4778 (± 0.08) 0.3545 (±0.05) 0.3152 (±0.03)
Values represent least square mean ± SEM. There were no significant differences among 
the groups.
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Table 3b. Serum and Plasma Values of Serum Lipids, Serum Estradiol and Progesterone, 
by HRT Use. Comparison of No Hormone Replacement Therapy (NHRT) Group to 
Hormone Replacement Group (HRT): Estrogen Only (EO) and Estrogen and Progestin 
(E/P).___________________________________________________________________
NHRT (n=36) HRT (n= 34)
Serum triglyceride (mg/dL) 118.75 (±15.07) 139.83 (± 14.00)
Serum HDL-cholesterol (mg/dL) 52.76 (±2.26) 53.18 (±2.14)
Serum LDL-cholesteroI (mg/dL) 148.06 (± 5.26) 141.48 (±5.98)
Serum total cholesterol (mg/dL) 224.59 (±6.22) 219.87 (±7.18)
Serum Lp (a) (mg/dl) 20.55 (± 2.86) 16.46 (± 2.94)
Total Cholesterol/HDL ratio 4.56 (± 0.25) 4.39 (± 0.23)
Estradiol (pg/ml) 16.93 (± 2.08) 19.16 (±3.28)
Progesterone (ng/ml) 0.4778 (± 0.08)a 0.3245 (± 0.02)
Values represent least square mean ± SEM. 
'Groups significantly different (p<0.01).
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Table 4a. Serum Antioxidants, LDL Antioxidants, ORAC and LDL Oxidation by HRT Use. Comparison of groups: No 
Hormone Replacement (NHRT), Estrogen Only (EO), and Estrogen and Progestin (E/P),
NHRT (n=36) EO (n=l 1) E/P (n=23)
Serum a-tocopherol (gmol/1) 34.80 (± 1.77) 38,19 (± 5.11) 38.68 (±3,16)
Serum (3-carotene (pmol/1) 0.631 (± 0,07) 0.945 (± 0.43) 0.777 (±0.16)
Serum retinol (pmol/l) 2.085 (± 0.09) 2.471 (±0.22) 2.362 (±0.10)
Serum lutein (pmol/l) 0.3008 (± 0,03) 0.3172 (± 0.05) 0.2837 (± 0.02)
LDL a-tocopherol (mol/mol LDL) 8,556 (± 1.30) 7.070 (±0,71) 8.500 (± 0.62)
LDL (3-carotene (mol/mol LDL) 0.315 (± 0.04) 0.378 (±0,14) 0.411 (±0.10)
a-tocopherol/LDL ratio 9.24 (± 0.45) 9.74 (± 1.25) 11.05 (± 0.85)
(3-carotene/LDL ratio 0.17 (±0.02) 0.24 (±0.10) 0.27 (± 0,08)
ORAC (pmol Trolox equiv/1) 4300.70 (± 201.70) 3792.79 (± 181.63) 3758.59 (± 188.40)
ORAC
(nmol Trolox equiv/mg protein)
45.94 (± 2.29) 39,01 (±5.86) 41.44 (± 10,93)
LDL oxidation
lag phase(min) 38.39 (±2.97) 39,11 (±8.67) 41.83 (±4.50)
rate of diene formation 
(ng/min/mg LDL protein)
12.94 (± 0.33)a 12,32 (± 0.64) 11.05 (± 0.31)
maximum diene formation 
(ng/mg LDL protein)
431.22 (±5,70) 409.11 (± 12,30) 419,09 (±8,32)
Values represent least square mean ± SEM. 
a Group significantly different from E/P group (p<0.001)
Table 4b. Serum Antioxidants, LDL Antioxidants, ORAC, and LDL Oxidation by 
HRT Use. Serum and Plasma Values o f Serum Lipids, Serum Estradiol and 
Progesterone, by HRT Use. Comparison of No Hormone Replacement Therapy 
(NHRT) Group to Hormone Replacement Group (HRT): Estrogen Only (EO) and
NHRT (n=36) HRT (n= 34)
Serum a-tocopherol (pmol/1) 34.80 (± 1.77) 38.52 (± 2.7)
Serum 3-carotene (pmol/1) 0.631 (±0.07) 0.831 (±0.27)
Serum retinol (pmol/1) 2.085 (± 0.09)a 2.398 (±0.10)
Serum lutein (pmol/1) 0.3008 (± 0.03) 0.2938 (±0.18)
LDL a-tocopherol (mol/mol LDL) 8.556 (± 1.30) 8.037 (± 0.49)
LDL 3-carotene (mol/mol LDL) 0.315 (±0.04) 0.400 (±0.81)
a-tocopherol/LDL ratio 9.24 (± 0.45) 10.64 (± 0.70)
3-carotene/LDL ratio 0.17 (±0.02) 0.259 (0.06)
ORAC (nmol Trolox equiv/1) 4300.70 (± 201.70)3 3769.65 (±138.73)
ORAC
(nmol Trolox equiv/mg protein)
45.94 (±2.29) 40.66 (± 1.64)
LDL oxidation
lag phase(min) 38.39 (±2.97) 41.06 (±3.98)
rate of diene formation
(ng/min/mg LDL protein)
12.94 (± 0.33)b 11.41 (±0.30)
maximum diene formation 
(ng/mg LDL protein)
431.22 (±5.70) 416.28 (±6.85)
Values represent least square mean ± SEM. 
1 Groups significantly different (p<0.05). 
b Groups significantly different (p<0.01).
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Table 5a. Lifestyle Factors by HRT Use. Comparison of All Groups: No Hormone
Replacement (NHRT), Estrogen Only (EO), and Estrogen & Progestin (E/P).
NHRT (n=33) EO (n= 11) E/P (n= 22)
Alcohol (drinks/mo) 12.27 (± 2.77) 7.64 (±3.70) 9.64 (± 2.05)
Exercise (years) 6.80 (± 1.8) 9.70 (± 4.0) 3.35 (± 1.0)
Exercise (min/wk) 129.69 (± 18.8) 103.33 (±29.2) 90.48 (± 17.9)
Exercise (times/wk) 3.36 (±0.4) 3.18 (±0.8) 2.27 (± 0.4)
Values represent least square mean ± SEM. There were no significant differences 
among groups.
Table 5b. Lifestyle Factors by HRT Use. Comparison of No Hormone 
Replacement Therapy (NHRT) Group to Hormone Replacement Therapy 
Group (HRT): Estrogen Only (EO) and Estrogen and Progestin (E/P) Groups.
NHRT (n=33) HRT (n= 331
Alcohol (drinks/mo) 12.27 (± 2.77) 8.97 (±2.1)
Exercise (years) 6.80 (± 1.8) 5.47 (± 1.12)
Exercise (min/wk) 129.69 (± 18.8) 94.33 (± 15.06)
Exercise (times/wk) 3.36 (±0.4) 2.58 (± 0.4)
Values represent least square mean ± SEM. There were no significant 
differences among groups.
Table 6a. Dietary Intake of Selected Nutrients from Three-day Diet Record by HRT Use. 
Comparison of all groups: No Hormone Replacement (NHRT), Estrogen Only (EO), and 
Estrogen and Progestin (E/P).
NHRT (n= 28) EO (n= 9) E/P (n= 17)
Calories (kcals) 1790.46 (± 59.46) 1712.56 (± 136.4) 1765.65 (± 71.8)
Fat (g) 51.69 (±4.3) 48.68 (± 6.8) 52.76 (± 4.2)
Fat (% of kcals) 24.79 (± 1.6) 24.03 (± 2.2) 25.59 (± 1.5)
Cholesterol (mg) 190.40 (± 19.2) 150.80 (±29.8) 179.70 (± 28.4)
Saturated Fat (g) 16.50 (± 1.8) 15.11 (±2.5) 15.36 (± 1.7)
Vitamin E (mg) 15.00 (± 2.2) 13.97 (±3.5) 11.86 (± 1.3)
a-tocopherol (mg) 7.96 (± 1.5) 8.63 (±3.0) 6.83 (± 0.9)
Vitamin A (RE) 1513.72 (±201.5) 1521.58 (±206.1) 1443.63 (± 320.2)
3-carotene (RE) 3432.88 (± 779.2) 1215.90 (±267.7) 2778.21 (±910.9)
Calcium (mg) 869.39 (± 67.7) 924.87 (±65.1) 803.1 (±87.0)
Iron (mg) 16.73 (± 2.6) 13.52 (± 1.2) 12.77 (± 0.9)
Dietary fiber (g) 19.44 (± 1.4) 18.30 (±2.6) 22.96 (±3.1)
Values represent least square mean ± SEM. There were no significant differences 
among groups.
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Table 6b. Dietary Intake o f Selected Nutrients from Three-day Diet Record by HRT 
Use. Comparison of No Hormone Replacement Therapy (NHRT) Group to Hormone 
Replacement Therapy Group (HRT): Estrogen Only (EO) and Estrogen and
NHRT (n= 28) HRT (n=26)
Calories (kcals) 1790.46 (± 59.46) 1747.27 (± 65.2)
Fat (g) 51.69 (±4.3) 51.35 (±3.6)
Fat (% of kcals) 24.79 (± 1.6) 25.05 (± 1.2)
Cholesterol (mg) 190.40 (± 19.2) 169.69 (±21.1)
Saturated Fat (g) 16.50 (± 1.8) 15.27 (± 1.4)
Vitamin E (mg) 15.00 (±2.2) 12.59 (± 1.5)
a-tocopherol (mg) 7.96 (± 1.5) 7.46 (± 1.2)
Vitamin A (RE) 1513.72 (±201.5) 1470.61 (±218.3)
3-carotene (RE) 3432.88 (± 779.2) 2237.41 (±614.2)
Calcium (mg) 869.39 (± 67.7) 845.24 (±61.4)
Iron (mg) 16.73 (± 2.6) 13.03 (±0.7)
Dietary fiber (g) 19.44 (a: 1.4) 21.34 (±2.2)
Values represent least square mean ± SEM. There were no significant differences 
among groups.
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Table 7a. Dietary Intake of Selected Nutrients from Food Frequency Questionnaire by HRT 
Use, Comparison of all groups: No Hormone Replacement (NHRT), Estrogen Only (EO), and 
Estrogen and Progestin (E/P), _________________________________________________
NHRT (n= 30) EO (n= 10) E/P (n=17)
Calories (kcals) 1327.75 (±81,2) 1403,20 (± 170.7) 1449.06 (±123.1)
Fat (g) 45,86 (±3.8) 48.88 (± 9.6) 51.86 (±5.6)
Fat (% of kcals) 33,02 (± 1,6) 30.50 (±2.4) 32.61 (±2.3)
Cholesterol (mg) 166,89 (± 14.2) 177.89 (±33.3) 205.70 (± 43,3)
Saturated Fat (g) 14,77 (± 1.4) 15.71 (±3.6) 17.29 (±2.1)
Vitamin E (oc-tocopherol 
equivalents)
9.93 (± 1.7) 9.78 (±2.5) 8.21 (±0.9)
Vitamin A (RE) 1191,81 (±110,84) 1297,57 (± 166,99) 1270.59 (± 189.53)
Retinol (MCG) 602.51 (± 59,5) 713.99 (± 100.9) 623.01 (±77.9)
3-carotene (MCG) 3111,35 (±385,9) 3025.96 (± 773.3) 3491.32 (± 834.3)
Lutein (MCG) 3494.35 (± 636,8) 2973.09 (± 1031,3) 2611.14 (±540.2)
Calcium (mg) 826.5267 (± 86.6) 971.79 (± 112.0) 860.24 (± 105.2)
Iron (mg) 11.45 (± 1.1) 12.29 (± 1.7) 12.32 (± 1.1)
Dietary fiber (g) 12,32 (±1.1) 12.18 (± 1.2) 13,02 (± 1.4)
Values represent least square mean ± SEM, There were no significant differences among groups,
Table 7b. Dietary Intake of Selected Nutrients from Food Frequency Questionnaire by 
HRT Use. Comparison of No Hormone Replacement Therapy (NHRT) Group to 
Hormone Replacement Therapy Group (HRT): Estrogen Only (EO) and Estrogen and
NHRT (n= 30) HRT (n= 27)
Calories (kcals) 1327.75 (±81.2) 1432.07 (±98.1)
Fat (g) 45.86 (±3.8) 50.76 (± 5.0)
Fat (% of kcals) 33.02 (± 1.6) 32.16 (± 1.7)
Cholesterol (mg) 166.89 (± 14.2) 195.40 (±29.6)
Saturated Fat (g) 14.77 (± 1.4) 16.70 (± 1.9)
Vitamin E (oc-tocopherol equivalents) 9.93 (± 1.7) 8.79 (±1.1)
Vitamin A (RE) 1191.81 (±110.84) 1280.59 (± 132.29)
Retinol (MCG) 602.51 (±59.5) 656.71 (±61.1 )
0-carotene (MCG) 3111.35 (±385.9) 3318.97 (±590.2)
Lutein (MCG) 3494.35 (± 636.8) 2745.19 (±500.6)
Calcium (mg) 826.5267 (± 86.6) 901.56 (±77.5)
Iron (mg) 11.45 (± 1.1) 12.31 (±0.9)
Dietary fiber (g) 12.32 (± 1.1) 12.71 (± 1.0)
Values represent least square mean ± SEM. 
groups.
There were no significant differences among
Table 8a. Vitamin E Intake with Diet and Supplements by HRT Use. Comparison of all 
groups: No Hormone Replacement (NHRT), Estrogen Only (EO), and Estrogen and
NHRT (n=31) EO (n= 10) E/P (n= 21)
Vitamin E from Diet (mg) 15.00 (± 2.2) 13.97 (±3.5) 11.86 (± 1.3 )
Vitamin E: Supplements (mg) 157.26 (±48.5) 54.44 (± 30.7) 224.12 (±81.1)
Total Vitamin E (mg) 158.49 (±44.1) 64.57 (± 28.0) 234.80 (± 68.5)
Values represent least square mean ± SEM. There were no significant differences among 
groups.
Table 8b. Vitamin E Intake with Diet and Supplements by HRT Use. Comparison of No 
Hormone Replacement Therapy (NHRT) Group to Hormone Replacement Therapy
NHRT (n=31) HRT (n= 31)
Vitamin E from Diet (mg) 15.00 (±2.2) 12.59 (± 1.5)
Vitamin E from Supplements (mg) 157.26 (±48.5) 165.38 (±55.9)
Total Vitamin E (mg) 158.49 (±44.1) 179.91 (±49.1)
Values represent least square mean ± SEM. There were no significant differences among 
groups.
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Table 9a. (3-Carotene Intake with Diet and Supplements by HRT Use. Comparison of 
all groups: No Hormone Replacement (NHRT), Estrogen Only (EO), and Estrogen 
and Progestin (E/P)._______ _______________ _______________ ______________
NHRT (n=28) EO (n=8) E/P (n=l7)


















Values represent least square mean ± SEM. There were no significant differences among 
groups.
Table 9b. |3-Carotene Intake with Diet and Supplements by HRT Use. Comparison of 
No Hormone Replacement Therapy (NHRT) Group to Hormone Replacement Therapy
Group (HRT): Estrogen Only (EO) and Estrogen and Progestin E/P) Groups.
NHRT (n=28) HRT (n=25)
3-Carotene from Diet (RE) 3432.88 (±779.18) 2237.41 (±614.23)
3-Carotene from Supplements (RE) 692.31 (±192.31) 928.57 (±215.20)
Total 3-Carotene (RE) 4088.02 (± 1188.05) 3419.76 (±1340.36)
Values represent least square mean ± SEM. There were no significant differences among 
groups.
Table 10a. Dine Score of Three-Day Food Intake by HRT Use. Comparison 
of all groups: No Hormone Replacement (NHRT), Estrogen Only (EO), and 
Estrogen and Progestin (E/P).______________________________________
NHRT (n=28) EO (n= 9) E/P (n= 17)
Dine Score 6.21 (± 0.31) 6.75 (±0.38) 5.62 (± 0.35)
Values represent least square mean ± SEM. There were no significant differences 
among groups.
Table 10b. Dine Score of Three-Day Food Intake by HRT Use. Comparison of No 
Hormone Replacement Therapy (NHRT) Group to Hormone Replacement Therapy 
Group (HRT): Estrogen Only (EO) and Estrogen and Progestin (E/P) Groups.
NHRT (n=28) HRT (n= 26)
Dine Score 6.21 (±0.31) 6.01 (±0.28)
Values represent least square mean ± SEM. There were no significant differences 
among groups.
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Table 1 la. Mean Scores of POMS Inventory Sub-scales by HRT Use. Comparison of all groups: No Hormone
Replacement (NHRT), Estrogen Only (EO), and Estrogen & ’rogestin
Range of Scores NHRT (n= 31) EO (n= 10) E/P (n=21)
Tension-Anxiety (T) 0-36 6.97 (±0.8) 8.90 (± 1.6) 6.96 (± 1.0)
Depression-Dejection (D) 0-60 5.20 (± 1.8) 9.20 (± 2.8) 4.16 (± 1.1)
Anger-Hostility (A) 0-48 4.81 (± 1.0) 5.81 (± 1.7) 4.65 (± 1.2)
Fatigue (F) 0-28 7.63 (± 0.9) 7,30 (±2.7) 5.24 (± 1.2)
Confusion-Bewiiderment (C) 0-28 4.66 (±0.7) 6.18 (± 1.6) 4.25 (±0.8)
Vigor (V) 0-32 18.23 (± 1.1) 17,10 (± 1.7) 18.00 (± 1.7)
Total Mood Score (T+D+A+F+C)- (V) 0-168 11.13 (±5.0) 23,22 (±9.1) 6.11 (±6.3)
Values represent least square mean ± SEM . There were no significant differences among groups.
Table 1 lb. Mean Scores of POMS Inventory Sub-scales by HRT Use, Comparison of No 
Hormone Replacement Therapy (NHRT) Group to Hormone Replacement Therapy Group 
(HRT): Estrogen Only (EO) and Estrogen and Progestin (E/P) Groups._______________
NHRT (n= 31) HRT (n=31)
Tension-Anxiety (T) 6.97 (± 0.8) 7.45 (± 4.7)
Depression-Dejection (D) 5.20 (± 1.8) 5.90 (± 1.3)
Anger-Hostility (A) 4.81 (± 1.0) 5.06 (± 1.0)
Fatigue (F) 7.63 (± 0.9) 5.90 (± 1.2)
Confusion-Bewiiderment (C) 4.66 (± 0.7) 4.94 (± 0.7)
Vigor (V) 18.23 (± 1.1) 17.69 (± 1.3)
Total Mood Score (T+D+A+F+C)- (V) 11.13 (±5.0) 11.81 (±5.3)
Values represent least square mean ± SEM. There were no significant among groups.
Table 12a. Mean Scores for Self-esteem Scale by HRT Use. Comparison of all groups: 
No Hormone Replacement (NHRT),Estrogen Only (EO), and Estrogen &
Progestin (E/P). _________________
NHRT (n= 33) EO (n= 11) E/P (n=21)
Self-esteem 8.62 (± 0.2) 8.07 (± 0.4) 8.56 (± 0.2)
Values represent least square mean ± SEM. There were no significant differences among 
groups.
Table 12b. Mean Scores for Self-esteem Scale by HRT Use. Comparison ofNo 
Hormone Replacement Therapy (NHRT) Group to Hormone Replacement Therapy 
Group (HRT: Estrogen Only (EO) and Estrogen and Progestin (E/P) Groups.
NHRT (n= 33) HRT (n= 32)
Self-esteem 8.62 (± 0.2) 8.39 (± 0.2)
Values represent least square mean ± SEM. There were no significant 
differences among groups.
Table 13a. Mean Scores for Experiences (Symptoms) Scale by HRT Use. Comparison 
of all groups: No Hormone Replacement (NHRT), Estrogen Only (EO), and Estrogen 
& Progestin (E/P).
NHRT (n= 16) EO (n= 5) E/P (n= 16)
Experiences 50.38 (± 2.8) 52.20 (± 4.8) 48.13 (±2.0)
Values represent least square mean ± SEM. There were no significant differences among 
groups.
Table 13b. Mean Scores for Experiences (Symptoms) Scale by HRT Use. Comparison 
of No Hormone Replacement Therapy (NHRT) Group to Hormone Replacement Therapy
NHRT (n= 16) HRT (n= 21)
Experiences 50.38 (±2.8) 49.01 (1.8)
Values represent least square mean ± SEM. There were no significant 
differences among groups.
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Health Concerns (M, 2,5)
Hysterectomy (n=22) 72,7 13,6 0 13.6
Relief of Symptoms (n=29) 20,7 6.9 31.0 41.4
Concern about Heart Disease (n=27) 22,2 0 44.4 33.3
Concern about Osteoporosis (n= 31) 6.5 16.1 25,8 51.6
Advice o f  Others (M: 1.8)
Advice of MD/Health Professional (n=29) 10,3 6.9 34.5 48.3
Advice friend/co-worker/family (n=24) 83,3 8.3 8.3 0
Advice of partner (n=24) 95,8 0 4.2 0
Psychological-Social Factors (M: 1.6)
Mood changes (n=26) 69,2 3.8 7.7 19.2
Concern about aging (n=26) 42.3 23.1 23.1 11.5
Sexual problems (n=24) 79,2 16.7 4.2 0













MD/Health care professional (n=61) 9.8 19.7 45.9 24.6
Mother (n=48) 77.1 18.8 4.2 0
Radio/television (n=51) •*> *> j j . j *»j  j . j 21.6 11.8
Workshops or Conferences (n=50) 50.0 10.0 20.0 20.0
Books/Pamphlets (n=61) 13.1 16.4 27.9 42.6
Partner (n=27) 95.3 4.7 0 0
Friend/relative (n=48) 41.7 31.3 20.8 6.3
Table 16. Alternate Therapies Used to Treat Menopausal Symptoms.





Natural HRT (n=l) 1.6
Relaxation techniques (n=l) 1.6
Vaginal Creams (n=l) 1.6
Vitamins/Minerals (n=6) 9.4
Table 17. Reported Reasons For Not Using HRT.
%
Fibrocystic breast disease (n= 25) 4.0
Do not like to take medication (n= 25) 16.0
No risk factors/ no need to use HRT (n= 25) 20.0
MD or health professional discourage use of HRT (n =25) 8.0
Do not want to have menstrual cycle (n= 25) 4.0
Too costly (n= 25) 4.0
Cannot remember to take medications (n= 26) 7.7
Breast cancer (n= 26) 3.8
Family history of breast cancer (n= 25) 11.5
Family history of cancer other than breast cancer (n= 25) 4.0
Fear of breast cancer (n= 26) 3.8
Concern about uterine or ovarian cancer (n= 27) 7.4
Concern over cancer in general (n=26) 15.4
Total o f cancer related concerns 45.9
125
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 18. Correlations between variables in study
r
Serum Lipoproteins
Serum HDL number alcoholic drinks/month .267*-
Serum HDL Body Mass Index (BMT) -.308*
Serum HDL Waist-Hip Ratio -.342**
Serum HDL ORAC -.248*
Serum HDL Serum Lutein .248*
Serum HDL Body Weight -.309*
Serum LDL a-tocopherol/LDL ratio -.269*
Serum LDL LDL P-carotene (mol/mol) LDL -.241*
Serum LDL Body Mass Index (BMI) .265*
Serum LDL Body Weight .262*
Serum LDL Serum retinol .362**
Serum triglycerides Body Mass Index (BMI) .354**
Serum triglycerides Serum retinol .325*
Serum triglycerides Waist-Hip Ratio -.315**
Serum triglycerides Maximum diene formation -.303*
Serum triglycerides Rate diene formation -.277*
Serum triglycerides LDL P-carotene (mol/mol) LDL -.261*
Serum triglycerides Body Weight .294*
Antioxidants
Serum a-tocopherol Vitamin E supplements .270*
Serum a-tocopherol Total vitamin E intake (diet & supplements) .289*
Serum a-tocopherol Rate of diene formation -.366**
Serum a-tocopherol a-tocopherol/LDL ratio .777**
Serum a-tocopherol LDL a-tocopherol (mol/mol LDL) .299*
Serum a-tocopherol Serum triglycerides
**00CO
Serum a-tocopherol Total CholesteroI/HDL Ratio .288*
Serum P-carotene LDL P-carotene (mol/mol) LDL .923**
Serum P-carotene P-carotene/LDL ratio .884**
Serum P-carotene P-carotene from supplements .603**
Serum P-carotene a-tocopherol/LDL ratio .358**
Serum P-carotene Body weight -.327**
Serum P-carotene Body Mass Index -.273*
LDL a-tocopherol(mol/mol) LDL ORAC -.250*
LDL a-tocopherol(mol/mol) LDL a-tocopherol/LDL ratio .260*
LDL a-tocopheroI(mol/mol) LDL Dietary vitamin E .443*
LDL P-carotene (mol/mol) LDL Total cholesterol/HDL Ratio -.288*
LDL P-carotene (mol/mol) LDL Total P-carotene (diet + supplements) .541**
LDL P-carotene (mol/mol) LDL P-carotene from supplements .408**
LDL P-carotene (mol/mol) LDL Body Weight -.391**
LDL P-carotene (mol/mol) LDL Body Mass Index (BMI) -.363**
LDL P-carotene (mol/mol) LDL Waist-Hip Ratio -.256*
126
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
LDL 3-carotene (mol/moI)LDL 3-carotene/LDL ratio .967**
LDL 3-carotene (mol/mol LDL) Dietary 3-carotene .307*
LDL 3-carotene (mol/mol) LDL Times exercise/week .292*
a-tocopherol/LDL ratio Rate diene formation -.544**
a-tocopherol/LDL ratio ORAC -.279*
a-tocopherol/LDL ratio Vitamin E from supplements .443**
a-tocopherol/LDL ratio Total vitamin E (diet & supplements) .420**
3-carotene/LDL ratio Times exercise per week .291*
3-carotene/LDL ratio Dietary 3-carotene .316*
3-carotene/LDL ratio Total 3-carotene (diet & supplements) .494**
3-carotene/LDL ratio 3-carotene intake from supplements .351**
3-carotene/LDL ratio Body Weight .363**
3-carotene/LDL ratio Serum LDL -.300*
3-carotene/LDL ratio Total choIesterol/HDL Ratio -.301*
3-carotene/LDL ratio Times exercise per week .291*
Body Mass Index (BMI) Total Cholesterol/HDL Ratio .391**
Body Mass Index (BMI) 3-carotene/LDL Ratio -.328**
Waist -Hip Ratio Total cholesteroI/HDL Ratio .377**
Rate diene formation ORAC .314**
Rate diene formation Total vitamin E intake (diet -(-supplements) -.264*
Rate diene formation Maximum diene formation .593**
Lifestyle Factors
Number drinks per month Total cholesteroI/HDL ratio -.264*
Number drinks per month minutes exercise/week .270*
Number drinks per month Lp(a) -.255*
Body Weight Total choIesterol/HDL ratio .373**
Food Frequency/Food Diary
Food Diarv: Total Calories FFQ: Total Calories .424**
Food Diary: Fat (grams) FFQ: Fat (grams) .414**
Food Diarv: Saturated Fat FFQ: Saturated Fat (grams) .454**
Food Diarv: % calories from fat FFQ: % calories from fat .637**
Food Diarv: Calcium (mg) FFQ: Calcium (mg) .579**
Food Diary: Iron (mg) FFQ: Iron (mg) 414* *
Food Diary: Fiber (grams) FFQ: Fiber (grams) .327**
Food Diary: Vitamin E FFQ: Vitamin E .588**
* p = < 0.05 (2-tailed) 
** p = < 0.01 (2-tailed)
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Figure 2. Sources of information on menopause
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APPENDIX B 
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MATERIALS
Items: Purchased from:
food models Nasco, Fort Atkinson, Wisconsin
Nutritionist IV™ Diet Analysis for Windows 
(version 4.1) software
First Data Bank, San Bruno, CA.
SPSS® (Statistical Package for the Social 
Sciences): Graduate Pack™ (Advanced Class 
Version 7.0 for Windows) software
SPSS, Inc.
444 North Michigan Avenue 
Chicago, Illinois 60611
serum separation Fisher Scientific, Pittsburgh, PA.
Plasma separation vacutainer tubes Fisher Scientific, Pittsburgh, PA.
Nalgene cryoviais Fisher Scientific, Pittsburgh, PA.
breakfast for subjects Bagelrv, Durham, NH 
Market Basket, Lee, NH
Optiseal tubes (#362185) Beckman Instruments, Inc., 
Fullerton, CA.
Acrodisc filters Fisher Scientific, Pittsburgh, PA.
Folin-Ciocalteau reagent Sigma Chemical Company, 
St. Louis, MOa
HPLC-grade hexane VWR Scientific, Boston. MA.
HPLC- grade methonol VWR Scientific, Boston, MA.
Methvlene chloride VWR Scientific, Boston, MA.
HPLC- grade ammonium acetate Fisher Scientific, Pittsburgh. PA.
Borosilicate amber glass vials Scientific Specialties Service Inc., 
Randal Istown. MD.
ultrapure gas, N2 Northeast Airgas, Manchester, NH
pipetman adustable pipettes Rainin Instrument Co.. Woburn. MA.
pipet tips Fisher Scientific, Pittsburgh, PA.
petroleum ether Fisher Scientific, Pittsburgh, PA.
Macra™ Lp(a) Enzyme Immunoassay Kit Strategic Diagnostics, Newark, 
Delaware
Milenia™ Progesterone EIA Kit Diagnostic Products Corporation, 
Los Angeles, CA.
Estradiol ELISA Test Kit Neogen Corporation, ELISA 
TechnoIogies®Division, 
Lexington, KY.
Triglyceride (INT) Enzymatic Kit 
(Catalog # 336-10)
Sigma Diagnostics, St. Louis, MO.
Cholesterol Enzymatic Kit (Catalog # 352-20) Sigma Diagnostics, St. Louis, MO.
HDL Enzymatic Kit (Catalog # 352-3) Sigma Diagnostics, St. Louis, MO.
a All other necessary supplies and equipment for the LDL isolation, and the LDL protein and 
oxidation measurements, were made available in the laboratory of Dr. Robert Nicolosi at the 
University of Massachusetts, Lowell, MA.
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APPENDIX C 
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U n i v e r s i t y  o f  N e w  H a m p s h i r e
Department of A nnul and Nutritional Sdcnccs 
CoUege of Life Sciences and Agriculture 
Kendall Hall
Durham. New Hampshire 03824-3590
UNH WOMEN'S HEALTH STUDY
Women’s heahh issues have ttken the spotlight in the 1990’s. More research is being 
done in the areas of heart disease, osteoporosis, and cancer in order to improve the quality 
of life for women. Last summer 367 women participated in foe UNH Women's Health 
Study here at the University of New Hampshire. We would like to expand this study 
population by inviting the Plymouth State College community to join us m our efforts.
You, or someone you know, are invited to participate in our ongoing research study on 
women’s health issues. The study covers areas such as physical, emotional, and social 
issues for women in society today. This current ttudy will consist of three parts.
The first part of the study is a comprehensive questionnaire, for women age 35 and over, 
covering many aspects o f women's beahh and will take approximately 20*30 minutes to 
complete. The individual responses to the questionnaire will remain confidential.
The second part of the study will involve an observational study investigating the effects 
of hormones on the risk factors associated with heart disease in postmenopausal women. 
The study will involve a diet history questionnaire and a Mood test to analyze serum lipids, 
antioxidant nutrients, and coagulation factors as thy relate to physiological and nutritional 
wellbeing. Women who are nonsmokers, between the ages of 50-65, and interested in 
learning more about this part of the study, may indicate so by checking the appropriate 
box on the attached sheet and they will be contacted by phone to determine eligibility. AD 
information gathered will remain confidential and participants will receive results of their 
blood cholesterol, lipid profile, Mood type and dietary analysis for their participation.
The third part of the study involves an interview on relationship and sexual issues.
Women 35 and over who are interested in participating, may indicate so by «**drwig foe 
appropriate box on the attached sheet and they vrill be contacted with further information.
If interested in any or all of the components of this phase of the Women’s Health Study, 
please check the appropriate box(s) on the attached sheet Ifyou are ineligible because of 
age or gender please pass this invitation on to someone dse who may be interested in 
participating in the study. Feel free to address you questions to any of the undersigned.
Sincerely yours,
£  <.*“< y
Kristine M. Baber, PhD. (862-2151) Karol Lacroix, PhD. (862-3007)
Kathryn Cataneo, M IA  (862*2001) Ruth A. Reilly, MO.E., RJD. (862-2573)
Joanne Curran-Cdentano, PLD. (862-2573)
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UNH WOMEN’S HEALTH STUDY
Please indicate by checking the appropriate box/s your interest in participating in my or all 
parts of the study and return in the enclosed envelope.
I (sign your name)___________________________________________ am
interested in participating in the following parts of the study:
□  Parti: HEALTH QUESTIONNIARE (Age 35 and over)
□  Part II: MENOPAUSE STUDY (Age 50-65)
□  Part m: RELATIONSHIP & SEXUALITY INTERVIEW (Age 35 and over)
Name______
Home Address
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U n i v e r s i t y  o f  N e w  H a m p s h i r e
Department of Animal and \utntionaI Sciences 
College of Life Sciences and Agriculture 
Kendall Hall
Durham. Neu- Hampshire 03624-3590
UNH WOMEN'S HEALTH STUDY
Dearftrticipant,
Thank you for agreeing to participate Is the Women's Health Study at the University of 
New Hampshire. The study covers physical, emotional, and social issues for women in 
society today.
Please do not include your name or any other personal identifiers on the questionnaire to 
help ensure the confidentiality of your responses. The code number on the questionnaire 
will be used only if you participate in other parts of the study. If there are any questions 
you feel uncomfortable responding to, simply skip those items and continue on with the 
remainder of the questionnaire.
After you have completed filling out the questionnaire, please place it in the large self- 
addressed envelope provided and mail. If you would like to receive a summary of the 
results of the study when available, please complete the enclosed self-addressed postcard 
and mail (please do not mail the postcard with the questionnaire).
Please feel free to address your questions to any of the undersigned.
Sincerely yours.
Joanne Curran-Celentano, PhD. (862-2573)
^ Z & lc rL y .
Karol Lacroix. PhD. (862-3007)
r d t/C  CL "iPt
Ruth A. ReUly, R.D. (862-2573)
M BA. (862-2001)
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Physiological Effects of Menopause
Objectives:
The objectives o f this study is to determine if there is a relationship between 
hormone status, diet, and exercise and the risk o f heart disease and stroke. We will 
evaluate this by measuring the levels of lipids, clotting protons, hormones and vitamins in 
the blood o f women who chose to use hormone replacement therapy and those who do 
not.
Protocol:
1. You will be notified if qualified for this phase of the study.
2. An appointment will be scheduled for you to have a fisting blood sample drawn. 
A trained phlebotomist will perform the blood draw from your arm (anticubetal 
vein) and approximately 20 ml (2/3 oz.) will be taken.
3. You will be given juice and a snack and asked to remain seated for about IS 
minutes to assure that you are comfortable following the blood draw.
4. Your height, weight and waist/hip ratio will be recorded.
5. You will be asked to complete a three day food diary and a health habits-history 
questionnaire.
Risks Associated with the Study:
There are very few risks associated with the blood draw procedure when taken by 
a trained phlebotomist. Occasionally, a hematoma (black and blue marie) will result if the 
phelbotomist has difficulty getting the specimen or if pressure is not properly applied 
following the process. If the subject is anxious on rare occassion she may feel light 
headed or faint. In the event that this happens, please notify the plebotomist, place your 
head between your knees and smelling salt will be administered.
INFORMED CONSENT
PLEASE READ THE FOLLOWING STATEMENTS AND RESPONDE AS TO 
WHETHER YOU ARE WILLING TO PARTICIPATE:
1. I understand that the use of human subjects in this project has been approved by the 
UNH Institutional Review Board for the Protection of Human Subjects in Research.
2. I understand the scope, aims and purpose o f this research project and the procedures to 
be followed and the expected duration of my participation.
3. I have received a description of any reasonable foreseeable risks or discomforts 
associated with my being a subject in this research, had them explained an understand 
them.
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4. I have received a description o f any potential benefit that may be accrued from this 
research and understand how they may affect me and others.
5. I understand that the confidentiality o f all data and records associated with my 
participation in this research, including my identity will be fully maintained.
6. I understand that my consent to participate in this research is entirely voluntary and 
that my refusal to participate will involve no prejudice, penalty or loss of benefit to which I 
would otherwise be entitled.
7. I further understand that if I consent to participate, I may discontinue my participation 
at any time without prejudice or penalty.
8. I confirm that no coercion of any kind was used in seeking my participation.
9. I understand that if I am hgured or require medical treatment, I may seek treatment at 
the University Health Services Center and will be charged for services rendered, unless 
covered by paid student-health fee.
10. I understand that if I have any questions pertaining to the research, I am encouraged 
to call Joanne Curran-Celentano at 862-2573 to discuss concerns in confidence.
11. I understand that I will not be provided financial incentive for my participation by the 
University of New Hampshire.
12. I understand that I will be given a summary of my results and will be invited to hear 
about the outcome of the research at the conclusion of the study.



















How long have you been post? 
Do you use any type of HRT?
What type_______________
Time of dav_____________
How long have you taken it? 
Dose











When is the last time you had your blood lipids measured? 










Medications: Do you presently take either over the counter or prescribed medications (other than 
HRT?)
Name of Drug Reason for Taking Dose Frequency How long
Supplements:
Name of Drug Reason for Taking Dose Frequency How long
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Code#:_
Group#:.
Remember, if  there are any questions you feel uncomfortable responding to,please 
feel free to skip those items and continue on with the remainder o f the questionnaire.
D e m o g r a ph ic  a n d  h e a l t h  H ist o r y  I n v en to r y
Today's Date:_______________________
Date ofBirth:__________________
Presect Height: Present Weight:_______________
Ethnicity: White:_______  African-American:________ Asian/American________
Hispanic:_________  Native American:__  Other________
Religious Affilisrimir
Current Reiatiocship Status: Never married:________
(check all that apply) Cohabitating:__________  # Years:____
Married: # Years:_______
Divorced:____________  # Years:___
Remarried:____________ # Years:____
Separated:____________  # Years:___
Widowed:____________  # Years:___
Highest Education Level: Please circle die highest grade at school you have completed or check the highest 





Doctorate Degree or other professional degree_______
Present Occupation:
Health History
1. Do you presently have modicaJ insurance? Yes No_
2. Your primary beahh care provider is (check one)-.
A gynecologist
A nurse practitioner. 
An internist______
A family practitiooer.
Other (Le. Naturopathic physkian)_
3. In the last five years have you been told that you have (check all that apply):
________ Diabetes Heart disease Ulcers
______________ f lM i m ' im a r M l  it i w t iW  T i m p  A n trm m  P m e i r
________ High biood pressure Kidney disease _________Thyroid Disease
________ Hardening of arteries  Liver disease ________ Sexually transmitted
________ Blood clotting problems Stroke diseases
________ Oall bladder disease __________________________________ Other
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4. Number of pregnancies:____
5. Number of children and ages:
6. Your age when first child was bom: Your age when last child was bom:
7. Please check when you had your last:
within 0-12 months I-2veana to  3-5 years aro more than 5 n a n  aeo
Physical Exam _ _ _ _ _ _ _ _ _ _  _ _ _ _ _  _ _ _ _ _  _ _ _ _ _ _ _ _
Mammogram ____________      _ _ _ _ _ _ _ _ _
Pap Smear
8.___ Briefly describe any problems with pregnancies, labor, delivery:______________________
9. Age at first mammogram:.
10. List past surgical operations (with approximate dates):.
Drug History
I f you check “yes” to aey o f the following, pUase indicate the type o f drag, your rtmton for taUug t ,  and 
Mow often you take it
1. Do you use any prescribed medications? Yes No_
Name of drug t t—«nn far airing/hcw Often
2. Do you use over-the-counter medication (such as aspirin)? Yes No
Name ofdrug P f™  ftrflfting/how often
3. Do you take vitamins/mineral supplements, herbs, or other health remedies? Yes No_
Name tcJar nutrient Reason far «rfrrw»/imi» often
4. Do you currently smoke cigarettes? Yes  No
If “yes”, the number of cigarettes, on the average, you smoke each day.
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5. Do you drink alcohol? Y ei  No.
If “yes” please indicate, on the average, the number ofservings (scrying •  IK oz. liquor or liquer; 12 oz. 
beer; or 4 oz. wine) you consume:
Per month______  Per week  Per day_____
Exercise Habits
(Please check which best represents your exercise routine.)
1. No regular expose _________
Exercise 2 times a week fnr(grcm«r than <r equal to)
 20mm. 30 mm.__ 40min-_SOmin- 60mm.
Exercise 3 times •  week for (greater then or equal to)
 20 min. 30mm.  40mm. 30mm. 60 mm.
Exercise 4 times a week for (greucr than or equal to)
20 min. 30 min.__ 40 min.___ SO mm. 60 min.
Exercise S times t  week far (greater then or equal to)
 20 min. 30 min.__ 40 min.__ SOmin.__60 min.
2. Number of years exercised at above rate:
3. Briefly describe your exercise routine: _
4. If you no longer exercise, why did you stop?
Diet History
1. Is your present weight your “usual weight”? _________________________________
2. Do you believe that your present weight is a beahhy weight for you? Yes_______ No__
If you answered “no” what would you consider a beahhy weight for you?________
3. Are you on a special diet? Yes No____
If “yes” what kind of diet?_______________________________________________
4. Are there any other facts about your lifestyle that you thtr.lr might influence your nutritkn&l habits?
Yes_______No___
If “yes”, explain:____________________________________________________________
5. Do you know of any foods to which you are allergic? Yes No.
If “yes", explain:_____________________________________ \
6. Do you consistently limit or eliminate any foods or food groups from your diet? Yes No.
If “yes”, please explain:_____________________________________________________
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Menstrual History
1. To the best of your recollection, bow oldwere you wbefi you first started your monthly period? _
Within the last 12 months have you noticed any changes in your monthly period? Yes No 
If “yes” please read the following statements and for each circle the response that conesponds to your 
experience at the present time.
My monthly period is less frequent than it used to be.
My monthly period is more frequent than it used to be.
My monthly period has decreased in number of days per month.
My monthly period has increased in number of days per month.
My monthly period blood flow is lighter than usual forme.
My monthly period blood flow is heavier than usual for me.
In my mommy period, more clots are expelled in the blood. 1 2  3
In my monthly period, fewer clots ate expelled in the blood. 1 2 3
3. At present are you using an oral contraceptive? Yes No
If'>ts", Brandftype: dose:_________







4. If you have used oral contraceptives in the past, bow many years in total did you do so?
S. Since you started menstruating, has your cycle stopped for more than three months (other than during 
pregnancy or breast-feeding)? Yes_______  No_______
If “yes", please explain:_________________________________________________________
6. According to the following definitions, which represents your present status?
_______ Premenopausal (Regular menstrual periods)
_______ Perimenopausal (In the Last 12 months you have skipped your period or you have noted
changes in regularity or flow)
_______ Menopausal (No regular menstrual cycle for 6-12 months)
_______ Postmenopausal (No menstrual period for 12 months or more)
_______ Hysterectomy: At what age?______
Hormone Replacement Therapy (HRT) History
1. Do you presently take any of the following?: Yes No
Brand Dose When did you begin?
Estrogen
Estrogen and Progesterone 
Progesterone
Testosterone (Le. Estratest)
I f “yes”please answer questions U2,3 and 4. 
I f “no” please answer questions w3,4,5 and 6.
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2. Please indicate by circling 1, 2, 3, or 4 to what extent each of the following factors influenced your 
decision to take hormone therapy.
Not influential Somewhat Moderately Extremely 
at a ll influential influential influential
Hysterectomy 1 2  3 4
Relief of physical menopausal symptoms (hot flashes.
urinary tract problems, vaginal dryness, etc.) 1 2  3 4
Concern about heart disease 1 2  3 4
Concern about osteoporosis 1 2  3 4
Advice ofM.D. or other health professional 1 2  3 4
Advice of fnead/coworker/family member 1 2  3 4
Advice of partner 1 2  3 4
Mood changes 1 2  3 4
Concern about aging 1 2  3 4
Sexual problems 1 2  3 4
Other  1 2  3 4
3. Please indicate by circling the responses 1,2,3, or 4 to what extent the following sources have provided 
you with information on menopause:
Least Somewhat Moderately Extremely 
infill motive tefimmx tre Informative itfijrmative
MD or other health professional 1 2  3
Mother 1 2  3
Radio/ television 1 2  3
Workshops or conferences 1 2  3
Books, pamphlets 1 2 3
Partner 1 2  3
Friend or relative 1 2  3
Other (please explain)  1 2  3
4. Are there any other therapies you use for treatment of menopausal symptoms (such as massage therapy, 
supplements, meditation etc)? Yes_____ No___
If "Yes”, please explain:___________________________________________________________
S. Explain why you have chosen not to use hormone therapy:
6. Have you taken HRT in the past? Yes No
If “yes”, how long did you take it and why did you stop taking it?
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RELATIONSHIP
CMM.Ckoe*.
Q ia ] f O u a m « ty ln a n ln a w a ia l in o n a H p w M H a o n » o n a y c u w c U d  
d ad n a  a a  « w « i w y  v  w c k ia h *  a n m o n a l  ancvo r a a u a l  p w tia rT
(H you a tw a a r a d  H e r  H d p to au a aU o n  11) Ym No
M M  k  a w  a a s  c t M a  e a m a r ? u w FwiWM
How Iona h a v a  m u  b a a n  in  M a  la tarionatto?
f w  i w  F o u e w e e  e u e s n o w ,  f u m e  c w c l e  l i e  * ■  
i w t  i e e * i E «  e e s r  h o w  r o u  * e  r o w  * E u m o * W F .
4. a io a n a W .h o w e lo a a  d o  w u < a a l am o a o n a < V » M ix o a r r a r ?
*. H o w i u j c f t c o n t e t l t i h a i a l n M t f  iN r to r a f tb ? J*gU5S>.
I .  H w re en w n w a  w > ¥ e u tt« M n » a lnW »iW M iontw p? OommmS
7.  a i a a n a r a l .h o w a m o i o r a f lv a n i e a a  w v a u H i m  w x i w e B M H p ?
a . t i o a n a r a l .h o w a a M a * y a g t« d a d a a M u W T iM u r ia iM c n a N o ?
a . How — I  a o a s v o x  c a rtn a r rnaai vouram otiona l n a a d i?
Flo<
N M a ta l JSL JSL
10. H ow — a f l o a a v o u o a n n a r m a a m u r a w u a in a a r lT ? N o ta ta l
HMFrOl
_SL
F o a  t i e  f o u o w m o  o u e r r o o ,  f u a k  e M c w n e  n u f o n k
H U T  MOtCATES HOW FREQUENTLY TOO F M m C M T E  F t THE
Home
14. T aucH naF ioB ino  o a rtn a r Wotml
IT.
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SELF Code*.
Group#
DIRECTIONS: PLEASE READ EACH OP THE STATEMENTS LISTED 
BELOW AND INDICATE HOW MUCH YOU PERSONALLY AGREE WITH 
EACH STATEMENT BY CIRCLING THE APPROPRIATE RESPONSE.
NOW DO YOU R EL ABOUT YOURSELF AS A PERSON?—
1 ■ 1 FEEL THAT 1 AM A PERSON OP WORTH. AT LEAST ONE ON EQUAL 
BASIS WITH OTHERS.
Snngiy 
Disco tae Disco r*e Aorae
Seongly
Aorae
1 2 S 4
2-1FEELTHAT 1 HAVE A NUMBER OF GOOO QUALITIES. 1 2 3 4
3. ALL IN ALL. 1 AM INCUNED TO FEEL THAT 1 AM A FAILURE 1 2 3 4
4. 1 AM ABLE TO DO THINGS AS WELL AS OTHER PEOPLE 1 2 3 4
5.1 FEEL 1 DO NOT HAVE MUCH TO BE PROUD OF. 1 2 3 4
6.1 TAKE A POSITIVE ATTITUDE TOWARD MYSELF. 1 2 3 4
7. ON THE WHOLE 1 AM SATISFIED WITH MYSELF. 1 2 3 4
8.1 WISH 1 COULD HAVE MORE RESPECT FOR MYSELF. 1 2 3 4
8.1 CERTAINLY FEEL USELESS AT TIMES. 1 2 3 4
10. AT TIMES 1 THINK 1 AM NO GOOD. 1 2 3 4
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HPEMENCES • * » '
Bw ie r o a : rlea sc  r e a p  t h e  ro llo w m q  sta t e m e n ts  and  p r c l e  a m  m o w n  t c u  reel  o o iw M ro H o a  t o  y o u r
BxREMENCCSATTHEEAcaENTtim e  o r  w ttm m t*  l a s t s a m o nths .
l « W W W B W I I I W W e B n i . T B W W I M I I .
1. CNANQES M MY SQOYISMRERATURE THAT MAKE ME PEEL COLD. OR NOT AMD SLUSHED MTME RACE.
Mb ___ L___ OMn A R M
1 > f 4
S.SWEAYNOOURMQTMEMOKT. 1 « a 4
S. VAOMAL OUTNESS CAUSMQ M M . SORENESS. OR OMOOMPONT BURRO SEXUAL ACTIVITY. 1 a a 4
4 . U C K  OF MIMNESS M MY VASMAL MUSetCS. 1 • f 4
B.VAOINAlMrECTONSWCLUOMOYEASTMSECTONS. 1 t a 4
S . SCEUNOS o r  UOMT m c a d ebn ess . 1 a ... f 4
T.BENSATBNSOrSCKNESS TO MY STOMACH OR NAUSEA. 1 a ? 4
4. T a « O N  AND RAM W MY HEAD (HEADACHES). 1 a f 4
S. NOTABLE CNANOES IN MY (CANTS BEATMO RATTERN. 1 a f 4
10. CMANOES m  SLEET PATTERNS (INSOMNIA). l a a 4
I t .  CHANGES W MY BODY UMSS SUCH AS YMQLM0. MUMSNESS. 1 a __ a 4
U  MOKE FRE0UENT RASSINQ OT WATER (URINATION). i a s 4
11 MORE RA1NPUL RASSINQ OT WATER (URINATION). i a a 4
14. ACCIDENTS IN RASSINQ WATER (URINARY MCONTMENCE) 1 a a 4
11. TORQETTUIMESS AND A LACK OR REMEMBERING t a s 4
11 LOW AROUSAL OR EXCREMENT DURING SEXUAL ACTIVITY. t S 4
IT. NON LEVELS OT AROUSAL OR EXCREMENT OURMO SEXUAL ACTMTY. i * a 4
IE. A NEED ROR LONQER REROD OT STMULAT10N TO ACHIEVE OROASM. 1 t a 4
IS . LESS PREOUENT ORQASUS THAN M THE RAST. i a a 4
SB. MORE FREQUENT OAQASHS THAN M THE RAST. 1 a a 4
S t .  LESS BRENSEOROASMS THAN M  THE RAST. i a a 4
S t  MORE WTEICS ORQASMS THAN MTME RAST. 1 a a 4
B .  RAMRA. ORGASMS. 1 a . a 4
M . SLEEOMO D U R M  OR AFTER MTEROOURSE. 1 a a 4
SB. RAM OR BURMMQ DURMO MTERCOURSE. 1 a a 4
as. LESS BITEREST M SEXUAL ACTTVTTY. 1 a a 4
ET. MORE MTEREST M SEXUAL ACTMTY. 1 a a 4
SB. EXTREME CNANQES M MY MOOD. 1 a a 4
149
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
MOODS CodM.
OlMp*.
WECnONS: KiJOW S  A UST OF tNOHDS THAT OOCMIE 
FEELMGS PEOPLE HAVE. Fl£ASE HEAD EACH ON£
CAREFULLY AND ORCLE THE NUMBER THAT SESTOESCRBES
YOUR ANSWER. ______________________________
MOW YOU HAVE K IN  FmJNO BURtiO IK  FAST WEEK 
M C U S M T O O A T ai
1. FRIENDLY
NOIMAI AIM* fttadvilW Qurt»»Brt tm nw
0 1 s S 4
S. TENSE 0 1 2 • 4
1. ANGRY 0 1 2 • 4
4. WORN o u r 0 1 2 S 4
K. UNHAPPY 0 1 2 • 4
X CLEAR-HEADED 0 1 2 S 4
7. LIVELY 0 1 • • 4
•.CONFUSED 0 1 2 • 4
• .  SORRY FOR THINGS DONE 0 1 2 • 4
10. SHAKY 0 1 2 • 4
11. LISTLESS 0 1 2 a 4
12. PEEVED 0 1 2 a 4
IX  CONSIDERATE 0 • a 4
14. SAD 0 1 2 a 4
IX  ACTIVE 0 1 2 a 4
IX  ON EDGE 0 1 2 a 4
17. GROUCHY 0 1 2 a 4
1A BLUE 0 1 2 a 4
18. ENERGETIC 0 1 '2 a 4
20. PANICKY 0 1 2 a 4
21. HOPELESS 0 1 2 a 4
22. RELAXED 0 1 2 a 4
23. UNWORTHY 0 1 2 a 4
24. SPITEFUL 0 1 2 a 4
2X  SYMPATHETIC 0 1 2 a
26. UNEASY 0 1 2 4
27. RESTLESS 0 1 2 a 4
2A  UNABLE TO CONCENTRATE 0 1 2 a 4
28. FATIGUED 0 1 2 a 4
•0 . HELPFUL 0 1 2 a 4
21. ANNOYED 0 1 2 a 4
S2. DISCOURAGED 0 1 2 a 4
• X  RESENTFUL 0 1 2 a 4
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A Bit E snm aV
84 NERVOUS 0 1 8 a 4
as LONELY 0 1 B a 4
a s  MISERABLE 0 1 f a 4
S7MUOOLED e 1 a a 4
SB CHEERFUL e 1 t a 4
a s  BITTER e 1 t a 4
40 EXHAUSTED e 1 8 a 4
41 ANXIOUS e 1 8 a 4
42 READY TO FIGHT e 1 8 a ^  -
43 GOOONATURED e 1 8 a 4
44 GLOOMY e 1 8 a 4
45 DESPERATE e 1 8 a 4
46 SLUGGISH e 1 8 a 4
47 REBEUJOUS 0 1 8 a 4
48 HELPLESS 0 1 8 3 4
46 WEARY e 1 8 a 4
SO BEWILDERED 0 1 8 3 4
81 ALERT 0 1 8 a 4
82 DECEIVED 0 1 8 3 4
83 FURIOUS e 1 8 a 4
64 EFFICIENT e 1 8 a 4
85 TRUSTING 0 1 8 3 4
86 FULL OF PEP e 1 8 a 4
87 BAD-TEMPERED 0 1 8 a 4
86 WORTHLESS 0 1 8 a 4
80 FORGETFUL e 1* 8 a 4
80 CAREFREE a 1 8 4
•1 TERRIFIED a 1 8 a 4
•2  GUILTY 0 1 8 a 4
63 VIGOROUS e 1 8 4
64 UNCERTAIN ABOUT THINGS e 1 8 a 4
• 5  BUSHED 0 1 8 a 4
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U nH WOMEN'S HEAIJH STUDY
F o o d  D i A R y
t f f
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HEALTH HABITS AND DIET QUESTIONNAIRE
This faun u b  you ■ variety of questions about your background, environment, and habits, which may 
affect or be related to your health. The information you provide will help sdenhsts to understand more about 
the causes of disease, this questionnaire wiB take about U-15 minutes to complete. Please fin in the information 
(•quested, or place a check in the appropriate space. If you arc not sure about an answer, phase estimate.
” r»e»Aci"
11 M
Hesse HUNT YOUR NAME (name of study pattidpawt)
LAST PUB tcooii
ADDRESS:
11 R U et u
»
TELEPHONE:
nn onr n SI state s ZIP
(H D ) -H D -Q ID
1. When w oe you bom? / ,  /
M o m * 5 y T a
2. How aid are you? ____yean
3. Sec 1  Male 2  Female
4. Race or ethnic background:
1 _  White, not of Hispanic origin 4  American Indian/Alaskan native 2 Black, not of Hispanic origin 5  Asian
 3 Hispanic 6 _ _ h eific  Wander
5. Please cM e the htg*w» grade in school you have completed: 
1 2 3 4 5 4 7 1 * 1 0  1 1 1 2  13 14 15 16 17+
6. How laO are you?  feet indies 7. How uandt do you weigh?
*. DO you rowke dgsnrttes now? 1 No 2 .  Yes










Vcnam S2.1. October. 1W7. OTEF. DtET.ONLY -1-
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*- During the peat year. k m  you taken any riaandne o r minerals? 
l _ N o  2__Y es. itiriy tegulariy 3  Yea. hut wot tignltity H V u ,
Whet do you lake fairty regularly? #  of P U S  per DAY. WEEK,
Multiple Vtaatim ate.
One a day type
Stress Mbs type --------pU tper
Therapeutic. Thatagmn type tim e many mffipams
Other Vdttatfat or IUt per pd?
Vifaadn A —  p as per------------- n i per piD
Vitamin C pO sper --------mgperpffl
VhaminE --------pOspor m p f S i
Gdcnim «  M o o te — PO sper------------- — « » p w p o
Other (What?) 1__ Yeast 2 ___ Saknium 3 _  Zinc 4__ Iron S Bat—am m e
S__ Cod BveroO
10. This section It ahnutynui eenfaedngliabiu . Thinking bad: overthe past yuar.howofatn  do you 
usually sat the food* taard on the n o t page?
R nt, check (/)  whether your a n a l aervbig afae ia m D . — d im  or large. (A —an portion ia 
about one-half the —  dium — ring rise shown. m  has; a  k^ge porbon ia about anr and a half 
ttaes as much, or more.)
Then. put a  NUMBER in the most appropriate cohnnn to tadkate HOW OFTEN, an the arcragt. 
you a t  the food. You may eat bananaa M ere —at (put a 2 m (hr ‘■act' column). If you never eat 
the food, check "Rarely/Never.* Please DO NOT SKIP foods. And pieaar BE CAREFUL which arf- 
ubui ytxi pat your anewer in. it will make a big diffaieim  if you aay "Hamburger once a day* 
when you mean "Hamburger once a week"!
One hem Bays *m aeaaon.* indicate how often you eat that juat in the 2-3 month tune wtwn that 
food it in aeaaon. (Be careful about overeabmating here.)
Please look at the am ple below. This penon
1) eata a medium aerving of cantaloupe once a week, in aeason.
2) has V4 grapefruit about twice a month.
3) has a small aerving of sweet potatoes about 3 tim et a year.
4) has a large hamburger or dieeaefeitger or meat loaf about fb v  times a week.





CsMaloupe (in season) kk medium /
Grapefruit (Vi) /
Swset potatoes, vams Hcup /














fO K  OFFICE USE
Q *.«* or IU: 1-90-100 3-J00490 >>400400 4-1000 >>9000 4-ML00D ?>3flLfl0MU00 t-SUBO t-UUk.
th  *» faBmrtng two pep*. —  — —  Vfatpend—  yiacas ad*dmarttod»"Howafwn*coinins.
mded* four c ta n a n  far eedi — SrL  . da aot taipitr *01*. ante, hasted, oade Not tasted. if
faoriaefallows: IS lr respondent does not stack a -












FRUITS *  VEGETABLES S M L
EXAMPLE-Applet. applesauce. p m (DarVTcup KJ
Apples. applesauce. paan (I) or M cup
Cantaloupe (at season) H medium
O m an I indium
Onnar w r  a re a  uatiuiituicr a  OK. lists
Ciapcftuit <M>
Other fruit mew. fortified (not drink* toe. Mass
I a n  onh aa baked baans. p im . kidney. i a n .  m at ddi Karp
To— Bn. tomato pot* (Dartax.
■rorco(i Hasp
Spbtadt MtUP
Mustard p i r n ,  nonip eeena. sollards Hasp
Coir tip*.-, cabfiaar. sauerkraut Hasp
Carres, or stand raaetablatcontainsnaaiTOts Hasp
Oiatniiltd 1 mad. bowl
Salad dtnnna.nseonnabelindudina on sand widtn) 2Tbisp.
Fimdi bin and bred polaton K nip
Sweet oota ton. yams H ctsp
Othrr ponton, b id  boded, baked. pomp talad. — had (l)or Hasp
Diet Hasp




•eel str*’ or poc pie with canoes, otter n p ttb ln 1 cup
Ln*r. mdudma chiden burrs 4 oz.
Pork, mdudma chops, roasts 2 chops or 4 oz.
Fried chicken 2am.erllepttct
Chicken or turkey. inastcd. stewed or broiled 2 am. or IIr. pace
Fned fish or fish aandwich 4 ox. or 1 land.
Othrr fish, broiled, baked 4 oz.
Spaahtlti. iaaaana. other pasta with mriato sauce leup
Hot dots 2 does
Ham. hatch piaats 2i&cas
Vatatablt mup. yeaetablt beef. aunesouna. to— to soup 1 — d. bowl
•READS / SALTY SNACKS / SPREADS s Im Il :
Whin braid (mdudma sandwtchn). bsaeb. ate., crackrrs 2 ificrt. 3cncks
Daik brad, tndudine whole whrst. rye. pumpernickel 2abces
Com brad, com muffins. ootn torfilias lined, piece
Salty attacks (such aa dupa. popcorn) 2handfiib
Paanuts. peanut butter 2TUap.
Maraanne an bread errufla 2 pats
■tsrier on brad or roOs 2mta
BREAKFAST POODS * N i
Hitth fiber, btnn or panola earaah. ahrtddad wheat lan d , bowl
Hiahhr torofiad cereals. auch as Product 19. Total, ar Most 1 med. bowl
Other arid maalt. ouch ao Cant Flakes. Rice Kritpan 1 mad. bowl
Cooked carab 1 med. bowl













I j H i
|__ L_ L_
|__ t1





















































f c i o u a 1 scoot)
Douehnwu. enofaes. cakea. pasov lac . wSoookies
Hes 1 mad. shea
Qocoiaw candy small bar. lae .
d a isy  produ cts. sev d u ces ■ H i
Cheeses and th sm  swsfi.notlnchidinetBBsat 2M snor2oa-
Whole adkardbeva. with whole ai3k (net Ind. an email •  oe-Blaaa
2% milk and be«s. with 2% adk (not bid. on email •  ee-alaas




Milk or aoamin coffee or wa 1 Tbiao.








11. How often do you aat the ikin an chicken? 
HowaftendoyauMtthefuanmMt?
How often do you odd salt to yew food? 
How often do you add pepper to your food?
12- Not daunting salad or potatoes, about how many servings of 
vegetables do you eat per day or per week? f
13. Not counting juices, how many servings of fruits do you 




THANK YOU VHW MUCH for ashing the Mow so 60 out this M am abon. 
Bevfwstd *y
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15 Relationship Status 
(never married)












23-24 Relationship Status 
(Remarried) _____________
25-26 Relationship Status 
(Separated) _____
27-28 Relationship Status 
(Widow) _____________
29 H ig l iw l  F i t i i f j t i n n a l  Level ----
30 Present Occupation ----
31 Present Occupation
(health related) _
32 M edial Insurance ----
33 Primary Healthcare Provider ----
34 SPACE
if  ho tu rn e r gtr€n code m0't"
35 Diabetes
36 f i i a m i i H w i m i  Disorder -
37 High Blood Pressure -
38 Hardening of Arteries
39 Blood Clot Problems
40 Gall Bladder disease —
41 Heart disease
42 T J in g  ^ i c e a t f ----






48 Thyroid disease ----
49 Sexually transmined diseases ----







57-58 Number of Pregnancies --
Line 1
59-60 Number of Children
61 Number of Children (Young child) ----
62 Number of Children (Teens) ----
63-64 Number of Adult Children
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Total Calories Within 10% of 
ICL for 
individual




Protein 10-15% of total 
kcals
+1.0 <6% ICL or 
>30% ICL
-1.0
Total Fat >45% ICL -1.0















45-80% of total 
kcal
+0.5 <25% ICL or 
>80% ICL
-0.5
Dietary Fiber 20-35 grams +0.5 <12 grams -0.5
Added Sugar <10% of total 
kcals
+1.0 >20% ICL -1.0
Cholesterol 300 mg or less +1.0
Sodium 500-2400 mg +0.5
Potassium 2000-5625 mg +0.5
Vitamin A 800 RE or more +0.5
Vitamin C 60 mg or more +0.5
Iron 15 mg or more +0.5
Calcium 800 mg or more +0.25
Phosphorus 800 mg or more +0.25
Alcohol >95 kcal/day -1.0
TOTAL 10.0 -6.0
ICL = Ideal Caloric Level
* Any value that does not fall within either of the given ranges is scored as 0
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APPENDIX D
GLOSSARY OF TERMS
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Glossary of Terms
Estrogen Replacement Therapy: Use of estrogen alone during menopause; typically not 
recommended for women with a uterus because of increased risk of endometrial cancer.
Hormone Replacement Therapy: Term usually used to denote the use of estrogen in 
combination with progestin during menopause. Also used as a generic term to denote any 
use of postmenopausal hormone therapy, including estrogen alone or testosterone alone or 
estrogen combination with progestin and/or testosterone.
Premenopause: the time when a woman is having regular menstrual cycles.
Perimenopause (Menopausal Transition): the time (usually a few years before the last 
menstrual period) when cycles are irregular and that is accompanied by wide hormonal 
fluctuations (239) which ends with menopause.
Menopause: defined as the last menstrual period and is usually diagnosed retrospectively 
after 12 months of amenorrhea (240).
Postmenopause: the time after menopause
Total (simple) hysterectomy: removal of the uterus a!one(241).
Total (simple) hysterectomy: hysterectomy with bilateral salpingo-oophorectomy: 
removal of the uterus, both fallopian tubes, and both ovaries (241).
Salipingn-oophorectomy: removal of one fallopian tube and one ovary (241).
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APPENDIX E
GLOSSARY OF ABBREVIATIONS
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Glossary of Abbreviations 
a-tocopherol: alpha tocopherol 
3-carotene: beta-carotene 
BMI: body mass index 
CEE: conjugated equine estrogen 
CHD: coronary heart disease 
CVD: cardiovascular disease 
EO: estrogen only group 
E/P: estrogen and progestin group 
ELISA: en2yme linked immunosorbent assay 
FFQ: food frequency questionnaire 
HDL-C: high-density lipoprotein cholesterol 
HHHQ: Health Habits and History Questionnaire 
HRT: hormone replacement therapy 
LDL-C: low-density lipoprotein 
Lp(a): lipoprotein (a)
MI: myocardial infarction (heart attack)
MPA: medroxyprogesterone acetate.
NCEP: National Cholesterol Education Panel 
NHRT: no hormone replacement therapy group 
OC: oral contraceptive 
ORAC: oxygen radical absorbency capacity
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POMS: Profile of Mood States Inventory 
TC: total cholesterol 
TG: (triacylglycerol) triglyceride 
VLDL-C: very-low density lipoprotein 
WHR: waist-hip ratio
UNHWHS: University o f New Hampshire Women's Health Study
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APPENDIX F 
HORMONE REPLACEMENT FORMULATIONS
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Hormone Replacement Formulations
SUBJECT ESTROGEN DOSE/dav PROGESTIN DOSE REGIME
3 Premarin® -3 mg
4 Premarin® .625 Provera® -5 mg continuous
9 Premarin® .3 mg every' other day
10 Premarin® .625 mg Provera® 2.5 mg continuous
15 Estraderm®
Patch
.005 mg Provera® 
or Cycrin®
10 mg. cyclic
18 Premarin® .625 mg Provera® cyclic
♦20 Prempro® .625 mg Prempro® 2.5 mg 1 tab. 2x a dav
21 Estrace® 1 mg Provera® 2.5 mg continuous
23 Premarin® .625 mg
27 Premarin® .625 mg
33 Premarin® Provera® continuous
36 Premarin® .625 mg
51 Premarin® .625 mg Provera® or 
Cycrin®
5 mg cyclic (Premarin® 1-2 Id. 
Provera®/Cycrin® 16- 
2 Id)
53 Premarin® .625 mg Provera® cyclic (Premarin® l-15d, 
Provera ®10-26d)
55 Estrace® Patch 1 mg Cvcrin® 2.5 mg cyclic
♦*56 Estratest® Provera® 2.5 mg continuous
57 Premarin® .3 mg
59 Premarin® Provera® continuous
**76 Estratest® .62/1.2 mg Aygestin® 5 mg continuous







82 Premarin® Cycrin® continuous
89 Premarin® .9 mg Provera® 2.5 mg continuous
95 Estrace® -5 mg
288 Premarin® .625 mg Provera® 2.5 mg continuous
295 Premarin® .625 mg Provera® 2.5 mg continuous
306 Estrace® 1 mg Cycrin® 10 mg cyclic (Estrace® 25d, 
Cycrin® lOd)
334 Premarin® .625 mg
336 Premarin® .625 mg
337 Estrace® Patch 1 mg Provera® 2.5 mg continuous
344 Premarin® .625 mg Provera® 5 mg cyclic (Premarin® l-25d, 
Provera® 16-25d)
*358 Prempro® .625 mg Prempro® 2.5 mg
368 Estrace® Patch 1 mg
375 Ogen® .625 mg
♦Prempro® is one pill that contains both estrogen and progestin. ** Estratest® contains testosterone and 
estrogen.
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